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Abstract 
The reprogramming of somatic cells to naïve pluripotency can be robustly achieved by 
the forced expression of four reprogramming factors: Oct4, Sox2, Klf4 and c-Myc. Among 
these reprogramming transcription factors, Oct4 plays a central role, as it is sufficient and 
essential for the induction of pluripotent cells. Oct4 interactome studies in embryonic stem 
cells (ESCs) revealed members of the Nucleosome Remodelling and Deacetylase (NuRD) 
complex as its highest confidence interactors. Mbd3 is an essential subunit of the NuRD 
complex, in the absence of which the complex is not assembled. Embryos lacking Mbd3 die 
shortly after implantation and Mbd3-null ESCs are viable but show severely impaired lineage 
commitment. Since the NuRD complex is a high confidence interactor of Oct4 and a key 
regulator of developmental cell state transitions, I investigated if NuRD is also involved in the 
biological process of the induction of pluripotency. 
I have addressed this question by means of genetic deletion or siRNA to manipulate 
Mbd3 levels in somatic cells. I demonstrated that the reprogramming of neural stem cells 
(NSCs) to pre-induced pluripotent stem cells (preiPSCs) is impacted by Mbd3 genetic 
deletion, and that Mbd3-null cells have delayed reprogramming kinetics. Likewise, using an 
inducible Mbd3 deletion strategy, I showed that the longer Mbd3 is intact the more NSCs 
reprogram to preiPSCs and finally to iPSCs. Using post-implantation epiblast-derived stem 
cells (EpiSCs), I showed that the reduction of Mbd3 by RNAi results in a complete 
impairment of Klf4-dependent reprogramming to iPSC and a 6 fold reduction in efficiency 
during Klf2-Nanog-dependent reprogramming. 
Moreover, I also performed the inverse experiments to examine the impact of Mbd3 
overexpression on reprogramming. I observed that Nanog-mediated reprogramming of MEF-
derived preiPSCs is facilitated in rate and extent by increased Mbd3, which results in 
increased NuRD complex levels. This increase in efficiency seems to be the result of a 
synergistic function of Nanog and Mbd3 in inducing the transcription of key pluripotency 
genes prior to the induction of reprogramming. A similar outcome is observed for Nanog-
dependent reprogramming of EpiSCs, where increased Mbd3 expression leads to increased 
efficiency.  
In summary, my results identify a key role of the Mbd3/NuRD complex in the induction 
of pluripotency and show that a chromatin complex which is required for cell differentiation 
also facilitates the reversion of these cells back to a pluripotent cell state. 
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Sumário 
A reprogramação de células somáticas a celulas estaminiais pluripotentes induzidas 
(iPSCs) pode ser conseguida através da sobreexpressão de quatro factores: Oct4, Sox2, Klf4 e 
c-Myc. Oct4 desempenha um papel fundamental, sendo suficiente e essencial para a geração 
de células pluripotentes induzidas. Análise do interactoma do Oct4 revelou que as 
subunidades do complexo NuRD (do inglês Nuclessome remodelling and Deacetylase 
complex) são os seus interactores principais. A subunidade Mbd3 é essencial para a geração 
do complexo, já que a sua ausência leva a que o complexo não se forme. Delecção do Mbd3 
não é compatível com desenvolvimento embrionário e, apesar de células estaminais 
embrionárias poderem existir sem Mbd3, estas apresentam problemas de diferenciação 
celular. Sendo o complexo NuRD um dos principais interactores do Oct4 e um complexo 
chave na regulação de transições celulares durante o desenvolvimento embionário, decidi 
investigar qual o papel desempenhado pelo NuRD no processo de pluripotência induzida. 
Para responder a esta questão fiz uso de diferentes delecções genéticas e ARN de 
interfência para manipular os níveis de Mbd3 em células somáticas. Nesta tese demonstrei 
que a remoção de Mbd3 leva a uma reduzida eficiência de reprogramação de células 
neuronais estaminais (NSC) a preiPSCs e, que as células que eventualmente reprogramam 
demoram mais tempo a fazê-lo. Através da remoção do Mbd3 em diferentes períodos, mostrei 
que quanto mais tarde o Mbd3 for removido, maior é o número de NSC que reprogramam em 
preiPSCs e eventualmente em iPSCs. Igualmente, usando células estaminais pluripotentes 
obtidas do epiblasto após implantação do blastocisto (EpiSCs),  demonstrei que a redução da 
expressão de Mbd3 por ARN de interferência impede a reprogramação mediada pela 
sobreexpressão do factor de reprogramação Klf4, e que a delecção genética do Mbd3 reduz 
até seis vezes a eficiência de reprogramação mediada pelos factores Klf2 e Nanog. 
Nesta tese investiguei também o impacto da sobreexpressão do Mbd3 na reprogramação 
celular. Demonstrei que a reprogramação mediada pelo Nanog de preiPSCs, obtidas de 
fibroblastos embrionários, a iPSCs, é facilitada pela sobreexpressão de Mbd3, que conduz a 
maiores níveis de complexo NuRD. Este aumento de eficiência parece ser fruto da sinergia 
entre o Nanog e o Mbd3 na indução de transcrição de genes necessários para pluripotència, 
antes da reprogramação das células em iPSCs. Resultados semelhantes foram obtidos na 
reprogramação de EpiSCs a iPSCs, onde a co-sobreexpressão de Nanog e Mbd3 leva a um 
aumento da eficiência da reprogramação celular. 
Nesta tese demonstrei que o complexo NuRD desempenha um papel vital na formação de 
células estaminais pluripotentes induzidas e que um complexo previamente associado a 
diferenciação celular também desempenha um papel na reversão a um estado pluripotente.  
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CHAPTER 1 – General Introduction 
  
2 
 
1.1 – Pluripotency in the embryo and in culture 
Mammalian development is a unidirectional process paralleled with a progressive loss of 
developmental potential. It begins with the formation of a unicellular zygote, and as cells 
divide and their numbers multiply, it ends with more than 200 specialized cell types being 
generated. Since all cells carry the same genome but have different functions, a key question 
is how these different stable cell states are established and maintained, and whether these 
states can be perturbed resulting in changes in cell fate. In this Introduction I will describe 
how pluripotency arises during mammalian development; how this cell state can be captured 
in vitro in the form of Embryonic Stem Cells (ESCs); the key gene regulatory network that 
controls the pluripotent state; the nuclear reprogramming of adult cells to a pluripotent state; 
and the role of the Nucleosome remodelling and Deacetylase complex (NuRD) during 
development and ESC maintenance. 
 
1.1.1 – The establishment of naïve pluripotency in the mouse embryo 
Mouse development progresses from a state of totipotency in the zygote, which is formed 
after the fertilization of the oocyte by sperm. The zygote undergoes 3-4 rounds of cleavage 
divisions, leading to the generation of a structure containing 8-16 totipotent blastomeres, 
called morula. At this stage, blastomeres start to compact and the first lineage choice takes 
place, resulting in the generation of two cell lineages with restricted developmental potential: 
trophectoderm (outside) and inner cell mass (ICM, inside) (Schrode et al., 2013) (Figure 
1.1.1A). The trophectoderm lineage, which will form part of the placenta, is specified by 
expression of trophectoderm specification factors Cdx2 and Gata3, which are activated by the 
transcription factor Tead4 (Nishioka et al., 2009; Ralston et al., 2010). Both cell polarity and 
differential activation of Hippo signalling in the cells of the compacted morula are implicated 
in the process of trophectoderm segregation. Outside cells that will become the trophectoderm 
are polarized, having inactive Hippo pathway, allowing Yap/Taz to be translocated to the 
nucleus, where they activate Tead4 (Nishioka et al., 2009). The Hippo signalling is activated 
in the unpolarised cells of ICM, which results in the phosphorylation and degradation of 
Yap/Taz, which keeps Tead4 repressed (Nishioka et al., 2009). On the other hand, ICM cells 
express the homeodomain protein Nanog and the Pit-Oct-Unc (POU) domain protein Oct4 
(also known as Pou5f1), which are repressed in trophectoderm cells (Nichols and Smith, 
2012; Niwa et al., 2005). Since Oct4 and Cdx2 reciprocally inhibit each other, the down-
regulation of Oct4 in trophectoderm cells due to Cdx2 expression and Cdx2 down-regulation 
in ICM cells due to Oct4 expression is likely to be a mechanism underlying the stabilization 
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of this first lineage specification (Nichols and Smith, 2012; Niwa et al., 2005) (Figure 
1.1.1B). 
 
Figure 1.1.1 – Schematic representation of mouse pre-implantation development.  
(A) After fertilization, the totipotent zygote undergoes several rounds of division leading to the 
generation of a compacted morula that consists of two cell lineages: trophectoderm (outside) and inner 
cell mass (ICM, inside). At the blastocyst stage, the cells from inner cell mass undergo a second fate 
decision, resulting in the segregation of the naïve pluripotent epiblast and primitive endoderm. (B) 
Schematization of the two lineage choices that take place during pre-implantation mouse development. 
The first gives rise to trophectoderm and ICM and the second leads to the allocation of epiblast and 
primitive endoderm. Typical markers of each cell lineage are indicated. Reciprocal inhibition between 
Oct4 (and possibly Nanog) and Cdx2 during the first lineage specification, and between Nanog and 
Gata6 during the second, are indicated. E: embryonic day. Adapted from (Schrode et al., 2013). 
 
Approximately 12 hours after the first lineage segregation (embryonic day E3.5), there is 
a formation of a cavity inside compacted morula, resulting in the generation of an early 
blastocyst where the ICM is pushed to one side. The cells within the ICM start expressing 
lineage-specific transcription factors, Nanog and Gata6, which are further restricted until a 
distribution of cells exhibiting mutually restricted transcription factor emerges (Chazaud et 
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al., 2006; Nichols and Smith, 2011). A subset of ICM cells down-regulate Gata6, while still 
expressing Nanog, priming them towards an epiblast state. The remaining ICM cells down-
regulate Nanog but maintain Gata6 expression and subsequently up-regulate Sox17, which 
biases them for a primitive endoderm state (Artus et al., 2011). At embryonic day 4.5 (E4.5), 
this “salt-and-pepper” distribution of epiblast- and primitive-endoderm primed cells is 
established, with primitive-endoderm cells sorted to form an epithelized layer positioned 
adjacent to the epiblast at the interface with the blastocyst cavity that will form the yolk sac 
(Nichols and Smith, 2011). Although different models have been hypothesized to explain this 
second lineage specification, the mechanisms are not fully understood. It is likely that a 
mechanism involving Gata6-induced repression of Nanog expression in the cells that will 
become primitive endoderm is in place (Niwa, 2007). However, there is no direct evidence to 
support this suggestion. The pre-implantation epiblast, also termed naïve epiblast, represents 
the pluripotent compartment of the embryo and will form all somatic and germline cells of the 
developing embryo (Nichols and Smith, 2011). Oct4 also plays a pivotal role in this lineage 
decision, since Oct4 deletion at the morula to blastocyst transition blocks ICM segregation 
into epiblast and primitive endoderm, implicating Oct4 in both epiblast and primitive 
endoderm differentiation (Le Bin et al., 2014).  
 
1.1.2 – Capturing naïve pluripotency in vitro 
The pluripotent cells of the pre-implantation epiblast can be captured in culture in the 
form of Embryonic Stem Cells (ESCs) (Evans and Kaufman, 1981; Martin, 1981). The initial 
derivations of ESCs were made possible due to the previous discovery and study of 
embryonic carcinoma cells (ECCs), another type of pluripotent cells generated from explants 
of teratocarcinomas (Hogan, 1976). Based on the same protocol as for ECCs isolation, ESCs 
were initially derived by the culture of blastocysts or ICM on a feeder layer of mitotically 
inactivated fibroblasts using media containing foetal calf serum (FCS) (Evans and Kaufman, 
1981; Martin, 1981). Mouse ESCs share many characteristics with the ICM cells, exhibiting 
expression of key pluripotency genes such as Oct4, Sox2 and Nanog, and two active X 
chromosomes in female cells. Mouse ESCs have two key features: self-renewal capacity, as 
they are able to be maintained indefinitely in culture; and developmental potential, as they can 
efficiently be differentiated into all three embryonic lineages in culture when subjected to 
differentiation stimuli (Doetschman et al., 1985; Nichols and Smith, 2012), or when 
introduced into the mouse kidney capsule, resulting in teratomas. ESCs can also be 
differentiated into germ cells in vitro (Geijsen et al., 2004; Toyooka et al., 2003), and can 
recapitulate full developmental potential when injected into blastocysts, contributing to the 
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three germ layers and to the germline (Bradley et al., 1984). Furthermore, it is possible to 
derive liveborn mice that are entirely composed of ESC derivatives (Nagy et al., 1993). 
 
1.1.3 – Key signalling pathways of ESCs 
Maintaining the pluripotent state of ESCs depends on key signalling pathways (Figure 
1.1.2). ESCs were first derived and cultured on a feeder layer in presence of serum (Evans and 
Kaufman, 1981; Martin, 1981). Subsequent studies identified the soluble signalling molecule 
leukaemia inhibitory factor (LIF) (Smith et al., 1988; Williams et al., 1988), which allows 
both the derivation and maintenance of ESCs in the absence of a feeder layer (Nichols et al., 
1990; Pease et al., 1990). LIF signalling is transduced through the LIF receptor (LIF-R) and 
glycoprotein 130 (gp130) and activates distinct signalling pathways involved in maintenance 
and differentiation of ESCs (Burdon et al., 1999; Matsuda et al., 1999; Niwa et al., 1998). The 
most potent signalling pathway activated is the Janus kinase- signal transducer and activator 
of transcription 3 (JAK/STAT3) pathway (Matsuda et al., 1999; Niwa et al., 1998), which 
promotes self-renewal by maintaining the expression of key transcription factors, such as Klf4 
(Niwa et al., 2009), Gbx2 (Tai and Ying, 2013), and Tfcp2l1 (Martello et al., 2013; Ye et al., 
2013). LIF also induces the phosphoinositide-3-kinase- protein kinase B/Akt (PI3K/Akt) 
pathway, mediating the transcription of Tbx3, which enhances Nanog expression, stimulating 
self-renewal (Niwa et al., 2009). The PI3K/Akt pathway can also be activated by insulin and 
insulin-like growth factors (IGFs) (Hemmings and Restuccia, 2012). However, LIF also 
stimulates the mitogen-activated protein kinase/ extracellular-signal-regulated kinase 
(MAPK/Erk) pathway (Burdon et al., 1999), which acts to promote differentiation. This 
differentiation effect of MAPK/Erk pathway seems to be compensated by the promotion of 
self-renewal caused by the JAK/STAT3 and PI3K induction. Other activators of the 
MEPK/Erk pathway include fibroblast growth factors (FGFs), mainly Fgf2 and Fgf4, whose 
addition to ESC culture triggers them to differentiate (Kunath et al., 2007). 
Further studies to identity the key components of the foetal serum, used during ESC 
culture, revealed that one of the most important active growth factors is bone morphogenetic 
protein 4 (BMP4) (Ying et al., 2003). Cultivation of ESCs in defined medium (serum-free) 
supplemented with BMP4 allows maintenance of ESCs in the absence of a feeder layer. 
Mechanistically, BMP4 seems to synergize with the LIF signalling, supporting self-renewal 
of ESCs by the induction of inhibitors of differentiation (Id) genes (Ying et al., 2003). 
Derivation of ESCs using serum and feeders is very inefficient and restricted to particular 
mouse strains, particularly to the 129 strain (Evans and Kaufman, 1981; Martin, 1981). The 
efficiency of ESC derivation is increased when LIF is added to medium (Smith et al., 1988; 
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Williams et al., 1988), and combination of LIF, BMP4 and the pharmacological inhibition of 
Erk was shown to allow ESC derivation from other mouse strains which had been refractory 
to serum-containing medium derivation, such as C57BL/6 (Batlle-Morera et al., 2008). 
Though the inhibition of Erk signalling plays a pivotal role in ESC derivation and culture, Erk 
inhibition alone is not sufficient to maintain ESCs self-renewal (Ying et al., 2008). However, 
the addition of a selective glycogen synthase kinase-3 (GSK3) inhibitor to the defined 
medium containing the Erk inhibitor allows the culture of self-renewing ESCs without any 
sign of cell differentiation (Ying et al., 2008). GSK3 inhibition leads to the de-repression of 
the canonical Wnt signalling pathway, which results in the release of Tcf3-mediated 
repression of pluripotency genes (Wray et al., 2011), such as Esrr (Martello et al., 2012). 
Interestingly, the exogenous supply of Wnt ligand, Wnt3a, is not sufficient to maintain self-
renewal in ESCs in which Erk signalling is blocked (Ying et al., 2008). Thus, the effect of 
GSK3 inhibition is thought not only to enhance the Wnt signalling but also to improve the 
general biosynthetic capacity of the cell (Sato et al., 2004). This defined medium containing 
inhibitors of both Erk (PD0325901, abbreviated PD03) and GSK3 (CHIR99021, abbreviated 
Chiron) is named 2i, and, even though LIF is not required for ESC culture using this media, 
the addition of LIF enhances self-renewal (Marks et al., 2012; Ying et al., 2008). Importantly, 
the usage of 2i/LIF medium allowed highly efficient derivation of ESC from embryos from 
various mouse strains (Nichols et al., 2009; Ying et al., 2008), mouse embryonic germ cells 
(EGCs) (Leitch et al., 2010), and also of pluripotent cells from other rodent species, such as 
germline competent rat ESCs (Buehr et al., 2008; Li et al., 2008) and rat EGCs (Leitch et al., 
2010). Lastly, it was recently reported that one more signalling pathway plays an important 
role in ESC self-renewal. It was demonstrated that inhibition of protein kinase C signalling 
(PKC) is sufficient for derivation and culture of ESCs in defined medium, an effect that seems 
dependent on the inhibition NF-kB activity, and is independent of the signalling pathways 
described above (Dutta et al., 2011). 
In summary, the culture of self-renewing ESCs is possible when self-renewal-associated 
pathways such as JAK/STAT3, PI3K/Akt or canonical Wnt signalling are stimulated; or when 
differentiation associated pathways such as MAPK/Erk pathway, GSK3 and PKC are 
inhibited. All these signalling pathways are schematized in Figure 1.1.2. 
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Figure 1.1.2 – Signalling pathways and key transcription factors in mouse ESCs. 
The main signalling pathways and transcription factors involved in ESC self-renewal are 
represented. The exogenous soluble proteins that activate the corresponding signalling cascades are in 
indicated in red, and the selective pharmacological inhibitors of corresponding enzymes are in 
indicated in blue. In the inner circle are the core pluripotency transcription factors (Oct4, Nanog and 
Sox2) and in the outer circle are other transcription factors that play a very important role in the 
maintenance of pluripotency. Of note, some transcription factors such as Stat3, Tcf3 and Tbx3 are 
regarded as the main bridges between JAK/STAT3, Wnt and PI3K/Akt signalling pathways inputs, 
and the transcriptional factor core of naïve pluripotency. For further details about the signalling 
pathways, please refer to the text. 
 
1.1.4 – Core transcriptional factor network of naïve pluripotency 
Naïve pluripotent ESCs are characterized by a unique network of transcription factors, 
with Oct4, Sox2 and Nanog being considered the main keepers of pluripotency.  
Oct4 (also known as Pou5f1) is a Pit-Oct-Unc (POU) family transcription factor. It was 
first identified as a transcription factor specifically expressed in ECCs, being down-regulated 
upon differentiation (Lenardo et al., 1989; Scholer et al., 1989; Scholer et al., 1990). Oct4 
expression was further identified as being restricted to pluripotent and germ-line cells 
(Scholer et al., 1990), and required for the establishment of the naïve pluripotent compartment 
in the embryo (Nichols et al., 1998). Oct4-null ESCs cannot be recovered from outgrowths of 
Oct4
-/-
 blastocysts (Nichols et al., 1998). Oct4 depletion in ESCs triggers their conversion into 
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trophectoderm, and its overexpression induces ESC differentiation into a mixture of lineages 
(Niwa et al., 2000). Interestingly, recently published work by our and the Chambers 
laboratory revealed that a defined level of Oct4 is essential not only for pluripotency 
maintenance, but also for the exit from pluripotency into differentiation, both in vitro and in 
vivo (Karwacki-Neisius et al., 2013; Radzisheuskaya et al., 2013). Therefore, the Oct4 levels 
have to be tightly controlled to sustain, and allow the exit from, pluripotency. 
The best-characterized Oct4 partner is the sex-determining region Y (SRY)-related box 
protein Sox2 (Rizzino, 2009). The cooperation between Oct4 and Sox2 was first described in 
ECCs, where their interaction was found to be required for cell-type-restricted activity of the 
Fgf4 enhancer (Dailey et al., 1994). Subsequent studies revealed that a similar mechanism 
exists in ESCs (Yuan et al., 1995), and that an Oct4/Sox2 binding element is present upstream 
of many pluripotent-associated genes (Chambers and Tomlinson, 2009). Sox2
-/-
 embryos fail 
to establish a naïve pluripotent epiblast at E4.5 and die shortly after implantation. ESCs 
cannot be derived from these embryos (Avilion et al., 2003). The conditional deletion of Sox2 
in ESCs results in trophectoderm differentiation (similar to Oct4 deletion), a phenotype that 
can be rescued by constitutive expression of Oct4 at wild type levels (Masui et al., 2007). 
Nanog is a homeodomain-containing protein, which was initially discovered by two 
groups that used two different approaches: Smith and colleagues isolated Nanog in a 
functional complementary DNA (cDNA) screen to identify factors that confer LIF-
independent self-renewal on ESC (Chambers et al., 2003); and Yamanaka and colleagues 
identified Nanog by comparing expressed sequence tags (EST) between ESCs and somatic 
cells (Mitsui et al., 2003). Similar to Oct4 and Sox2 deletion, Nanog
-/-
 embryos failed to 
establish a naïve pluripotent compartment and died before implantation, and no ESCs can be 
derived from these blastocysts (Mitsui et al., 2003). Yet, pluripotent Nanog-null ESCs can be 
generated and maintained in vitro using targeting by homologous recombination, despite 
being highly prone to differentiation. They contribute to all tissues in chimeric mice upon 
blastocyst injection (Chambers et al., 2007). However, Nanog
-/-
 ESCs fail to mature in the 
genital ridge, failing to contribute to the germline (Chambers et al., 2007).  
Oct4, Sox2 and Nanog constitute the core of transcription factors which are associated 
with the pluripotency state. They are essential for the establishment of pluripotent cells in vivo 
and for ESC maintenance and function. Other transcription factors have been identified and 
functionally validated as playing pivotal roles in ESC self-renewal and differentiation (Table 
1.1.1; more information about their roles in ESCs can be found in (Nichols and Smith, 2012)). 
These are regarded as regulators of pluripotency, since they are individually dispensable for 
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ESC maintenance, but work together to regulate the expression of the core transcription 
factors, and thus, the pluripotent state (Figure 1.1.2). 
 
Table 1.1.1 – Phenotypes associated with key mouse ESC transcription factors. 
Transcription 
factor 
Embryonic 
phenotype 
ESC loss of function 
phenotype 
ESC gain of 
function 
phenotype 
References 
Esrr Placental 
failure; mid-
gestation 
lethality 
None (in 2i/LIF) LIF-
independent 
self-renewal 
(Festuccia et al., 
2012; Luo et al., 
1997; Martello et 
al., 2012) 
Klf2 Viable None (by RNAi) LIF-
independent 
self-renewal 
(Hall et al., 2009; 
Jiang et al., 2008; 
Kuo et al., 1997) 
Klf4 Viable None (by RNAi) LIF-
independent 
self-renewal 
(Hall et al., 2009; 
Jiang et al., 2008; 
Segre et al., 1999) 
Klf5 Early 
Implantation 
defect; 
embryonic 
lethality 
None LIF-
independent 
self-renewal 
(Ema et al., 2008; 
Hall et al., 2009; 
Jiang et al., 2008) 
Nanog Loss of epiblast 
and primitive 
endoderm 
Prone to 
differentiation, but 
continue self-
renewing 
LIF-
independent 
self-renewal 
(Chambers et al., 
2003; Chambers et 
al., 2007; Mitsui et 
al., 2003; Silva et 
al., 2009) 
Nr5a1/2 Early post-
implantation 
lethality; failed 
gastrulation 
None No evident 
role 
(Gu et al., 2005; 
Guo and Smith, 
2010) 
Nr0b1 Not reported Differentiation, 
mainly to 
trophectoderm 
No evident 
role 
(Khalfallah et al., 
2009; Niakan et al., 
2006; van den Berg 
et al., 2010) 
Oct4 ICM becomes 
trophectoderm 
Differentiation to 
trophectoderm 
Differentiation (Nichols et al., 
1998; Niwa et al., 
2000) 
Rex1 Viable None No evident 
role 
(Climent et al., 
2013; Masui et al., 
2008; Scotland et 
al., 2009) 
Sall4 Early post-
implantation 
lethality 
Tendency for 
spontaneous 
differentiation 
No evident 
role 
(Sakaki-Yumoto et 
al., 2006; Tsubooka 
et al., 2009; Yuri et 
al., 2009; Zhang et 
al., 2006) 
Sox2 Early post-
implantation 
lethality 
Differentiation to 
trophectoderm 
Not reported (Avilion et al., 
2003; Masui et al., 
2007) 
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Stat3 Post-gastrulation 
lethality 
None (in 2i/LIF) Exogenous 
activation of 
LIF signalling 
substitutes for 
LIF 
(Do et al., 2013; 
Takeda et al., 1997; 
Ying et al., 2008) 
Tbx3 Mid-gestation 
lethality 
Partially impaired 
self-renewal (RNAi) 
LIF-
independent 
self-renewal 
(Davenport et al., 
2003; Ivanova et al., 
2006; Niwa et al., 
2009) 
Tcf3 Disrupted axial 
patterning; 
lethality at 
gastrulation  
Reduced LIF 
dependence 
Differentiation (Guo et al., 2011; 
Pereira et al., 2006; 
Wray et al., 2011) 
Tfcp2l1 Viable None (in 2i/LIF) LIF-
independent 
self-renewal 
(Martello et al., 
2013; Yamaguchi et 
al., 2005; Ye et al., 
2013) 
Tfe3 Viable None (in 2i/LIF) Nuclear 
expression can 
cause cells to 
withstand 
differentiation 
(Betschinger et al., 
2013; 
Steingrimsson et al., 
2002) 
 
RNAi – RNA interference; Esrr: Estrogen-related receptor ; Klf2/4/5: Krüppel-like Factor 
2/4/5; Nr5a1/2: Nuclear receptor subfamily 5 group A member ½; Nr0b1: Nuclear receptor subfamily 
0 group B member 1; Oct4: Octamer-binding transcription factor 4; Rex1: Reduced expression 1; 
Sox2: Sex-determining region Y (SRY)-box2; Stat3: Signal transducer and activator of transcription 3; 
Tbx3: T-box transcription factor 3; Tcf3: Transcription factor 3; Tfcp2l1: Transcription factor CP2-
like 1; Tfe3: Transcription factor E3. 
 
Pluripotent ESCs are thought to be maintained due to the regulation of pluripotency 
transcription factors by positive-feedback loops, which enables their ongoing expression until 
this core network is dismantled (Boyer et al., 2005; Jaenisch and Young, 2008; Young, 2011). 
In addition to positive auto-regulation, these pluripotency factors act cooperatively with 
members of repressive chromatin-modifying machinery (like Polycomb repressive complexes, 
PRCs) to repress the expression of lineage-specification genes (Young, 2011). Moreover, 
several transcription factors that regulate the pluripotent state are known mediators of key 
ESC signalling pathways (Figure 1.1.2), demonstrating that the pluripotent state is maintained 
due to an intricate connection between the environment (culture conditions) and transcription 
factors. 
In summary, pluripotent cells, both in the embryo and in culture, are sustained by a 
flexible transcription factor network which is responsive to different signals, which can either 
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sustain pluripotency or disassemble the naïve pluripotency associated transcriptional network, 
leading to cell differentiation.  
 
 
 
1.1.5 – Post-implantation epiblast and primed pluripotent stem cells 
As described above, at E4.5 the blastocyst is composed of three structures: the naïve 
pluripotent epiblast, the primitive-endoderm epithelia and the trophectoderm. This mature 
blastocyst then implants into the uterus, a process that is paralleled with the morphological 
transformation of the naïve epiblast into a cup-shaped structure, known as the egg cylinder 
(Figure 1.1.3). Since the embryo is now physically constrained, the continuous growth of the 
epiblast is possible due to its movement into the blastocyst cavity. At this stage, female 
epiblast cells undergo random X chromosome inactivation, naïve pluripotency markers such 
as Rex1, Klf4 and Essr are down-regulated and lineage-commitment genes such as Fgf5 and 
T-brachyury start to be expressed (Nichols and Smith, 2009).  
Since Oct4 and Nanog are expressed in the post-implantation epiblast, this structure is 
regarded as pluripotent. Yet, attempts to derive ESCs from the post-implantation epiblast 
using standard ESC conditions have failed (Nichols and Smith, 2009). However, post-
implantation epiblast-derived stem cells (EpiSCs) can derived if Fgf2 and Activin A-
containing serum-free medium is used (Brons et al., 2007; Tesar et al., 2007). EpiSCs are 
dependent on Fgf signalling, being morphologically and molecularly distinguishable from 
ESCs (Figure 1.1.3). Like the cells of the post-implantation epiblast, they express Oct4 but 
not Rex1 and Klf4, and up-regulate expression of Fgf5 and T-brachyury (Nichols and Smith, 
2009). Genetic studies indicated that Oct4 expression is required for post-implantation 
pluripotency, whereas Nanog is not (Osorno et al., 2012). EpiSCs can be differentiated into all 
embryonic lineages (Brons et al., 2007; Tesar et al., 2007) including primordial germ cells 
(Hayashi and Surani, 2009), but they do not contribute efficiently to chimeras when injected 
into blastocysts. However, if EpiSCs are injected in the post-implantation epiblast explanted 
in culture, they can contribute to all tissues and germline (Huang et al., 2012). EpiSCs can 
also be established by the culture of ESCs (Guo et al., 2009) or the pre-implantation epiblast 
(Najm et al., 2011) in Fgf2/Activin A, which triggers the differentiation of these naïve cells 
into the primed pluripotent state. 
Interestingly, although human ESCs are isolated from pre-implantation blastocysts like 
mouse ESCs (Thomson et al., 1998), they share more characteristics with mouse EpiSCs than 
mouse ESCs (Hanna et al., 2010b; Nichols and Smith, 2009). The morphological and 
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biological similarities between human ESCs and mouse EpiSCs suggest that human ESCs 
correspond to a primed state of pluripotency. Whether the naïve human pluripotent state exist 
remains open. Indeed, recent efforts to establish naïve human ESCs showed that different 
human ESCs can be established, which are more similar to mouse ESCs (Chan et al., 2013; 
Gafni et al., 2013; Hanna et al., 2010a). However, further characterization of these cells is 
necessary, addressing if these cells are true naïve pluripotent cells or correspond to a different 
primed state.  
In summary, different pluripotent cells can be derived from the mouse embryo: ESCs, 
which are derived from the pre-implantation epiblast, and EpiSCs, derived from the post-
implantation epiblast. Since ESCs fail to re-enter blastocyst development, they represent a 
more committed pluripotent state, called the primed pluripotent state, which is molecularly 
distinguishable from the naïve pluripotent state. 
 
 
 
 
 
 
 
 
 
 
 
 
 
(figure on next page) 
Figure 1.1.3 – Comparison of Naïve and Primed Pluripotent states. 
Pluripotency comes in two flavours during embryo development: ground state naïve pluripotency, 
which is established in the epiblast of the mature blastocyst (E4.5) and can be captured in vitro in the 
form of ESCs (culture in 2i/LIF or serum+LIF); and primed pluripotency, which is established in the 
post-implantation epiblast (E5.5), a cup-shaped epithelium that becomes primed for lineage 
specification and commitment in response to external stimulus from the extra-embryonic tissues, and 
can be captured in vitro in the form of  EpiSCs (culture in Fgf2 and Activin A). EpiSCs can also be 
generated by the differentiation of ESCs after their exposure to Fgf2 and Actvin A. EpiSCs can be 
reverted back after the forced expression of transcription factors, such as Klf4, Klf2 or Nanog, 
followed by culture in 2i/LIF (Guo et al., 2009; Silva et al., 2009). Tables indicate the differences and 
similarities between ESCs and EpiSCs. Embryo images from (Nichols and Smith, 2009) 
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1.2 – Nuclear reprogramming 
During embryo development, pluripotent cells in the epiblast start to commit to become 
precursors of different germ layers (endoderm, ectoderm and mesoderm), which will then 
give rise to the cells and tissues of an adult. The process of cellular differentiation was 
thought to be irreversible and unidirectional, and was represented by Waddington as a marble 
rolling down the mountain of developmental potential. This classical view of development 
hypothesized that different cell types and states were defined by boundaries that could not be 
crossed. However, several studies challenged this view, demonstrating the even terminally 
differentiated cells are “plastic” and amenable to switch fate, being able to be converted back 
to a pluripotent state or to a different cell type, altering their gene expression, and therefore 
their fate. This process is termed nuclear reprogramming, and can be achieved in vitro by 
three different experimental approaches: somatic cell nuclear transfer, cell fusion, and 
transcription factor-mediated direct reprogramming. 
Somatic cell nuclear transfer (SCNT) consists of the transfer of the nucleus from a 
somatic cell into an enucleated oocyte (an oocyte whose nucleus has been removed) (Figure 
1.2.1A). The first SCNT experiments were performed in amphibians using either nuclei from 
early blastocysts (Briggs and King, 1952) or intestinal cells (Gurdon, 1962a, b; Gurdon et al., 
1958). Results from Gurdon and colleagues showed that the exposure of somatic nuclei to the 
cytoplasm of oocyte is enough to reprogram this nucleus to a pluripotent state, which is able 
to re-enter development and create an entire normal adult frog (Gurdon et al., 1958). These 
seminal experiments proved that all the genes that are required to create an entire organism 
are present in the nucleus of all specialized cells, indicating that during development no 
permanent genetic changes occur, and that all cell boundaries are epigenetically defined. 
Forty years later, SCNT was successfully reported in mammals, with Dolly sheep being the 
first cloned mammal (Campbell et al., 1996; Wilmut et al., 1997). For that, the blastocyst 
formed after cell division of a manipulated oocyte (now with a “somatic” nucleus) was 
transferred into the uterus of a foster female sheep, where it could implant and continue 
embryonic development (Campbell et al., 1996). The same protocol was then used to generate 
the first cloned mouse (Wakayama et al., 1998) and to generate mouse ESCs (SCNT-ESCs) 
from adult mice (Munsie et al., 2000). SCNT-ESCs can re-enter blastocyst development and 
contribute to cloned mice (Hochedlinger and Jaenisch, 2002). Many efforts were made to 
derive patient-specific human SCNT-ESCs using this method. However, after many attempts, 
only recently did scientists succeed in establishing human SCNT-ESCs (Chung et al., 2014; 
Kang et al., 2014; Tachibana et al., 2013; Yamada et al., 2014). 
15 
 
Cell fusion consists of the fusion of two cells to form a single identity (Figure 1.2.1B). 
Cell fusion occurs in two steps. Firstly, short-lived products which do not proliferate, termed 
heterokaryons, are generated. These represent two nuclei in a common cytoplasm. Then, the 
nuclei fuse generating tetraploid hybrids through a very inefficient process that requires cell 
proliferation. Cell fusion was first developed to study the impact of one genome over the 
other, which led to the discovery of trans-acting repressors by the fusion of two somatic cells 
(Davidson et al., 1966; Harris et al., 1969). By fusing cells from different species, which leads 
to the formation of mixed-species heterokaryons, cell fusion also provided the first definitive 
evidence that silent genes could be activated (Blau et al., 1983; Blau et al., 1985). Further 
studies shown that nuclei of adult mouse thymocytes could be reprogrammed back to 
pluripotency by fusion with either EGCs (Tada et al., 1997) or ESCs (Tada et al., 2001). The 
tetraploid hybrids resulting from the fusion between thymocytes and ESCs exhibited the 
properties of pluripotent cells (gene expression, differentiation into all germ layers), and could 
contribute to chimeric embryos, although very inefficiently, due to their tetraploid genome 
(Tada et al., 2001). Human somatic cells can also be reprogrammed to pluripotent cells after 
fusion with human ESCs (Cowan et al., 2005). The efficiency of somatic cell-ESC cell fusion 
can be boosted if either the somatic cells or ESCs used overexpress Nanog (Silva et al., 2006). 
This study led to the discovery of the first reprogramming factor, which together with the 
ESC machinery can enhance reprogramming efficiency. However, the overexpression of 
Nanog alone in somatic cells is not sufficient to drive their reprogramming to a pluripotent 
state (Silva et al., 2006). 
Transcription factor-mediated reprogramming consists of the direct alteration of cell fate 
by the forced expression of tissue-specific transcription factors. The fact that single 
transcription factors can trigger a cascade of events, leading to altered gene expression 
profiles that ultimately result in phenotypic alteration was first identified in the fly. Forced 
expression of key transcription factors in D. melanogaster larvae led to the development of an 
additional set of legs instead of antennae (Schneuwly et al., 1987), or to the formation of 
functional eyes on the legs, antennae and wings (Gehring, 1996). Alteration of cell fate by the 
ectopic expression of transcription factors was then reported in the mouse, where the forced 
expression of MyoD induces the conversion of fibroblasts or other cell types to myoblasts 
(Davis et al., 1987; Weintraub et al., 1989). This process of direct programming of a cell type 
into another, bypassing an intermediate pluripotent state, by the forced expression of 
transcription factors that are characteristic of the desired cell type is termed 
transdifferentiation (Graf and Enver, 2009). In 2006, Takahashi and Yamanaka demonstrated 
that a similar approach can be employed to reprogram mouse embryonic or adult fibroblast 
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back to pluripotency (Takahashi and Yamanaka, 2006). In this seminal study, 24 genes that 
are normally expressed in ESCs were cloned and delivered retrovirally into fibroblasts. These 
factors were then screened for their ability to collectively induce pluripotency, which was 
assessed by the reactivation of endogenous F box only protein 15 (Fbx15) in transduced cells, 
a gene previously identified as being specific to ESCs (Tokuzawa et al., 2003). Two-weeks 
after the transduction of the 24 factors, Fbx15-positive colonies emerged, at a 0.01–0.1% 
efficiency, showing similar morphology, growth and gene expression to ESCs, forming 
teratomas when injected into mice (Takahashi and Yamanaka, 2006). Since these cells were 
induced back to pluripotency, they were named induced pluripotent stem cells (iPSCs). By the 
progressive elimination of factors, Takahashi and Yamanaka found a cocktail of four factors 
that is sufficient induce pluripotency from fibroblasts: Oct4, Sox2, Klf4 and c-Myc, which 
will be referred throughout the as reprogramming factors, OSKM, the “Yamanaka cocktail” 
or the “Yamanaka factors” (Takahashi and Yamanaka, 2006) (Figure 1.2.1C).  
The initial iPSCs generated by Takahashi and Yamanaka are thought to be 
reprogramming intermediates and not truly pluripotent cells, since when injected into a mouse 
blastocyst, they do not contribute to adult chimeric animals (Takahashi and Yamanaka, 2006). 
However, when the emerging iPSCs are selected for Nanog or Oct4 expression instead of 
Fbx15 expression, truly naïve germ-line competent pluripotent cells can be isolated, and are 
able to re-enter blastocyst development and generate germ-line competent adult mouse 
chimeras (Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007), or to give rise to “all-
iPSC”-derived mice through tetraploid complementation (Boland et al., 2009; Kang et al., 
2009; Zhao et al., 2009). Another hallmark of induced pluripotency is the reactivation of the 
inactivated in chromosome of somatic female cells (Stadtfeld et al., 2008b). Within a year of 
this discovery, human iPSCs were generated from human fibroblasts by the ectopic 
expression of the OSKM transcription factors (Park et al., 2008; Takahashi et al., 2007), or 
using a similar cocktail (Yu et al., 2007). As with mouse iPSCs, human iPSCs can be 
differentiated into all germ lineages. 
Five decades have passed since the discovery that somatic nuclei can be reprogrammed 
back to a pluripotent state, and that reprogrammed cells are able to re-enter embryo 
development and generate an entirely new animal (Gurdon, 1962a, b; Gurdon et al., 1958). 
Now it is possible to convert somatic cells directly into pluripotent cells by the forced 
expression of ESC transcription factors, without the use of eggs or ESCs, or the destruction of 
embryos (Takahashi and Yamanaka, 2006). In the next section I will further discuss the 
process of induced pluripotency, mainly focusing on recent technical advances and the 
epigenetic changes that take place during this process. 
17 
 
 
 
Figure 1.2.1 – Three approaches to nuclear reprogramming to pluripotency. 
(A) Somatic cell nuclear transfer: a diploid somatic nucleus is transferred into an enucleated 
oocyte, and is reprogramed to a pluripotent state. Through cell division, a blastocyst is formed, which 
can be used for ESC derivation or can be re-introduced into a foster mother to generate a cloned 
animal. (B) Cell fusion: somatic cells are fused to pluripotent cells (like ESCs), which generates short-
lived heterokaryons with two spatially-separated nuclei. When the nuclei fuse and cells start to 
proliferate, tetraploid hybrids are formed. (C) Transcription factor-mediated reprogramming: somatic 
cells are transduced with a set of defined transcription factors (OSKM), which induce reprogramming 
to an induced pluripotent state, leading to the generation of iPSCs. 1n: Haploid; 2n: diploid; 4n: 
tetraploid. Refer to text for further details.  
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1.3 – Induced pluripotent stem cells 
The reprogramming of the epigenome (chromatin modifications that may affect gene 
expression) of somatic cells to an induced pluripotent state can be achieved by the ectopic 
expression of Oct4, Sox2, Klf4 and c-Myc (OSKM) (Takahashi and Yamanaka, 2006). The 
advent of iPSCs has opened unprecedented new perspectives in both regenerative medicine 
and drug discovery. However, before this technology can be used in a clinical setting, it is 
important to understand the molecular mechanisms underlying their generation. In this section 
I will review the major technical advances, the role of OSKM and the epigenetic changes 
during iPSC generation. 
 
1.3.1 – Technical advances in iPSC generation 
Numerous alterations to the original protocol have been made in order to increase the 
efficiency and safety of iPSC generation. Since they were first established from mouse and 
human somatic cells, iPSCs have been generated from a number of different species, for 
example rats (Li et al., 2009b) or rhesus monkeys (Liu et al., 2008), among others. They have 
also been established from different cell types (Stadtfeld and Hochedlinger, 2010), such as 
lymphocytes (Hanna et al., 2008), stomach and liver (Aoi et al., 2008), neural stem cells (Kim 
et al., 2009b; Kim et al., 2008), pancreatic  cells (Stadtfeld et al., 2008a), or haematopoietic 
cells (Eminli et al., 2009; Guo et al., 2014). These experiments showed that the efficiency of 
inducing pluripotency strongly depends on the origin of somatic cell, ranging from 0.01% 
when fibroblasts are used (Takahashi and Yamanaka, 2006), to almost 100% if ultra-
proliferative granulocyte-monocyte progenitors are used (Guo et al., 2014). This data 
indicates that reprogramming efficiency is dependent on the proliferation rate of the original 
somatic cells. 
Initially, factors were delivered into target cells by their transduction with constitutively 
active retroviral vectors (Takahashi and Yamanaka, 2006). This is a very clever delivery 
method, since retroviral transgenes become silenced when cells enter pluripotency, blocking 
their further expression upon iPSC generation, in a process that involves both DNA (Silva et 
al., 2008; Stadtfeld et al., 2008b) and histone (Lei et al., 1996) methyltransferases. In order to 
improve the safety of iPSC generation, different strategies were soon developed, such as the 
use of doxycycline-inducible polycystronic vectors encoding all reprogramming factors 
(Carey et al., 2009; Sommer et al., 2009), the use of piggyBac vectors containing loxP sites 
that can be subsequently excised (Kaji et al., 2009; Woltjen et al., 2009), and the delivery of 
reprogramming factors as recombinant proteins (Zhou et al., 2009) or synthetic modified 
messenger RNA (mRNA) (Warren et al., 2010), for example. 
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Other modifications to the initial protocol to increase the efficiency of transcription factor 
induced pluripotency consisted of different culture conditions and the use of small molecules. 
These small molecules can act as modulators of the epigenetic machinery or signalling 
pathways, which in some cases results in the replacement of some reprogramming factors. 
The inhibition of DNA methyltransferases with 5-aza-cytidine (Mikkelsen et al., 2008) or the 
inhibition of histone deacetylase (HDACs) with valproic acid (Huangfu et al., 2008) was 
shown to increase OSKM-mediated reprogramming. Similarly, the use of 2i/LIF conditions 
increases iPSC generation and allows the progression of cells blocked during reprogramming 
named preiPSCs, to naïve pluripotency (Silva et al., 2008). This enhancement of 
reprogramming efficiency is probably due to the combined action of 2i in both the 
establishment and maintenance of the transcription factor network of naïve pluripotency 
(Wray et al., 2011; Ying et al., 2008), and also the induction of PR domain zinc finger protein 
14 (Prdm14) expression, which directly represses de novo methyltransferases Dnmt3a and 
Dnmt3b (Blaschke et al., 2013; Ficz et al., 2013; Habibi et al., 2013; Leitch et al., 2013; 
Yamaji et al., 2013). The inhibition of transforming growth factor- (TGF-β) signalling can 
also increase reprogramming efficiency, and replace the forced expression of Sox2 and c-Myc 
(Ichida et al., 2009; Maherali and Hochedlinger, 2009), probably due to the endogenous 
activation of Nanog expression. The addition of vitamin C to the reprogramming medium was 
also shown to enhance the induction of pluripotency from fibroblasts (Esteban et al., 2010). 
Mechanistically, vitamin C leads to increased expression of histone demethylases Jhdm1a/1b, 
with concomitant reduced histone 3 lysine 36 di- and tri-methylation (H3K36me2/3), 
alleviating cell senescence by removing H4K36me2/3 from the lnk4/Arf (p16/p19) locus, 
repressing its expression (Liang et al., 2012; Wang et al., 2011). Indeed, the expression of the 
Ink4/Arf locus has been shown by many groups to be a major barrier for induced pluripotency 
(Hong et al., 2009; Kawamura et al., 2009; Li et al., 2009a; Marion et al., 2009a; Utikal et al., 
2009). Jhdm1b also cooperates with Oct4 to activate the expression of mesenchymal-to-
epithelial transition (MET) genes, pluripotency-associated microRNAs (miRs) cluster 
302/367, and pluripotency genes (Liang et al., 2012; Wang et al., 2011). Vitamin C was also 
shown to induce global DNA demethylation in mouse ESCs by enhancing ten-eleven 
translocation methylcytosine dioxygenase (TET) activity (Blaschke et al., 2013). Lastly, 
vitamin C was reported to play a positive role in induced pluripotency by regulating H3K9 
methylation status at the core pluripotency genes (Chen et al., 2013a), and also by maintaining 
the correct imprinting status of the Dlk-Dio3 locus by regulating H3K4me3 which attenuates 
its expression levels (Stadtfeld et al., 2012). 
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After a long quest to develop transgene-free reprogramming methods (Li et al., 2013), 
Deng and colleagues showed that the combined inhibition of the signalling pathways and 
some components of the epigenetic machinery is sufficient for the induction of pluripotency 
in mouse fibroblasts (Hou et al., 2013). They demonstrated that medium containing valproic 
acid (HDAC inhibitor), Chiron (Gsk3 inhibitor), 616452 (Tgf inhibitor), TTNPB (synthetic 
retinoic acid receptor ligand), forskolin (cyclic adenosine monophosphate agonist) and 
DZNep (S-adenosylhomocysteine hydrolase inhibitor), followed by 2i culture (medium 
named “VC6TFZ plus 2i”), reprograms mouse fibroblasts to germline-competent iPSCs (Hou 
et al., 2013). It remains to be tested if similar conditions can also reprogram human somatic 
cells.  
Less than a decade has passed since the discovery of iPSCs and significant advances have 
already been made. The manipulation of reprogramming methodologies has not only enabled 
the more efficient generation of better iPSCs, but has also provided some insights into the 
mechanisms governing induced pluripotency. These technologies can now be used to 
understand the biology of induced pluripotency.  
 
1.3.4 – The role of OSKM during induced pluripotency 
The initial Yamanaka cocktail was constituted of the reprogramming factors Oct4, Sox2, 
Klf4 and c-Myc (OSKM). Oct4 and Sox2 are part of the transcription factor core of the naïve 
pluripotency (Young, 2011) and are essential for embryo development (Avilion et al., 2003; 
Nichols et al., 1998). The rationale behind Klf4 and c-Myc is more obscure, since both factors 
are not required for embryo development and ESC maintenance (Baudino et al., 2002; 
Ivanova et al., 2006; Segre et al., 1999). Ablation of ectopic c-Myc was the first modification 
made to the initial reprogramming cocktail (Nakagawa et al., 2008; Wernig et al., 2008), 
which showed that iPSCs could be generated in the absence of the oncogene c-Myc, but that 
comes at the expense of efficiency. All the Yamanaka factors can be replaced by other 
transcription factors, for example: SKM can be replaced by their family homologs (Nakagawa 
et al., 2008); Klf4 and c-Myc can be replaced by Nanog and Lin28 (Yu et al., 2007), or by 
Esrr (Feng et al., 2009); c-Myc can replaced by Glis1 (Maekawa et al., 2011); and Oct4 can 
be replaced by Nr5a1 or Nr5a2 (Heng et al., 2010) or by Tet1 (Gao et al., 2013). Moreover, 
the recently acquired understanding of the downstream effects of each OSKM factor led to the 
generation of new cocktails that can replace OSKM entirely, such as Esrr, Lin28 and Sall4, 
plus Nanog or Dppa2 (Buganim et al., 2012). More surprisingly, it was recently demonstrated 
that lineage-specific transcription factors could replace both Oct4 (replaced by Gata4/6, Sox7, 
C/EBP, HNF4a or Grb2) and Sox2 (replaced by Sox1/3 or Rcor2) during the reprogramming 
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of mouse (Shu et al., 2013) or human fibroblasts (Montserrat et al., 2013). This shows that 
there is a high degree of flexibility among the factors that induce pluripotency.  
As part of an effort to develop reprogramming methods that allow reprogramming factor 
expression without the need for genomic integration of foreign DNA, two independent groups 
have shown that both mouse and human somatic cells can be reprogrammed to pluripotent 
stem cells by forced expression of miRs, completely eliminating the need for ectopic OSKM 
expression (Anokye-Danso et al., 2011; Miyoshi et al., 2011). Two cocktails of miRs that are 
normally highly expressed in ESCs were used: five miRs from the 302/367 cluster (Anokye-
Danso et al., 2011), or seven miRs belonging to the miR302, 200, and 369 families (Miyoshi 
et al., 2011). However, although many other groups reported that reprogramming efficiency 
can be enhanced or that individual “Yamanaka factors” can be replaced by forced expression 
of miRs (Judson et al., 2013; Parchem et al., 2014; Sridharan and Plath, 2011; Subramanyam 
et al., 2011), no further reporters were published about miR-only mediated reprogramming. In 
fact, these two reports failed to be reproduced by different laboratories all over the world. 
Little is known about how the ectopic expression of OSKM drives the conversion of 
somatic cells to a pluripotent state. The oncogene c-Myc has been shown to act predominantly 
during the earlier phases of reprogramming (Polo et al., 2012; Sridharan et al., 2009), a phase 
marked by increased proliferation and the initiation of MET (Li et al., 2010; Mikkelsen et al., 
2008; Samavarchi-Tehrani et al., 2010). Mechanistically, c-Myc induces the down-regulation 
of Tgf-1/2 receptors, resulting in reduced Tgf- signalling, a repressor of MET (Li et al., 
2010; Liu et al., 2013). OSK factors have also have been implicated in the MET regulation. 
Oct4/Sox2 suppress the epithelial-to-mesenchymal transition (EMT) by repressing both SnaiI 
(Li et al., 2010) and Zeb2 expression, through the activation of the miRNA-200 family that 
represses Zeb2 (Wang et al., 2013a). Klf4 was found to enhance MET by inducing epithelial 
genes such as E-cadherin (Li et al., 2010). However, although OSK are involved in a 
facilitation of MET, these factors are more associated with transcriptional changes that occur 
in the later phases of reprogramming (Polo et al., 2012), characterized by the activation of 
core pluripotency circuitry, transgene silencing and complete epigenetic resetting (Apostolou 
and Hochedlinger, 2013; Buganim et al., 2013; Papp and Plath, 2013; Plath and Lowry, 
2011).  
How do OSKM work to assist genome-wide reprogramming? The four OSKM factors 
have been shown to co-occupy open chromatin immediately after transduction, binding the 
promoters of both active and repressed genes (Koche et al., 2011; Sridharan et al., 2009). 
Adding to this fact, the three factors, OSK, bind to distal elements with high nucleosome 
occupancy that lack pre-existing histone modifications (Soufi et al., 2012). These genomic 
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sites are different from the ones bound by these pluripotency factors in pluripotent cells 
(Koche et al., 2011), which led to the notion that OSK are “pioneer factors” that guide 
reprogramming through promiscuous binding to distal enhancers (Soufi et al., 2012) (Figure 
1.3.1). The “pioneer” OSK factors might be responsible for chromatin remodelling and the 
activation of genes that are essential for the establishment and maintenance of pluripotency 
(Soufi et al., 2012). This process is likely to be facilitated by the recruitment of other factors 
like c-Myc, which has been recently hypothesized to act as general amplifier of gene 
expression by increasing the transcription of active promoters (Lin et al., 2012; Nie et al., 
2012). In addition to the possibility that Oct4 and Klf4 might act as “pioneer factors” to 
induce pluripotency, they also have an established function in promoting the establishment 
and maintenance of the core pluripotency circuitry (Hall et al., 2009). 
Although the molecular mechanisms underlying induced pluripotency are still very much 
a black box, some evidence suggest that OSK drive genome-wide remodelling through their 
promiscuous interaction with closed chromatin, leading to the activation of pluripotency 
genes (Soufi et al., 2012). This process seems to be facilitated by c-Myc, which not only leads 
to increased proliferation, which is extremely important for reprogramming, but also enhances 
transcription (Lin et al., 2012; Nie et al., 2012). Since recent evidence has shown that the 
OSKM factors can be replaced by lineage specifiers (Montserrat et al., 2013; Shu et al., 
2013), or by a completely different set of transcription factors (Buganim et al., 2012), or even 
by chemical compounds (Hou et al., 2013), it is of interest to address if cells being 
reprogrammed by alternative approaches pass through the same sequence of events described 
above.  
 
1.3.4 – Epigenetic changes during induced pluripotency 
Induced pluripotency is fundamentally an epigenetic phenomenon. Cell specialization 
from pluripotent cells during embryonic development or during in vitro differentiation is 
characterized by extensive chromatin remodelling that results mainly in the deposition of 
repressive marks followed by chromatin compaction (Gifford et al., 2013; Xie et al., 2013; 
Zhu et al., 2013). For induced pluripotency to occur, this somatic epigenetic signature has to 
be erased and a new pluripotency epigenome has to be established. Changes include, but are 
not restricted to, global chromatin organization, the resetting of post-translational histone 
modifications, DNA demethylation of key pluripotency genes and the re-activation of inactive 
X chromosome (Mikkelsen et al., 2008; Polo et al., 2012; Stadtfeld et al., 2008b; Wernig et 
al., 2007). In this section I will review how chromatin evolves during induced pluripotency, 
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elucidating the roles of main chromatin marks and chromatin regulators during 
reprogramming. 
For somatic cells to be stably reprogrammed to a pluripotent state, somatic chromatin has 
to be dismantled, meaning that the reprogramming factors have to engage with the epigenetic 
machinery. Recent studies shown that OSKM binding correlates with immediate changes in 
histone modification early after reprogramming initiation (Koche et al., 2011; Polo et al., 
2012; Soufi et al., 2012; Sridharan et al., 2009). This leads to the hypothetical assumption that 
the binding of OSKM throughout the genome somehow marks regions that will ultimately be 
remodelled. Three different classes of genes can be defined, based on OSKM accessibility, 
histone marks and kinetics of chromatin remodelling and transcription: somatic and EMT 
genes, early pluripotency and MET genes, and late pluripotency genes (Figure 1.3.1). Somatic 
and EMT genes, such as the fibroblast-specific and EMT gene SnaiI, are transcriptionally 
active and marked by an open chromatin state and H3K4me2/3 activation-associated marks in 
somatic cells (Soufi et al., 2012). These are immediately bound by OSKM without the need of 
further chromatin remodelling, starting to lose H3K4me2/3 and become heterochromatic, 
acquiring H3K27me3 marks, which results in transcriptional silencing (Koche et al., 2011; 
Soufi et al., 2012). Early pluripotency-associated and MET genes, such Fbx15 and Sal-like 
protein 4 (Sall4), whose early activation is essentially required for induced pluripotency, are 
marked by repressive marks such as H3K27me3 and are transcriptionally inactive in somatic 
cells (Soufi et al., 2012). Hours after OSKM induction, OSK “pioneer” factors quickly 
occupy the enhancers of these genes, allowing the remodelling of these high-density 
nucleosome regions, leading to the deposition of H3K4me2/3 at enhancers and promoters, 
which results in gene re-activation a few days later (Koche et al., 2011; Soufi et al., 2012). A 
third class of genes include the late pluripotency genes, such as Nanog and Sox2, whose 
enhancers and promoters contain H3K27me3 and H3K9me2/3 repressive marks in somatic 
cells, and are refractory to OSKM binding (Buganim et al., 2012; Soufi et al., 2012). These 
genes require more chromatin remodelling for OSKM binding and transcriptional activation, 
and are re-activated only at later stages of the reprogramming process (Mikkelsen et al., 2008; 
Polo et al., 2012; Soufi et al., 2012). The generated iPSCs fully reactivate the expression of 
pluripotency genes, that now contain high levels of H3K4me2/3, and silence genes from the 
original somatic cells and mark them with H3K27me3 (Mikkelsen et al., 2008; Polo et al., 
2012; Soufi et al., 2012).  
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Figure 1.3.1 – OSKM binding and Chromatin remodelling during induced pluripotency. 
Three classes of genes can be grouped based on their transcriptional activation/ repression 
kinetics: somatic and EMT genes, early pluripotency and MET genes, and late pluripotency genes. 
Somatic and EMT genes are marked by H3K4me2/3 in somatic cells, are immediately bound by 
OSKM after ectopic expression and start to accumulate H3K27me3 and methylated DNA, becoming 
transcriptionally inactive. Early pluripotency and MET genes which are hypermethylated and marked 
by H3K27me3, are transcriptionally inactive in somatic cells, are occupied by OSK “pioneer” factors 
immediately after OSKM induction, which allows their remodelling and transcriptional activation. 
Late pluripotency genes are enriched for H3K9me2/3 and H3K27me3 marks in somatic cells which 
repress OSKM binding, resulting in delayed transcriptional re-activation. Re-activation of 
pluripotency genes is marked by complete enhancer and promoter demethylation, which requires an 
intermediate step of 5- methylcytosine (5-mC) oxidation to 5-hydroxymethylcytosine (5-hmC) prior to 
pluripotency entry. 
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Stable reprogramming of somatic cells requires the full and persistent re-activation of 
pluripotency associated genes, together with the complete silencing of somatic genes. This is 
possible due to the complete demethylation of enhancers and promoters of ESC-related genes, 
and the hypermethylation of the somatic genes (Mikkelsen et al., 2008; Wernig et al., 2007) 
(Figure 1.3.1). Whereas changes in histone modification begin to occur early during 
reprogramming, driving the initiation of this process, DNA demethylation occurs only late in 
the process (Polo et al., 2012). This is in accordance with what is observed during cell 
differentiation, where changes in histone modification typically precede DNA methylation 
changes, indicating that DNA methylation is a more stable modification required for the 
stabilization of cellular phenotype (Gifford et al., 2013; Xie et al., 2013). Both passive 
(replication-dependent) and active demethylation mechanisms have been shown to play a 
pivotal role in induced pluripotency. Inhibition of DNA demethylation maintenance by DNA 
methyltransferase Dmnt1 inhibition enhances reprogramming efficiency (Mikkelsen et al., 
2008). Active DNA demethylation, involving oxidation of methylcytosines (5-mC) to 
hydroxymethylcytosines (5-hmC) by Tet enzymes followed by thymine DNA glycosylase 
(TDG)-mediated base excision repair into unmodified cytosine (Kohli and Zhang, 2013), is 
required for efficient reprogramming. Tet2 mediates the priming of key pluripotency genes, 
such as Esrr and Nanog, early after OSKM induction by promoting active DNA 
demethylation (Di Stefano et al., 2014; Doege et al., 2012), and the ectopic expression of 
Tet1/2 with Nanog was shown to increase reprogramming efficiency (Costa et al., 2013). Due 
to Tet-mediated re-activation of the Oct4 locus, Tet1 can substitute for ectopic Oct4 
expression in reprogramming (Gao et al., 2013). Moreover, Tet1/2/3 triple-knockout (KO) 
somatic cells show reduced reprogramming efficiency, maybe due to a failure in the 
activation of MET genes (Hu et al., 2014), although Tet1
-/- 
(Dawlaty et al., 2011), Tet1/2 
double-KO (Dawlaty et al., 2013), or Tet1/2/3 triple-KO mice (Wang et al., 2013b), which 
exhibit aberrant methylation levels, are viable and fertile. The poly ADP-ribose polymerase 1 
(Parp1) was also shown to promote induced pluripotency, by the regulation 5-mC levels, and 
thus 5-hmC levels, which are required for Oct4 activation (Doege et al., 2012). Lastly, one 
group reported that activation-induced cytidine deaminase-dependent (Aid) DNA 
demethylation is required for the generation of high-quality iPSCs (Kumar et al., 2013). 
However, further work from others groups revealed that Aid is dispensable for induced 
pluripotency (Habib et al., 2014; Shimamoto et al., 2014). 
More than 100 different histone post-translational modifications have been identified 
(Bannister and Kouzarides, 2011; Bernstein et al., 2007; Kouzarides, 2007). Above I 
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described the kinetics of the deposition or removal of key chromatin markers after the 
induction of the reprogramming factors. In the Table 1.3.1 other selected chromatin marks 
that have been identified as playing an important role induced pluripotency are listed, as well 
as some examples of their dynamics during reprogramming.  
 
Table 1.3.1 – List of selected chromatin marks and their role during induced pluripotency. 
Chromatin 
mark 
Assumed function  Dynamics during 
reprogramming (example) 
References 
H3K4me1 Marks active or 
poised enhancers 
Increase at proliferation and 
metabolism genes 
(Creyghton et al., 2010; 
Rada-Iglesias et al., 
2011) 
H3K4me2 Marks active or 
poised enhancers 
and promoters 
Decrease at somatic genes; 
Increase at pluripotency 
genes 
(Koche et al., 2011; 
Soufi et al., 2012; 
Sridharan et al., 2009) 
H3K4me3 Marks TSS of 
active and poised 
genes 
Decrease at somatic genes; 
Increase at proliferation, 
metabolism and 
pluripotency genes 
(Koche et al., 2011; 
Maherali et al., 2007; 
Soufi et al., 2012; 
Sridharan et al., 2009) 
H3K9me3 Marks 
heterochromatic 
regions 
Decrease at late 
pluripotency genes 
(Chen et al., 2013b; 
Soufi et al., 2012; 
Sridharan et al., 2013) 
H3K9ac Marks TSS of 
active genes 
Increase at Oct4 targets (Esch et al., 2013; 
Singhal et al., 2010) 
H3K27me3 Marks repressed 
genes 
Increase at somatic and 
EMT genes; Decrease at 
pluripotency genes 
(Koche et al., 2011; 
Maherali et al., 2007; 
Mansour et al., 2012; 
Polo et al., 2012; 
Sridharan et al., 2009) 
H3K27ac Marks open 
chromatin and 
active enhancers 
Global increase during 
reprogramming, mainly at 
pluripotency genes 
(Creyghton et al., 2010; 
Mattout et al., 2011; 
Rada-Iglesias et al., 
2011) 
H3K36me2 Marks potential 
regulatory regions 
Increase at early 
pluripotency genes 
(Liang et al., 2012; Wang 
et al., 2011) 
H3K36me3 Marks active genes Increase at pluripotency 
genes 
(Koche et al., 2011; 
Liang et al., 2012; Wang 
et al., 2011) 
H3K79me2 Marks active genes Decrease at MEF and EMT 
genes 
(Onder et al., 2012) 
H1citR54 Marks chromatin 
decondensation 
Increase at pluripotency 
genes 
(Christophorou et al., 
2014) 
5-mC Marks repressed 
genes 
Deposited at somatic genes; 
Erased from pluripotency 
genes 
(Mikkelsen et al., 2008; 
Polo et al., 2012; Wernig 
et al., 2007) 
5-hmC Marks gene 
reactivation and 
priming 
Increase at MET and  
pluripotency genes (Oct4, 
Esrr) 
(Chen et al., 2013a; 
Costa et al., 2013; Doege 
et al., 2012; Gao et al., 
2013; Hu et al., 2014) 
27 
 
H: Histone; K: Lysine; R: Arginine; me: methylation; ac: acetylation; cit: Citrullination; 5-mC: 5-
methylcytosine; 5-hmC: 5-hydroxymethylcytosine; TSS: transcription start site; MET: mesenchymal-
to-epithelial transition; EMT: epithelial-to-mesenchymal transition; MEFs: mouse embryonic 
fibroblasts. 
 
As seen in Table 1.3.1, nuclear reprogramming is accompanied by a complete change in 
histone modification patterns, indicating that induced pluripotency is controlled by the 
kinetics of histone modification. This means that the efficiency and kinetics of nuclear 
reprogramming can be enhanced by manipulating the expression of chromatin modifying 
enzymes and proteins involved in the “writing”, “reading” or “erasing” of chromatin marks. 
Based on the outcome after depletion and/ or overexpression of different chromatin 
modulators, they can be considered as “drivers” (D) or “blockers” (B) of induced pluripotency 
(Table 1.3.2). In the context of this thesis, “drivers” of reprogramming are chromatin 
modulators whose activity facilitate or is required for induced pluripotency. Consequently, 
their pharmacological inhibition or protein deletion usually results in reduced reprograming 
efficiency, while their pharmacological activation or protein overexpression results in 
enhanced reprogramming efficiency. Conversely, “blockers” of reprogramming are chromatin 
modulators that inhibit reprogramming, which means that their depletion or inhibition 
increases reprogramming efficiency, and/ or their overexpression or enhanced activation 
decreases it. By applying these criteria, several “drivers” and “blockers” of induced 
pluripotency were identified (Table 1.3.2). They were divided into different categories: 
histone demethylases, histone methyltransferases, histone variants, chromatin remodellers, 
proteins involved in the 3D chromatin organization, DNA methylation, and others. Table 
1.3.2 also includes a description of their roles in reprogramming. 
 
Table 1.3.2 – List chromatin modulators and their main role during induced pluripotency. 
 Chromatin 
modulator 
D/B Function and role in reprogramming References 
H
is
to
n
e 
d
em
et
h
y
la
se
s 
Jmjd1a/b 
(Kdm3a/b), 
Jmjd2c 
(Kdm4c) 
D H3K9 demethylases; KD reduces 
reprogramming; OE enhances reprogramming; 
Regulates dynamic switch between open-close 
chromatin 
(Chen et al., 
2013b) 
Cbx3 B H3K9me “reader”; KD reduces reprogramming 
by repressing Nanog expression together with 
H3K9 methyltransferases  
(Sridharan et al., 
2013) 
Jmjd3 B H3K27 demethylase; KO enhances 
reprogramming; Suppresses lnk4/Arf locus 
(senescence) and targets PHF20, required for 
Oct4 expression, for ubiquitination 
 
(Zhao et al., 
2013) 
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Utx 
(Kdm6a) 
D H3K27 demethylase; KO reduces 
reprogramming by inefficient H3K27me 
demethylation of pluripotency genes 
(Mansour et al., 
2012) 
Jhdm1a/b 
(Kdm2a/b) 
D H3K36 demethylases; KD reduces 
reprogramming; OE enhances reprogramming; 
Cooperate with Oct4, Required for early 
activation of MET and pluripotency genes, and 
repression of lnk4/Arf locus 
(Liang et al., 
2012; Wang et 
al., 2011) 
H
is
to
n
e 
m
et
h
y
lt
ra
n
sf
er
a
se
s 
Ehmt1 
(G9a), 
Ehmt2, 
Setdb1, 
(ESET), 
Suv39h1/2 
B H3K9 methyltransferases; KD enhances 
reprogramming by allowing more efficient 
OSKM binding genes in somatic cells marked 
by H3K9me3 
(Chen et al., 
2013b; Onder et 
al., 2012; 
Sridharan et al., 
2013) 
PRCs (Ezh2, 
Eed, Suz12, 
Bmi1, 
Ring1) 
D H3K27 methyltransferases; KD reduces 
reprogramming; Required for maintaining a 
transcriptional gene repression  
(Fragola et al., 
2013; Onder et 
al., 2012) 
Dot1L B H3K79 methyltransferase; KD or chemical 
inhibition enhances reprogramming by 
repressing expression of EMT genes 
(Onder et al., 
2012) 
Wdr5 
complex 
D H3K4me “effector”, member of mammalian 
Trithorax complex; KD reduces 
reprogramming; Interacts with Oct4 and 
facilitates activation of pluripotency genes 
(Ang et al., 
2011) 
H
is
to
n
e 
v
a
ri
a
n
ts
 macroH2A B Histone variant; KD enhances reprogramming; 
OE reduces reprogramming; Maintain 
pluripotent genes in repressed state  
(Gaspar-Maia et 
al., 2013; 
Pasque et al., 
2012) 
TH2A/B D Histone variant; OE enhances reprogramming; 
Required to induce transcriptionally active open 
chromatin 
(Shinagawa et 
al., 2014) 
C
h
ro
m
a
ti
n
 r
em
o
d
el
le
rs
 
Chd1 D Chromatin-remodeler; KD reduces 
reprogramming; Required for chromatin 
decondensation at pluripotent genes 
(Gaspar-Maia et 
al., 2009) 
SWI/SNF 
(Baf155, 
Brg1, Brm) 
D Chromatin-remodelling complex (also known 
as BAF); OE enhances reprogramming; 
enhance Oct4 binding by increasing H3K4me3 
and H3K9ac euchromatin marks and 
demethylation at pluripotency genes 
(Esch et al., 
2013; Singhal et 
al., 2010) 
INO80 
complex 
D Chromatin-remodelling complex; KD reduces 
reprogramming; Required for Mediator and 
RNA polymerase II recruitment for 
pluripotency genes activation 
 
(Wang et al., 
2014) 
3
D
 C
h
ro
m
a
ti
n
 Cohesin-
mediator 
complexes 
D Architectural proteins; KD reduces 
reprogramming by blocking long-range 
chromatin interactions (Oct4 intrachromosomal 
looping and Nanog locus genome-wide 
interactions) induced by OSKM that contribute 
for activation of pluripotency genes 
 
(Apostolou et 
al., 2013; Wei et 
al., 2013; Zhang 
et al., 2013) 
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D
N
A
 m
et
h
y
la
ti
o
n
 
Dnmt1 B DNA methyltransferase; KD or chemical 
inhibition enhances reprogramming by 
enhancing demethylation of pluripotency genes 
(Mikkelsen et 
al., 2008) 
Dnmt3a/b X de novo DNA methyltransferase; Double-KO 
cells reprogram with same efficiency as wild 
type cells; Dispensable for reprogramming 
(Pawlak and 
Jaenisch, 2011) 
Tet1/2/3 D Methylcytosine dioxygenases that oxidase 5-
mC to 5-hmC; Triple-KO block 
reprogramming; Prime pluripotency (Esrr, 
Oct4) and MET genes activation; Tet1/2 OE 
enhance Nanog-mediated reprogramming 
(Costa et al., 
2013; Doege et 
al., 2012; Gao et 
al., 2013; Hu et 
al., 2014) 
Parp1 D Poly ADP-ribose polymerase; KO blocks 
reprogramming; Regulates 5-mC and Oct4 
recruitment at pluripotency genes 
(Doege et al., 
2012) 
Aid X DNA demethylation; KO cells reprogram with 
same efficiency as wild type cells; Dispensable 
for reprogramming 
(Habib et al., 
2014; Kumar et 
al., 2013; 
Shimamoto et 
al., 2014) 
O
th
er
s 
Hdacs B Histone deacetylases; Chemical inhibition 
enhances reprogramming by activation of 
pluripotency genes 
(Huangfu et al., 
2008; Mali et 
al., 2010) 
Padi4 D Citrullination of arginine residues; KD reduces 
reprogramming; Disrupts the binding of H1 
from chromatin, resulting in decondensation 
(Christophorou 
et al., 2014) 
Terc D Telomerase; KO reduces reprogramming; 
Required for rejuvenation of telomeres to ESC-
like state; Decrease of H3K9m3 repressive 
mark at telemetric regions during 
reprogramming 
(Marion et al., 
2009b) 
TFIID D Regulates RNA polymerase II function; KD 
reduces reprogramming; Together with OSKM 
induce stable pluripotency genes expression  
(Pijnappel et al., 
2013) 
Brca1/2, 
Rad51 
D Homology-directed DNA repair; KO reduces 
reprogramming; OSKM increases DNA DSB 
marker H2AX levels; p53 deletion rescues 
reprogramming defects of Brca1/2-null MEFs   
(Gonzalez et al., 
2013) 
SCC/XPC D Nucleotide excision repair complex; KD 
reduces reprogramming; co-activator of Oct4 
and Sox2 for Nanog and Oct4 activation 
(Fong et al., 
2011) 
 
D/B: “Driver” (facilitates), or “Blocker” (inhibits) of induced pluripotency (see text for 
definition”). X – “Driver” or “Blocker” definition does not apply; OE: overexpression; KD: 
Knockdown; KO: Knockout; Jmjd1a/b: Jumonji domain-containing 1a/b; Cbx3: Chromobox homolog 
3; Jhdm1a/b: Jumonji domain-containing histone demethylase 1a/b; Utx: Lysine-specific demethylase 
6a; Ehmt1/2: Histone-lysine N-methyltransferas 1/2; Setdb1: SET domain, bifurcated 1; Suv39h1/2: 
Suppressor of variegation 3-9 homolog 1; PRCs: Polycomb repressive complexes; Ezh2: enhancer of 
zeste homolog 2; Eed: embryonic ectoderm development; Suz12: Suppressor of zeste 12; Bmi1: B 
lymphoma Mo-MLV insertion region 1 homolog; Dot1L: DOT-like 1; Wdr5: WD repeat domain 5; 
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TH2A/B: Testis-specific H2A/B; Chd1: Chromodomain helicase DNA binding protein 1; SWI/SNF: 
SWItch/Sucrose Non-Fermentable; Baf155: BRG1-associated factor 155; Brg1: Brahma-related gene 
1; Brm: Brahma; Dnmt1: DNA methyltransferase 1; Dnmt3a/b: de novo DNA methyltransferase 3a/b; 
Tet1/2/3: Ten-eleven translocation methylcytosine dioxygenase 1/2/3; Parp1: Poly-(ADP-ribose) 
polymerase 1; Aid: Activation-induced cytidine deaminase; Hdac: Histone deacetylase; Padi4: 
Peptidylarginine deiminase 4; Terc: Telomerase RNA component; TFIID: Transcription factor IID; 
Brca1/2: Breast cancer type 1/2 susceptibility protein; SCC/XPC: stem cell co-activator complex/ 
Xeroderma pigmentosum complementation group c; PHD20: PHD finger protein 20; DSD: Double-
strand break; H2AX: phosphorylated histone H2AXH: Histone; K: Lysine; me: methylation; ac: 
acetylation; EMT: epithelial-to-mesenchymal transition; MET: mesenchymal-to-epithelial transition 
 
In summary, all evidence suggests that the re-establishment of a pluripotent epigenetic 
state is the main feature during reprogramming. In addition to local chromatin, whose 
repressive environment presents a major barrier somatic cell reprogramming, 3D chromatin 
architecture has also been implicated in induced pluripotency. Indeed, by assessing Oct4 locus 
intrachromosomal looping and Nanog locus genome-wide chromatin interactions, it was 
demonstrated which enhancer–promoter co-associations were unique to pluripotent cells and 
that these are required for transcriptional activation of pluripotency genes during 
reprogramming (Apostolou et al., 2013; Wei et al., 2013; Zhang et al., 2013). Further studies 
will aim to better understand the interaction between the induction of the reprogramming 
factors, and the resetting of the somatic and the establishment of the pluripotent epigenome. It 
will also be very important to understand the epigenetic events that take place during 
reprogramming using different reprogramming methodologies, such as chemical 
reprogramming, and compare them to transcription factor-mediated reprogramming. New 
clues about the molecular sequence of events might emerge from those comparisons. 
 
1.3.5 – Role of Oct4 and Nanog on induced pluripotency 
Once the pluripotent state is re-established after the forced expression of exogenous 
factors, it is maintained by the re-activation of the endogenous pluripotency-associated 
transcription circuitry. As seen in section 1.1.4, pluripotency is maintained by an intricate 
inter-connection between signalling pathways and different transcription factors which control 
cell function. Of these, Nanog, Oct4 and Sox2 are the main components of the pluripotency 
network, playing crucial roles in induced pluripotency.  
Nanog was not a part of the original reprogramming cocktail, but selection of the 
emerging colonies for endogenous Nanog and Oct4 expression enabled the isolation of germ-
line competent iPSCs (Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007). Nanog 
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overexpression enhances OSKM-mediated reprogramming (Hanna et al., 2009; Theunissen et 
al., 2011b), and when used in combination with other defined factors can completely 
substitute OSKM in reprogramming (Buganim et al., 2012). Tet1/2 and Nanog co-
overexpression can boost reprogramming efficiency even further (Costa et al., 2013). Initial 
reports described that endogenous Nanog is not required for initial stages of reprogramming, 
being extremely required for final stages of reprogramming during 2i/LIF culture (Silva et al., 
2009), which could be rescued by ectopic expression of mouse Nanog or its homologs and 
orthologues (Theunissen et al., 2011a). Further studies indicate that Nanog can be bypassed if 
its downstream targets are ectopically provided, such as Esrrb (Festuccia et al., 2012), or 
activated STAT3 in combination with Esrrb or Klf4 (Stuart et al., 2014). Moreover, using 
different reprogramming protocols, it was recently shown that Nanog-null mouse embryonic 
fibroblasts (MEFs) can be reprogrammed to iPSCs, although at lower efficiencies than wild 
type MEFs (Carter et al., 2014), a process which can be enhanced if vitamin C is provided 
(Schwarz et al., 2014). 
The role of Oct4 in induced pluripotency has been extensively studied since the discovery 
of iPSCs. Oct4 is the only “Yamanaka factor” that cannot be replaced by members of its 
family, Oct1 and Oct6 (Nakagawa et al., 2008), but can be replaced by its human and xenopus 
homologues, or medaka and axolotl ortologues (Esch et al., 2013; Tapia et al., 2012). Oct4 
can also be replaced by Nr5a1/2 (Heng et al., 2010) or by Tet1 (Gao et al., 2013), but in both 
cases that seems to be possible due to the activation of endogenous Oct4. Importantly, Oct4 is 
the only “Yamanaka factor” that can induce reprogramming of somatic cells alone. Studies 
from the Scholer laboratory shown that Oct4 overexpression is sufficient to induce 
pluripotency from neural stem cell (Kim et al., 2009a; Kim et al., 2009b). Genetic Oct4 
deletion ablates reprogramming (unpublished data by our laboratory), which is in accordance 
with the fact that Oct4
-/-
 ESCs cannot be maintained and differentiate into trophectoderm 
(Niwa et al., 2000). Interestingly, rescue experiments showed that independently of the Oct4 
transgene levels in reprogramming intermediates, the resulting iPSCs exhibited a defined 
ESC-level of Oct4 (Radzisheuskaya et al., 2013). These results demonstrated that endogenous 
Oct4 is essential for induced pluripotency, which does not seem to be the case for SCNT-
mediated reprogramming, since enucleated Oct4
-/-
 oocytes can reprogram somatic cells back 
to pluripotency (Wu et al., 2013). 
The role of Sox2 in induced pluripotency has been less characterized. Since Sox2 is 
indispensable for ESC maintenance (Masui et al., 2007), it is acceptable to say that the re-
establishment of pluripotency is not possible in the absence of endogenous Sox2. However, 
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the Sox2 levels which are tolerable for induced pluripotency, and the time window where 
Sox2 is required, are questions which remain open.  
As described above and in the previous sections, Nanog and Oct4 play essential roles in 
the establishment and maintenance of pluripotency, both in vitro and in vivo. This has 
stimulated many scientists to understand their mechanisms of action. One way to identify 
those mechanisms is to identify their protein interactome, which might reveal core 
interactions which control Nanog and Oct4 function. Nanog protein-protein interactions have 
been extensively studied. The Nanog protein interactome in ESCs was analysed by mass-
spectrometry analysis and was first reported in 2006 (Wang et al., 2006). This was recently 
refined and expanded by two independent laboratories (Costa et al., 2013; Gagliardi et al., 
2013). The Oct4 protein interactome in ESCs was unveiled in 2010 (Pardo et al., 2010; van 
den Berg et al., 2010), and then further expanded in 2012 (Ding et al., 2012). An interactome 
map of Nanog and Oct4 proteins, together with the identified interactomes of other 
transcription factors, such as Essr, Sall4, Nr0b1 and Tcfcp2l1, has been created by the 
Chambers laboratory and is shown in Figure 1.3.2. 
 
 
 
 
 
 
 
 
 
 
 
(figure on next page) 
Figure 1.3.2 – Nanog and Oct4 protein interactomes. 
Map of identified protein-protein interaction centred on Nanog and Oct4, together with 
interaction centred on other ESC-specific transcription factors Essr, Sall4, Nr0b1 and Tcfcp2l1. Blue 
circles correspond to the Nanog interactions found by the Chambers laboratory (Gagliardi et al., 
2013), whereas the pink circles are the protein interacts of the other protein-protein interaction studies 
centred on other transcription factors (green) discovered by the Poot and Chambers laboratories (van 
den Berg et al., 2010). The Nucleosome remodelling and Deacetylase complex (NuRD), a common 
interactor of many transcription factors, including Nanog and Oct4, is also indicated. Image adapted 
from (Gagliardi et al., 2013). 
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Analysis of all published Nanog and Oct4 protein interaction networks revealed that 
amongst their highest-confident interactors are not only other core transcription components, 
but also multiple proteins with an epigenetic function (Costa et al., 2013; Ding et al., 2012; 
Gagliardi et al., 2013; Pardo et al., 2010; van den Berg et al., 2010). This indicates that Nanog 
and Oct4 might control the pluripotent state by engaging with multiple components of the 
epigenetic machinery. Oct4 has been found to interact with multiple subunits of different 
chromatin-modifying complexes with documented roles in development and ESC function 
(Ding et al., 2012; Pardo et al., 2010; van den Berg et al., 2010). The Oct4 high-confidence 
interactors are the members of the Nucleosome Remodelling and Deacetylation (NuRD), such 
as ATP-dependent chromatin remodeler Mi-2, the GATA zinc finger domain containing 2A 
and 2B (Gatad2a/b), the histone deacetylases 1 and 2 (Hdac1/2), the methyl-CpG-binding 
domain 3 (Mbd3), the metastasis associated proteins 1, 2 and 3 (Mta1/2/3) and the 
retinoblastoma binding protein 7 (Rbbp7) (Ding et al., 2012; Pardo et al., 2010; van den Berg 
et al., 2010). The same holds true for Nanog, where chromatin regulators rank very high in its 
protein network, which includes Tet1 and all components of the NuRD complex which 
interact with Oct4 except Rbbp7 and Hdac1 (Costa et al., 2013; Gagliardi et al., 2013). Of all 
the core members of the NuRD complex, only Rbbp4 was not found to interact with either 
Oct4 or Nanog. Although many other chromatin regulators have been studied in the context of 
induced pluripotency (previous section), the role the NuRD complex in reprogramming was 
not addressed until the start of this thesis. 
Reprogramming is an epigenetic process where the epigenetic machinery plays a pivotal 
role in the establishment and maintenance of pluripotency. Taking into account that one the 
key components of the epigenetic machinery, the NuRD complex, is a high-confidence 
interactor of both Nanog and Oct4, I decided to investigate its function in induced 
pluripotency. In the next section I will review current knowledge about the role of the NuRD 
complex during early embryo development and in ESC biology. 
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1.4 – Nucleosome Remodelling and Deacetylase complex 
The NuRD complex was first purified in 1998 using nuclear extracts of human cells 
(Tong et al., 1998; Xue et al., 1998; Zhang et al., 1998) and Xenopus laevis eggs (Wade et al., 
1998). The NuRD complex was described after immunoprecipitation of the ATP-dependent 
chromatin remodeler Mi-2, which was discovered three years earlier as an auto-antigen in 
dermatomyositis (Ge et al., 1995; Seelig et al., 1995). Closer inspection of the purified large 
multi-subunit complex led to the description of its initially identified subunits: Hdac1/2, 
Rbbp4 and 7 and Mta1. NuRD is the only complex with histone deacetylase and ATP-
dependent chromatin remodelling activity, provided by Hdac1/2 and Mi-2a/ subunits, 
respectively (Lai and Wade, 2011; McDonel et al., 2009). Further characterization of the 
NuRD complex revealed the other core subunits: Mbd2 and 3 (Hendrich and Bird, 1998; 
Wade et al., 1999; Zhang et al., 1999), Mta2 (Zhang et al., 1999) and Mta3 (Fujita et al., 
2004; Fujita et al., 2003), and the Gatad2a and 2b (Gatad2a/b) (Brackertz et al., 2006) (Figure 
1.4.1A). Other proteins have been hypothesized to be a part of the NuRD complex, such as 
the cell-cycle inhibitor Cdk2ap1 (Le Guezennec et al., 2006) and the proteins of the Sall 
family (Lauberth and Rauchman, 2006; Lu et al., 2009; Yuri et al., 2009), which will not be 
discussed in this thesis. After its initial purification from xenopus and human cells, 
homologues of the complex were found in many different species, including Arabidopsis 
thaliana (Ahringer, 2000; Ogas et al., 1999), Drosophila melanogaster (Tweedie et al., 1999; 
Wade et al., 1999), and mouse (Hendrich and Bird, 1998; Wade et al., 1999; Zhang et al., 
1999). Two NuRD complexes with different biochemical and functional properties can be 
isolated, Mbd2/NuRD or Mbd3/NuRD, and the main difference between them is the mutually 
exclusive use of either Mbd2 or Mbd3 (Le Guezennec et al., 2006). Generally, Mi-2 is the 
ATPase subunit assembled in the NuRD complex, but in some cases, this can be replaced by 
Mi-2 (Allen et al., 2013). In the context of this thesis, the NuRD complex refers to the 
Mbd3/Mi-2/NuRD complex. 
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Figure 1.4.1 – The architecture of the NuRD complex. 
(A) Schematic representation of the NuRD complex.  The core components of the complex are 
represented, and the way they connect between each other reflects validated interactions. Several 
subunits have been shown to interact with DNA or histones, or with other co-factors (Co-F), which 
modulate NuRD function and specificity (Allen et al., 2013). (B) Schematic structure of the core 
subunits of the NuRD complex. PHD1/2: Plant homeodomain 1/2; CD1/2: Chromodomains 1/2; 
DUF1/2: Domains of unknown function 1/2; RB: Retinoblastoma; GR: Glycine-Arginine; MBD: 
Methyl-CpG-binding domain; TDR: Transcriptional repression domain; CC: Coiled-coil motif; E: 
Glutamic acid; WD: Tryptophan-aspartic acid; BAH: Bromo-adjacent homology; ELM: Egl-27 and 
MTA1 homology domain; SANT: domain found in the SWI-SNF, ADA, the co-repressor N-CoR and 
TFIIIB; GATA-ZnF: GATA zinc finger; CR1/2: Conserved regions 1/2. 
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Mi-2 (220kDa) is the largest component of the NuRD complex and is encoded by the 
Chd4 gene. It was first identified as autoantigen in an autoimmune disease dermatomyositis 
(Ge et al., 1995; Seelig et al., 1995). It contains multiple functional domains: two plant 
homeodomains (PHD) which bind to H3K4 and H3K9me3 residues (Mansfield et al., 2011; 
Musselman et al., 2009); two chromodomains (CD) which bind to DNA (Bouazoune et al., 
2002); an ATPase/ helicase domain which binds nucleosomes and uses energy provided from 
ATP hydrolysis to move them (Bouazoune et al., 2002); and two domains of unknown 
function (DUF) (Figure 1.4.1B).  On top of being a defining member of the NuRD complex, 
much evidence suggest that Mi-2 also functions independently of NuRD, playing important 
roles in cell cycle regulation and the DNA-damage response (Amaya et al., 2013; 
O'Shaughnessy and Hendrich, 2013).  
Hdac1 and 2 (50kDa) are histone deacetylases with one Hdac domain each and they 
catalyse the removal of acetyl groups from histone tails, resulting in chromatin compaction 
and transcriptional repression (Figure 1.4.1B). In addition to NuRD, they can also be a part of 
other complexes, such as Sin3A, CoREST, NCoR/SMRT and ESC-specific NODE (Allen et 
al., 2013).  
Mbd3 (30kDa) is a member of the methyl-CpG-binding domain (MBD) family of 
proteins that, in contrast to the other four members (including Mbd2), does not bind 
methylated DNA (Hashimoto et al., 2012; Saito and Ishikawa, 2002). Yet, Mbd3 has been 
shown to bind to hydroxymethylated DNA (Hashimoto et al., 2012; Yildirim et al., 2011). On 
top of the MBD, Mbd3 contains a coiled-coil (CC) motif and a poly-glutamate (E) region, 
whose function is unknown (Allen et al., 2013) (Figure 1.4.1B). Mbd3 is essential for keeping 
all NuRD subunits together, acting as a scaffold protein, in the absence of which the complex 
is not assembled (Kaji et al., 2006). 
Rbbp4 and 7 (50kDa) are composed of a region of tryptophan-aspartic acid (WD) repeats, 
which have been shown to bind to histone H4 (Murzina et al., 2008) and the co-factor friend 
of GATA 1 (FOG-1) (Lejon et al., 2011) (Figure 1.4.1B). They were first purified through 
their interaction with the retinoblastoma tumour suppressor (Qian et al., 1993), and bind to 
many chromatin-modifying complexes, such as NuRD, Sin3A and PRC2 (Allen et al., 2013). 
Mta1, 2 and 3 (70-80kDa) were initially discovered as proteins involved in breast cancer 
metastasis (Toh et al., 1994), and are found in mutually-exclusive NuRD complexes, which is 
suggestive that the NuRD complex has different functions depending on its Mta subunit 
assembly (Bowen et al., 2004). Mta proteins contain a bromo-adjacent homology (BAH) 
domain which binds to histones (Armache et al., 2011); a Egl-27 and MTA1 homology 
domain (ELM) which might bind DNA or proteins; a SANT domain (found in SWI/SNF, 
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ADA, the co-repressor N-CoR and TFIIIB) which binds DNA and histones (Horton et al., 
2007); and a Gata zinc finger (GATA-ZnF) domain that can interact with DNA and recruit 
proteins (Liew et al., 2005) (Figure 1.4.1B). 
Gatad2a and 2b (70kDa) contain two conserved regions (CR) and a GATA-ZnF domain 
which are also responsible for histone binding, and bind to unmodified histones and to Mbd3 
(Brackertz et al., 2006; Gong et al., 2006) (Figure 1.4.1B). Their function is not clear. 
Commonly, each Mbd3/Mi-2/NuRD complex contains both Gatad2a and 2b proteins, both 
Hdac1 and 2, and both Rbbp4 and 7, but only one Mta protein (McDonel et al., 2009).  
As mentioned above, the NuRD complex can be found in different species and in 
different tissues, showing that the biology of the NuRD complex goes beyond pluripotency. It 
has been shown that, depending on its subunit composition, the NuRD complex can have 
different functions related to DNA biology, ranging from chromatin organization and 
transcriptional control, to DNA repair and genomic stability (Denslow and Wade, 2007). Its 
different subunit composition leads to the interaction of the NuRD complex with different 
proteins, which is a major mechanism of controlling NuRD activity and localization and 
impacts its function (Bowen et al., 2004). Whether the transcriptional programme controls 
NuRD’s architecture and its interactions, or whether it is the other way around, still remains to 
be understood. This is particularly evident in cancer, where NuRD activity has been shown to 
both promote and suppress tumorigenesis, depending on the cell type and microenvironment 
(Lai and Wade, 2011). This impedes the use of NuRD as therapeutic target. NuRD loss has 
been associated with aging-associated chromatin defects, such as heterochromatin loss and 
DNA damage (Pegoraro et al., 2009). 
In summary, NuRD is a multifunctional complex that contains a dual enzymatic activity 
and whose aberration is associated with human disease. Although the NuRD complex has 
been shown to play different biological roles in different tissues and species, only the role of 
the NuRD complex in cell fate decisions will be discussed in this thesis. In the next section I 
will review the role of the NuRD complex during early embryo development and maintenance 
of the pluripotent state. 
 
1.4.2 – The role of Mbd3 in early embryonic development and pluripotency 
Loss-of-function studies revealed that the NuRD complex fails to assemble in the absence 
of the core component Mbd3 (Kaji et al., 2006), meaning that Mbd3-null cells can be 
considered NuRD-null cells. Mouse embryos lacking Mbd3 expression die early in embryonic 
development (Hendrich et al., 2001). Mbd3
-/-
 embryos are indistinguishable from wild type 
until E4.5, exhibiting a morphologically normal segregation of the trophectoderm, epiblast 
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and primitive endoderm (Kaji et al., 2007). This indicates that the NuRD complex is not 
required for cell viability and for the two initial cell fate decisions of the blastocyst. This does 
not seem to be due to compensation by maternal Mbd3 contribution, since immunostaining 
reveals that Mbd3 disappears at the morula stage in Mbd3
-/-
 embryos (Kaji et al., 2007). From 
the early post-implantation state (E5.5), Mbd3
-/-
 embryos exhibit aberrant development, 
failing to differentiate and ultimately die (Kaji et al., 2007). E5.5 Mbd3-null embryos fail to 
form an organized extra-embryonic endoderm and visceral endoderm, and do not show 
maturation and expansion of the epiblast, exhibiting only a few Oct4-positive cells that 
remain proximally located as in E3.5 and E4.5. The failure in epiblast expansion does not 
seem to be the result of an arrest in proliferation or of the apoptosis of Oct4-positve cells, 
since these cells express markers of proliferating cells (Ki67), and no Oct4-Caspase-3 (marker 
of apoptosis) double-positive cells were found. Many of these Oct4-posive cells are also 
Gata4-positive, something never observed in E5.5 wild type embryos, but characteristic of 
E4.5 KO and wild type embryos (Kaji et al., 2007). It is therefore possible to conclude that 
Mbd3, and thus the NuRD complex, is necessary for the normal development of many 
embryonic and extra-embryonic tissues during early post-implantation development (Figure 
1.4.2). Moreover, no ESC lines could be established from Mbd3
-/-
 ICM outgrowths which 
contained few, if any, Oct4-positive cells, and could not be expanded (Kaji et al., 2007). 
Importantly, heterozygous Mbd3 embryos did not show any phenotype, being 
indistinguishable from wild type embryos at all stages analysed, and ESCs could be derived 
from their ICM outgrowths (Kaji et al., 2007) (Figure 1.4.2).  
While Mbd3 is required for ESC derivation from the embryo, it is not required for ESC 
self-renewal, since Mbd3-null ESC can be stably generated by gene targeting (Kaji et al., 
2006). Mbd3
-/-
 ESC are viable, exhibiting slower proliferation, which is consistent with the 
role of NuRD in cell cycle progression (Lai and Wade, 2011; Sims and Wade, 2011). These 
cells are unable to exit self-renewal and undergo spontaneous differentiation upon LIF 
withdrawal (Kaji et al., 2006; Reynolds et al., 2012a) (Figure 1.4.2). Mbd3-null ESCs also fail 
to commit to differentiated lineages in an embryoid body (EB) assay that mimics embryonic 
development (Doetschman et al., 1985), failing to down-regulate the expression of 
pluripotency genes (such as Oct4, Nanog, Rex1) and up-regulate lineage-specific markers 
(such as T brachyury, Gata6) (Kaji et al., 2006). They also do not contribute to chimeric 
embryos (Kaji et al., 2006). Surprisingly, when Mbd3
-/-
 ESC are treated with retinoic acid in 
the absence of LIF, they lose Oct4 expression and exit self-renewal (Kaji et al., 2006). This 
indicates that these cells are still responsive to certain stimuli, and that the NuRD complex 
might not be an absolute requirement for the exit from naïve pluripotency. 
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Figure 1.4.2 – In vivo and in vitro phenotypes associated with the lack of Mbd3. 
From fertilization until E4.5, wild type and Mbd3-null embryos are morphologically 
indistinguishable. At E5.5 the embryo implants and starts undergoing morphological changes, 
including cavitation and the expansion of the epiblast, features that are absent in Mbd3-/- embryos, 
which eventually die. ESCs cannot be derived from Mbd3-/- embryos, but can be established in vitro, 
exhibiting impaired differentiation. Green arrows indicate normal development or differentiation; Red 
blunt arrows represent a requirement for Mbd3.  
 
How the NuRD complex regulates pluripotency is still unknown. Two recent reports from 
the Hendrich laboratory have provided new insights into how the intricate balance between 
pluripotency and differentiation is maintained, uncovering an important role of the NuRD 
complex (Reynolds et al., 2012a; Reynolds et al., 2012b). Mbd3
-/-
 ESCs cultured in normal 
culture conditions (serum plus LIF) express homogenous high levels of the pluripotency 
genes Klf4, Klf5, Tbx3 and Rex1 (Reynolds et al., 2012a), genes whose expression is usually 
heterogeneous in wild type ESCs (Toyooka et al., 2008). This is suggestive that the NuRD 
complex might act to repress the expression of these pluripotency genes, an action that might 
be a required step for the exit of self-renewal and differentiation. Indeed, KD of Klf4 and Klf5 
resulted in a marked rescue of Mbd3
-/-
 ESC differentiation (Reynolds et al., 2012a). In another 
study by the same laboratory, it was found that NuRD-mediated deacetylase activity 
(mediated by the Hdac1/2) contributes to reduced H3K27ac at NuRD target genes, which then 
become available for H3K27me3 action by PRC2 (Reynolds et al., 2012b). Mbd3 deletion, or 
Hdac inhibition, leads to high levels of H3K27ac at NuRD targets, resulting in the impaired 
binding of PRC2 components and decreased H3K27me3 levels. This indicates a relationship 
extra-embryonic 
endoderm
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between the acetylation levels controlled by NuRD and the methylation levels controlled by 
PRC2. Moreover, the loss of either NuRD or PRC2 activity create overlapping gene 
expression changes, including the up-regulation of genes involved in embryonic development 
(Reynolds et al., 2012b).  
The results described above seem to indicate that ESC’s ability to self-renew, while 
maintaining their differentiation potential, is dictated by a balance between opposing 
chromatin modifications which might be, at least in part, controlled by NuRD and PRC2. It is 
feasible to assume that this plastic state is induced by chromatin modifications and controlled 
by both the core transcription factor circuitry and external clues, transduced in the form of 
signalling pathways, such as LIF signalling. A model can then be created, where pluripotency 
is maintained by the positive action of pluripotency-associated transcription factors and LIF 
signalling and these compete with the repressive action of NuRD and PRC2 (Hu and Wade, 
2012; Reynolds et al., 2012a; Reynolds et al., 2012b). Upon the loss of LIF signalling, the 
repressive action of NuRD and PRC2 dominate, resulting in differentiation. In agreement with 
this model, the deletion of PRC2 complex members Ezh2 (Shen et al., 2008), Suz12 (Pasini et 
al., 2007) and Eed (Boyer et al., 2006; Chamberlain et al., 2008; Leeb et al., 2010), or Mbd3 
deletion (Kaji et al., 2006) blocks differentiation upon LIF withdrawal. This also seems to be 
in accordance with the observation that Mbd3
-/-
 ESCs cultured in serum conditions seem to 
have a transcriptional program similar to wild type ESCs cultured in 2i medium (Reynolds et 
al., 2012a). Lastly, LIF signalling seems to be directly connected to chromatin status, since 
Stat3’s binding to target genes can be potentiated by the chromatin remodelling ESC-specific 
BAF complex (esBAF) (Ho et al., 2009a; Ho et al., 2011; Ho et al., 2009b). The ATPase 
subunit of esBAF, Brg, was found to be required for Stat3 binding to target loci, mainly by 
repressing PRC2 binding (Ho et al., 2011). Disruption of the esBAF complex leads to rapid 
polycomb binding and H3K27me3-mediated silencing of many Brg-activated genes genome-
wide (Ho et al., 2011). As with all models, this model does not fully describe all ESC 
behaviours, but it provides an integrative view of how transcription factors, signalling 
pathways and chromatin regulators might regulate the complicated ESC biology. 
On top of its function controlling pluripotency-associated genes expression, the NuRD 
complex was also shown to maintain the boundary between embryonic and trophectoderm 
fates in ESCs (Latos et al., 2012; Zhu et al., 2009). Mbd3
-/-
 ESCs have been shown to commit 
towards the normally inaccessible trophectoderm lineage in a EB assay (Kaji et al., 2006), and 
the efficiency of this differentiation can be enhanced by the culture of Mbd3
-/-
 ESCs in 
trophoblast stem cell medium (Latos et al., 2012).  
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In summary, the Mbd3/NuRD complex plays a fundamental role in cell state transitions, 
and its activity is necessary for proper embryonic development, mainly for the expansion and 
differentiation of the epiblast, and for ESC commitment in vitro. Thus, the Mbd3/NuRD 
complex is an important component of the cellular machinery, but the reasons why it is so 
important are yet to be fully defined. 
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1.5 – Scope of the study 
It has been less than a decade since the breakthrough discovery that somatic cells can be 
reprogrammed back to a pluripotent state by the forced expression of defined factors, and 
already important discoveries have been made to understand the mechanisms underlying this 
transition. As described in section 1.3.4, chromatin remodelling plays an important role in 
reprogramming to naïve pluripotency. Surprisingly, the role of the chromatin remodelling 
complex NuRD, a key regulator of developmental cell state transitions (section 1.4.2) and a 
high confidence interactor of both key pluripotency transcription factors Oct4 and Nanog 
(section 1.3.5), in induced pluripotency has never been addressed until the start of this thesis. 
Thus, the main aim of this thesis is to study the role of the NuRD complex in induced 
pluripotency. I will start by addressing the impact of the disruption of the NuRD complex on 
somatic cell reprogramming. I will move to assess how induced pluripotency progresses when 
NuRD activity is enhanced. I will finish by analysing how the NuRD complex might 
mechanistically function during reprogramming, studying its molecular interactions and their 
role in NuRD activity. 
 
  
 
 
 
 
 
 
 
 
 
CHAPTER 2 – Materials and Methods 
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2.1 – Cell culture 
2.1.1 – Culture media and routine cell line manipulations 
PLAT-E, pre-induced Pluripotent Stem Cells (preiPSCs) and mouse embryonic 
fibroblasts (MEFs) were cultured in GMEM (Cat. No.: G5154, Sigma-Aldrich) supplemented 
with 10% FCS (Cat. No.: F7524, Sigma-Aldrich), 1x non-essential amino acid (NEAA; Cat. 
No.: M11-003, PAA), 1x Penicillin/ Streptomycin (Pen/Strep: Cat. No.: P11-010, PAA), 1 
mM sodium pyruvate (Cat. No.: S11-003, PAA), 0.1 mM -mercaptoethanol (Cat. No.: 
31350-010, Life Technologies), 2 mM L-glutamine (Cat. No.: 25030-024, Life Technologies) 
and 20 ng/ml of leukemia inhibitory factor (LIF; Department of Biochemistry, University of 
Cambridge) - indicated as Serum plus LIF, S+LIF, medium throughout. 
Embryonic Stem Cells (ESCs) and induced Pluripotent Stem Cells (iPSCs) were 
maintained in N2B27-based medium composed of DMEM/F12 (Cat. No.: 11320-033, Life 
Technologies) and Neurobasal (Cat. No.: 21103-049, Life Technologies) in 1:1 ratio with 1x 
Pen/Strep, 0.1 mM -mercaptoethanol, 2 mM L-glutamine, 1:200 N2 supplement (Cat. No.: 
F005-004, PAA), and 1:100 B27 supplement (Cat. No.: 17504-044, Life Technologies) 
supplemented 20 ng/ml of LIF and 2i inhibitors: CHIR99021 (3 μM) and PD0325901 (1 μM) 
- indicated as 2i/LIF throughout (Ying et al., 2008). 
Neural Stem Cells (NSCs) were cultured in DMEM/F-12 with 1x NEAA, 0.1 mM -
mercaptoethanol, 1x Pen/Strep, 1:100 B27 supplement, 1:200 N2 supplement, 4.5 μM HEPES 
(Cat. No.: S11-001, PAA), 0.03 M glucose (Cat. No.: G528, Sigma-Aldrich), 120 μg/ml BSA 
(Cat. No.: 15260-037, Life Technologies), supplemented with 10 ng/mL of Epidermal growth 
factor (Egf; Cat. No.:315-09, Peprotech) and 20 ng/ml of fibroblast growth factor 2 (Fgf2; 
Department of Biochemistry, University of Cambridge) - indicated as Egf+Fgf2 medium 
throughout. 
Epiblast Stem Cells (EpiSCs) were maintained in N2B27-based medium containing 12 
ng/ml of Fgf2 and 20 ng/ml of Activin A (Department of Biochemistry, University of 
Cambridge) - indicated as Fgf2/Act.A medium throughout. 
For selection of stable transgenic clones, cells were cultured in the presence of 
antibiotics. Hygromycin B (Cat. No.: P02-015, PAA) was used at 200 ug/ml, blasticidin (Cat. 
No.: A11139, Life Technologies) at 20 ug/ml, puromycin (Cat. No.: P9620, Sigma-Aldrich) at 
1 ug/ml and Zeocyn (Cat. No.: R25001, Life Technologies) at 100 g/ml. 
For Cre-mediated transgene excision, the cells were treated with 500 nM of 4-
hydroxytamoxifen (4-OHT; Cat. No.: H7904, Sigma-Aldrich). 
EpiSCs were cultured on plastic which had been coated for 30 min with 10 μg/mL 
fibronectin (Cat. No.: FC-010, Millipore), and NSCs were cultured on plastic coated for 3 
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hours with 10 μg/mL laminin (Cat. No.: L2020, Sigma-Aldrich) in phosphate buffered saline 
(PBS). PLAT-E cells were cultured on plastic without substrate. All other cell types were 
grown on 0.10% gelatine (Cat. No.: G1890, Sigma-Aldrich).  
For cell passaging, cells cultured in serum-containing media were dissociated with 
trypsin (Cat. No.: 15090046, Life Technologies) after washing with PBS, and cells cultured in 
serum-free media were dissociated with accutase (Cat. No.: L11-007, PAA). After their 
treatment with dissociation enzyme, the cells were centrifuged and replated at the desired 
density in fresh media. 
All cell types were manipulated in a sterile BioMAT Class II Microbiological Safety 
Cabinet (Thermo Scientific) and maintained in a humidified Sanyo incubator (MCO-18M) at 
37° and 7% CO2. 
All cell types were frozen in S+LIF supplemented with 10% dimethyl sulfoxide (DMSO; 
Cat. No.: A3372,0100, AppliChem) in cryovials. Cells were first put in a -80
0
C freezer and 
transferred to a liquid nitrogen tank 2-14 days later. 
 
2.1.2 – Cell derivation 
NSCs: brains from Mbd3
fl/fl
 and Mbd3
ex1fl/ex1fl
 E13.5 embryos were dissected, dissociated 
in Egf+Fgf2 medium and plated onto the laminin-coated cell culture flasks. Mbd3
fl/-
 NSCs 
were derived from ESCs as described (Pollard et al., 2006). Briefly, ESCs were seeded onto 
gelatinized 10 cm dishes in N2B27 medium for 7 days. After this period, cells were 
trypsinized and plated on non-gelatinized dishes for 3 days in Egf+Fgf2 medium. The 
emergent neurospheres were then seeded on gelatinized plates and maintained in monolayer 
in Egf+Fgf2 medium. For Cre-mediated excision of the Mbd3 floxed allele, Mbd3
fl/-
 NSCs 
were nucleofected with a pCAG-Cre-ires-Puro plasmid and clonal lines of Mbd3
-/-
 NSCs were 
expanded. 
MEFs: organ-free carcasses from E12.5 or 13.5 embryos were dissociated into small 
pieces, trypsinised and plated in S+LIF medium. 
EpiSCs: Mbd3
fl/-
 and Mbd3
-/-
 EpiSCs were derived from ESCs as previously described 
(Guo et al., 2009). Briefly, ESCs transfected with pPB-EOS-GFP-ires-Puro (EOS-GiP - 
GFPiresPuro under the control of early transposon promoter and Oct-4 and Sox2 enhancers) 
and were cultured in Fgf2/Act.A medium for at least 10 passages before analysis. To obtain a 
pure EpiSC culture, GFP
+
 cells were removed by fluorescence-activated cell sorting (FACS). 
Genotypes were analysed by polymerase chain reaction (PCR) using the Mbd3 genotyping 
primer pair (Table 2.1). 
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2.1.3 – Generation of transgenic cell lines 
NSCs and preiPSCs were transfected using Amaxa Nucleofection Technology (Lonza 
AG). 2 x 10
6
 cells were used per transfection and program T-020 was used. ESCs, iPSCs and 
EpiSCs were transfected in suspension using Lipofectamine 2000 (Cat. No.: 11668-019, Life 
Technologies). Both protocols were performed according to the manufacturer’s instructions. 
piggyBac transposon (pPB) plasmids were co-transfected with piggybac transposase 
expression vector pBase (mixture of 1:1) to generate stable cell lines. Selection for transgenes 
was applied for at least 3 passages before experiments were set up. 
 
2.1.4 – siRNA knockdown 
Knockdown was carried out using the Flexitube siRNAs (Qiagen) listed in Table 2.1. For 
Mbd3 knockdown, four different small interference RNAs (siRNAs) (Mm_Mbd3_1, 2, 3 and 
5) were individually tested and three of them were chosen to be used as a pool in subsequent 
experiments: siRNA #1, #3 and #5. AllStars Negative Control siRNA (Cat. No.: 1027280, 
QIAGEN) was used as a control. The final concentration of siRNAs for transfection was 0.2 
M/cm2. For reprogramming experiments, EpiSCs were transfected with the siRNAs using 
the Lipofectamine RNAiMAX transfection reagent (Cat. No.: 13778-150, Life Technologies) 
according to the manufacturer’s protocol. The media was switched to 2i/LIF 24h after 
transfection. 
 
2.1.4 – NSC, MEF and preiPSC reprogramming experiments 
To generate retroviruses containing the reprogramming factors, 2 x 10
6
 PLAT-E cells 
(per transfection) were seeded in 10 cm dishes and transfected the next day with 9 μg of 
pMXs plasmid (MKO or MKOS in case of NSCs and MEFs, respectively; where indicated, 
pMXs-GFP was also used) using the FuGENE 6 transfection reagent (Cat. No.: E2691, 
Promega) according to the manufacturer’s instructions. The medium was switched to S+LIF 
the next day. The retrovirus-containing supernatants from PLAT-E cultures were collected 48 
hours post-transfection and filtered using 0.45 m filters. Polybrene (Cat.No.:H9268, Sigma-
Aldrich) was added to the filtered supernatants to a final concentration of 4 g/ml. The 
mixture was then applied to the plated NSCs or MEFs. In case of NSCs, 24h after incubation, 
the virus-containing medium was replaced with Egf+Fgf2 medium for 2-3 days, after which 
the cells were switched to S+LIF medium in the case of NSCs, or to S+LIF in the case of 
MEFs, to enable preiPSC (reprogramming intermediate) formation. MEFs were maintained in 
S+LIF throughout. The emergent preiPSCs were then switched to 2i/LIF medium to induce 
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complete reprogramming. Where indicated in the text, preiPSCs were passaged and stably 
transfected at the preiPSC stage, plated in S+LIF and switched to in 2i/LIF conditions 1-2 
days later. Nanog-GFP MEF derived preiPSCs were chosen to address the synergy between 
Nanog and Mbd3 during reprogramming since they very inefficiently convert to naïve 
pluripotency in 2i/LIF conditions, unless transfected with additional factors (cells used in 
(Costa et al., 2013)). Where cells contained a reprogramming reporter (Nanog-GFPiresPuro or 
Oct4-GFPiresPuro), 1 ug/ml puromycin was added to 2i/LIF cultures six days after the 
medium switch. Reprogramming experiments were ended 12 days after the medium switch to 
2i/LIF. The number of NSCs, MEFs or preiPSCs plated differ from experiment to experiment 
and are indicated in the figure legends. 
 
2.1.5 – EpiSC reprogramming 
Transgenic EpiSCs were plated in Fgf2/Act.A medium and switched to 2i/LIF conditions 
the next day. Once the medium is switched to 2i/LIF the EpiSCs no longer proliferate, unless 
they undergo reprogramming, making the resulting iPSC colonies representative of the initial 
plated EpiSC numbers. Where cells contained a reprogramming reporter (Oct4-GFPiresPuro 
of EOS-GFPiresPuro), 1 ug/ml puromycin was added to 2i/LIF cultures six days after the 
medium switch. Reprogramming experiments were ended 12 days after the medium switch to 
2i/LIF. The number of EpiSCs plated differs from experiment to experiment and in indicated 
in the figure legends. 
 
2.1.6 – piggyBac transposon reprogramming 
The PB-TAP IRI attP2LMKOSimO or PB-TAP IRI tetO-STEMCCAimO (500 ng), pPB-
CAG-rtTA (500 ng) and pCyL43 piggyBac transposase expression vector (500 ng) were 
introduced into MEFs with the Nanog-GFP reporter (Chambers et al., 2007),
 
which were 
seeded at 1.0 x 10
5
 cells per well in a 6-well plate on the day before transfection and 
transfected using 6 l of FugeneHD (Cat. No.: E2311, Promega). Twenty-four hours later, the 
culture medium was changed to S+LIF medium supplemented with 1.0 g/ml doxycycline 
(DOX) (Cat. No.: 198955, MP Biomedicals), 10 g/ml vitamin C (Cat. No.: A4403, Sigma-
Aldrich) and 500 nM Alk inhibitor A 83-01 (Cat. No.: 2939, TOCRIS Bioscience) (+DVA). 
This medium was changed every two days until day 13 of reprogramming. Lentiviral 
infection with pLKO.1 encoding short hairpin RNA (shRNA) expression against Mbd3 
(shMbd3.2 and shMbd3.5), Hygromycin and Zeocin resistant genes (shHyg and shZeo) was 
carried out 24 hours after DOX administration. Cell lysates from one of the triplicate wells at 
day 7 of reprogramming were used for western blotting analysis to confirm Mbd3 
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knockdown. For Mbd3 exon1 deletion, the retroviral Cre-ERt2 expression vector was infected 
24 hours after PB-TAP MKOSimO piggybac transfection with Fugene. At the same time the 
culture medium was changed to S+LIF +DVA medium. 4-OHT was added at this point or 48 
hours later, and kept in the culture medium for 48 hours. Cell lysates from one of the triplicate 
wells at day 7 of reprogramming were used for Western blotting analysis to confirm Mbd3 
depletion. 
 
2.1.7 – Cell differentiation 
For embryoid body differentiation, 1.5 x 10
6 
cells were plated in non-adherent 10 cm 
bacterial dishes in serum - LIF medium. Samples were collected at day 3, 5 and 7 of 
differentiation and analysed by quantitative reverse transcriptase PCR (qRT-PCR). After the 
last time-point, embryoid bodies were plated on 0.10% gelatine and the generation of beating 
cells was analysed over the next 2-3 days. For assessing ESCs/iPSCs differentiation in 
monolayer, 0.2 x 10
6 
cells were plated on 0.10% gelatine and cultured in serum - LIF medium. 
Samples were collected at day 2, 4, 6, 8 and 10 of differentiation and analysed by flow 
cytometry. Clonal LIF-independent self-renewal was assessed by plating 2000 ESCs/iPSCs 
per well in a 6-well plate in serum minus LIF medium. AP-staining was performed at day 3, 5 
and 7. 
 
2.1.8 – Cell proliferation analysis 
Cell proliferation was assessed by counting cells every 24h using the Vi-Cell XR Cell 
Viability analyser (Cat. No.: 731050, Beckman Coulter). For iPSCs proliferation analysis, 
2000 cells were plated per 96-well plate and assayed with CellTiter 96 AQueous One Solution 
Cell Proliferation Assay (G3580, Promega) every 24h. 
 
2.2 – Plasmids 
pMX-Klf4 (Cat. No.: 13370), pMX-Oct3/4 (Cat. No.: 13366), pMX-c-Myc (Cat. No.: 
13375), pMX-Sox2 (Cat. No.: 13367) and pLKO.1 (Cat. No.: 8453) were obtained from 
Addgene repository; pCyL43 (PBase) and pPB-CAG-rtTA were obtained from Sanger 
Institute’s plasmid repository; pDONR211 (Cat. No.:12536-017) was obtained from Life 
Technologies; pPB-CAG-Nanog-pA-pgk-hph, pPB-CAG-Klf4-pA-pgk-hph, pPB-CAG-
DEST-pA-pgk-hph and pMX-GFP were kindly provided by Dr Thorold Theunissen; pPB-
CAG-Klf2.2A.Nanog-Cherry-ires-zeo, pPB-CAG-DEST-ires-zeo, pPB-CAG-Tet1-pA-pgk-
hph and pPB-CAG-Tet2-ires-bsd were kindly provided by Dr Yael Costa; pPB-CAG-Nr5a2-
pA-pgk-hph and pPB-CAG-DEST-ires-bsd were kindly provided by Moyra Lawrence; 
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pCAG-Cre-ires-Puro and pCAG-Mbd3bireshygro were kindly provided by Dr Brian 
Hendrich; pCAG-CreERt2
NLS
-IRES-BSD was kindly provided by Dr Joerg Betschinger; pPB-
EOS-GFP-ires-Puro (pPB-EOS-GiP) was kindly provided by Dr Ge Guo. PB-TAP IRI 
attP2LMKOSimO, PB-TAP IRI tetO-STEMCCAimO (iOKSM; Oct4-F2A-Klf4-ires-Sox2-
E2A-c-Myc) and PB-TAP MKOSimO (iMKOS) were kindly provided by Dr Keisuke Kaji. 
They were generated by transferring STAMCCA reprogramming cassette into PB-TAP IRI 
piggyback backbone with ires-mOrange (O'Malley et al., 2013; Sommer et al., 2009), and 
MKOSimO cassette into PB-tetO backbone (Woltjen et al., 2009), respectively. 
For cloning of the pPB-CAG-Mbd3b-ires-bsd and pPB-CAG-Mbd3c-ires-bsd plasmids, 
Mbd3b was amplified from pCAG-Mbd3bireshygro and Mbd3c from mouse ESC cDNA, 
using primers introducing attB arms for Gateway cloning (Table 2.1). The amplified 
transgenes were purified from 1% agarose gels (Cat. No.: A9539, Sigma-Aldrich) and 300 ng 
was incubated with 150 ng of pDONR211 vector and 3 l of BP Clonase II enzyme mix (Cat. 
No.: 11789-020, Life Technologies) in TE buffer to final volume of 15 l (BP reaction - 
incubation at room temperature, overnight). After incubation, 300 ng of pPB-CAG-DEST-
ires-bsd destination plasmid and 3 l of LR Clonase II enzyme mix (Cat. No.: 11791-020, 
Life Technologies) were added to BP reaction (LR reaction - incubation at room temperature, 
5 hours). After 5 hours, Proteinase K was added to the LR (incubation at 37
0
C, 10 min). 2 l 
of the final reaction were transformed into chemically competent E. cloni bacterial cells (Cat. 
No.: 60106, Lucigen), according to the manufacturer’s protocol. All constructs were 
sequenced by Sanger-sequencing (Department of Biochemistry, University of Cambridge) 
using internal primers (Table 2.1).  
 
2.3 – RNA isolation, cDNA synthesis and qRT-PCR 
Total RNA was isolated from cells using the RNeasy mini kit (Cat. No.: 74104, 
QIAGEN) in accordance to the manufacturer’s protocol. After purification, 1 µg of total RNA 
was reverse transcribed into cDNA using the SuperScript III First-Strand Synthesis SuperMix 
kit (Cat. No.: 18080-400, Life Technologies). 10 ng of cDNA was used for qRT-PCR 
reactions that were set up in triplicates using either TaqMan Universal PCR Master Mix (Cat. 
No.: 4352042, Life Technologies) or Fast SYBR Green Master Mix (Cat. No.: 4385612, Life 
Technologies). TaqMan gene expression assays (Life Technologies) or specific primers (see 
Table 2.1) were used for each gene analysed. qRT-PCR experiments were  performed using 
StepOnePlus Real Time PCR System (Cat. No.: 4376600, Life Technologies). Delta Ct values 
to Gapdh were calculated and brought to power -2. Where indicated, the values were 
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normalized to the highest value. Error bars represent standard deviation (STDEV) of technical 
triplicates. 
 
Table 2.1 – Primers and si/shRNA oligos used in the study. 
Mbd3 genotyping primers 
Mbd3 gen. FP ACTGCTCCAGCTTGGTACAG 
Mbd3 gen. RP AATCAGATCACTTCAGCTCC 
Cloning primers 
attB-Mbd3b FP GGGGACAAGTTTGTACAAAAAAGCAGGCTT
CACCATGGAGCGGAAGAGCCCCA 
attB-Mbd3b RP GGGGACCACTTTGTACAAGAAAGCTGGGTC
CTACACTCGCTCTGGCTCC 
attB-Mbd3b inter. FP CTGGCACGTTACCTGGGCGGAT 
attB-Mbd3 inter. RP TGCTGCGGAACTTCTTCCCGCT 
attB-Mbd3c FP GGGGACAAGTTTGTACAAAAAAGCAGGCTT
CACCATGGCGCGCATTTGGTTTGG 
attB-Mbd3c RP GGGGACCACTTTGTACAAGAAAGCTGGGTC
CTACACTCGCTCTGGCTCC 
attB-Mbd3c inter. FP ACGGGGAGGCACCACTGGACAA 
attB-Mbd3 inter. RP CGGGCAAGCTCCTCCACATGAG 
Primers used with SYBR green 
Mbd3 FP AGAAGAACCCTGGTGTGTGG 
Mbd3 RV TGTACCAGCTCCTCCTGCTT 
Pl-1 FP ATTTTGACTACCCTGCTTGGTCT 
Pl-1 RP TCTACATAACTGAGGAGGGGAAAG 
Gapdh FP CCCACTAACATCAAATGGGG 
Gapdh RP CCTTCCACAATGCCAAAGTT 
Olig2 FP CTGCTGGCGCGAAACTACAT 
Olig2 RP CGCTCACCAGTCGCTTCAT 
Blbp FP AGACCCGAGTTCCTCCAGTT 
Blbp RP ATCACCACTTTGCCACCTTC 
Sox2 FP TCCAAAAACTAATCACAACAATCG 
Sox2 RP GAAGTGCAATTGGGATGAAAA 
Nr5a2 FP CCAGAAAACATGCAAGTGTCTCAA 
Nr5a2 RP CGTGAGGAGACCGTAATGGTA 
Applied Biosystems Taqman probes 
Nanog Mm02384862_g1 
Rex1 Mm03053975_g1 
Klf4 Mm00516104_m1 
Klf2 Mm01244979_g1 
Fgf5 Mm00438919_m1 
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Lefty1 Mm00438615_m1 
T-Brachyury Mm01318252_m1 
Gapdh 4352339E 
Esrr Mm00442411_m1 
Gata4 Mm00484689_m1 
Nr0b1 Mm00431729_m1 
Tet1 Mm01169087_m1 
Tet2 Mm00524395_m1 
Applied Biosystems custom Taqman probes 
Retroviral Klf4 FP TGGTACGGGAAATCACAAGTTTGTA 
Retroviral Klf4 RP GAGCAGAGCGTCGCTGA 
Retroviral Klf4 probe FAM-CCCCTTCACCATGGCTG-MGB 
Retroviral Oct4 FP TGGTACGGGAAATCACAAGTTTGTA 
Retroviral Oct4 RP GGTGAGAAGGCGAAGTCTGAAG 
Retroviral Oct4 probe FAM-CACCTTCCCCATGGCTG-MGB 
Retroviral cMyc FP TGGTACGGGAAATCACAAGTTTGTA 
Retroviral cMyc RP GGTCATAGTTCCTGTTGGTGAAGTT 
Retroviral cMyc probe FAM-CCCTTCACCATGCCCC-MGB 
Retroviral Sox2 FP TGGTACGGGAAATCACAAGTTTGTA 
Retroviral Sox2 RP GCCCGGCGGCTTCA 
Retroviral Sox2 probe FAM-CTCCGTCTCCATCATGTTAT-MGB 
Endogenous Oct4 FP TTCCACCAGGCCCCC 
Endogenous Oct4 RP GGTGAGAAGGCGAAGTCTGAAG 
Endogenous Oct4 probe FAM-CCCACCTTCCCCATGGCT-MGB 
siRNAs from Qiagen 
Mm_Mbd3_1 - SI00206836 CGGAAAGATGTTGATGAACAA 
Mm_Mbd3_2 - SI00206843 ACCGGTGACCAAGATCACCAA 
Mm_Mbd3_3 - SI00206850 CAGGACCATGGACTTGCCCAA 
Mm_Mbd3_5 - SI02740045 AAGTCACTTTCCTTCAATAAA 
AllStars Negative Control siRNA Cat. No.: 1027280 
Upper strand oligos used for lentiviral knockdown vectors 
shMbd3.2 Upper 
strand 
CCGGGCGCTATGATTCTTCCAACCACTCGA
GTGGTTGGAAGAATCATAGCGCTTTTT 
Bottom 
strand 
AATTAAAAAGCGCTATGATTCTTCCAACCA
CTCGAGTGGTTGGAAGAATCATAGCGC 
shMbd3.5 Upper 
strand 
CCGGAAGTCACTTTCCTTCAATAAACTCGA
GTTTATTGAAGGAAAGTGACTTTTTTT 
Bottom 
strand 
AATTAAAAAAAGTCACTTTCCTTCAATAAA
CTCGAGTTTATTGAAGGAAAGTGACTT 
shHyg Upper 
strand 
CCGGGCGAAGAATCTCGTGCTTTCACTCGA
GTGAAAGCACGAGATTCTTCGCTTTTT 
53 
 
Bottom 
strand 
AATTAAAAAGCGAAGAATCTCGTGCTTTCA
CTCGAGTGAAAGCACGAGATTCTTCGC 
shZeo Upper 
strand 
CCGGGCCAAGTTGACCAGTGCCGTTCTCGA
GAACGGCACTGGTCAACTTGGCTTTTT 
Bottom 
strand 
AATTAAAAAGCCAAGTTGACCAGTGCCGTT
CTCGAGAACGGCACTGGTCAACTTGGC 
 
 
2.4 – Blastocyst injection, chimera generation and germline 
transmission assessment 
For blastocyst injection, standard microinjection methodology using host blastocysts of 
C57BL/6 strain was employed. Floxed pPB transgenes were excised using TAT-Cre treatment 
before injection. Injected blastocysts were transferred to recipient mice to assess the 
contribution to chimeras. Generated chimeras were back-crossed with C57BL/6 mice to 
assess germline transmission.  
 
2.5 – Alkaline Phosphatase staining 
Cells were fixed with a citrate-acetone-formaldehyde solution and stained for 30 min 
using the Alkaline Phosphatase (AP) kit (Cat. No.: 86R-1KT, Sigma-Aldrich) according to 
manufacturer’s instructions. 
 
2.6 – Flow cytometry and imaging 
Flow cytometry analysis was performed using a fully calibrated BD LSRFortessa 
analyser (488nm, 635nm, 406nm and 561nm). GFP was excited by a 488nm laser and 
detected using a 530/30 filter. DAPI (406nm 450/50) was used to exclude dead cells. 
Acquisition gates were set using FACS DIVA software and post-acquisition analysis was 
performed using FlowJo software (Treestar). Briefly, live, single, and intact cells were 
identified based on viability dye exclusion, SSC-W, and FSC-A v SSC-A parameters, 
respectively. Lastly, GFP positive cells were identified based on the untransfected control. A 
minimum of 10,000 single intact live cells was acquired. Cell sorting was performed using a 
Beckman Coulter MoFlo Legacy Cell Sorter (488nm, 355nm and 648nm), following a similar 
gating strategy as described above. Live cells were imaged with inverted Olympus IX51 
microscope supplied with the Leica DFC310 FX digital colour camera, and processed with 
Leica software. 
 
54 
 
2.7 – Western blotting 
Protein extracts were obtained by incubation of cells with RIPA buffer – PBS (Cat. No.: 
D8537, Sigma-Aldrich), 1% IGEPAL (Cat. No.: I3021, Sigma-Aldrich), 0.1% SDS (Cat. No.: 
BP1311-1, Fisher Scientific), 0.1 mM EDTA (Cat. No.: 15575-038, Life Technologies) 
supplemented with proteinase inhibitors (Cat. No.: 05 892 970 001, Roche). Total protein was 
quantified using BCA protein assay kit (Cat. No.: 23227, Thermo Scientific). Protein samples 
were denatured using NuPAGE LDS sample buffer (Cat. No.: NP0007, Life Technologies) 
supplemented with 10% DTT (Cat. No.: 43816, Sigma-Aldrich). The same amount of protein 
was loaded into Novex NuPAGE 10% Bis-Tris gels (NP0301BOX, Life Technologies) for all 
the samples. Protein transfer was carried out with the iBlot 2 system (Cat. No. IB21001, Life 
Technologies) using nitrocellulose iBlot 2 transfer stacks (Cat. No.: IB23001, Life 
Technologies). The following primary antibodies used: rabbit polyclonal Mbd3 antibody 
(Cat.No.: A302-528A, Bethyl, 1:2000), rabbit polyclonal Nanog antibody (Cat. No.: A300-
397A, Bethyl, 1:5000) goat polyclonal Mta2 antibody (C-20) (Cat. No.: sc-9447, Santa Cruz, 
1:1000) and mouse monoclonal antibody α-tubulin (Cat. No.: ab7291, Abcam, 1:5000). 
Secondary HRP-conjugated antibodies used: anti-rabbit (Cat. No.: NA934VS, GE Healthcare, 
1:10000), anti-mouse (Cat. No.: NA931VS, GE Healthcare, 1:10000) and anti-goat (Cat. No.: 
sc-2020, Santa Cruz, 1:2000). Blocking was carried out using 5% milk (Cat. No.: 70166, 
Sigma-Aldrich)/0.1% tween-20 (Cat. No.: P1379, Sigma-Aldrich) in PBS (blocking solution) 
for 1 hour at room temperature. Primary antibodies were diluted in blocking solution and 
membranes were incubated with antibody overnight at 4
0
C. Three washing steps of 10 min 
were carried out with blocking solution after primary antibody incubation. Secondary 
antibodies were diluted in blocking solution and incubated with membranes for 1 hour at 
room temperature. Then three washing steps of 20 min were performed with 0.1% tween-20 
in PBS. Membranes were developed using the ECL Prime detection Kit (Cat. No.: RPN2232, 
GE Healthcare) according to the manufacturer’s instructions. Membrane re-probing with 
another primary antibody was carried out after stripping the membrane with 100 mM -
Mercaptoethanol, 2% SDS and 62.5 mM Tris-HCl solution in water for 30 min at 50
0
C.  
 
2.8 – DNA dot blot 
To prepare DNA samples, 20X Saline-Sodium Citrate (SSC – 3M Sodium chloride (Cat. 
No.: 31434, Sigma-Aldrich) and 0.3M triSodium citrate dihydrate (Cat. No.: S1804, Sigma-
Aldrich) in water, pH 7.0),  and water were added to the DNA to give a final concentration of 
6X SSC in the minimum possible volume. DNA was denatured by incubation the samples for 
10 min at 100
0
C. Samples were then placed on ice and diluted by adding an equal volume of 
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20X SSC. To prepare the membrane for application of the samples, a grid of 1 cm x 1 cm 
squares was marked in uncharged hybond-C extra nitrocellulose membranes (Cat. No.: 45-
000-930, GE Healthcare) with a blunt pencil and the membrane was incubated in 6X SSC for 
10 min at room temperature. After incubation, the membranes were allowed to air-dry for 10 
min and samples were applied. Up to 2 l were applied each time, with each spot being 
allowed to dry before the next aliquot was applied on top, if more sample was required. After 
all samples were applied, the membranes were placed between two sheets of Watman paper 
and cross-linked in a Hoefer UVC 500 ultraviolet cross-linker (Cat. No.: 80-6222-31, GE 
Healthcare) using 1200 J/cm2 energy. The membranes were then rehydrated by incubation in 
2X SSC for 5 min at room temperature. After air-drying for 10 min, the membranes were 
incubated overnight at 4
0
C with blocking solution (10% milk/ 1% bovine serum albumin / 
0.1% tween-20 in PBS). For 5-hydroxymethylcytosine (5-hmC) detection, the membranes 
were incubated with anti-5-hmC rabbit polyclonal antibody (Cat. No.: 39769, Active Motif, 
1:1000) for 1.5 hours at room temperature and washed 4 x 10 min with 0.1% tween-20 in 
PBS. After washing off the primary antibody, the membranes were incubated with HRP-
conjugated anti-rabbit (Cat. No.: NA934VS, GE Healthcare, 1:10000) for 1 hour at room 
temperature. Primary and secondary antibodies were diluted in blocking solution. The 
membranes were washed 3 x 20 min in 0.1% tween-20 in PBS and developed using the ECL 
Prime detection Kit (Cat. No.: RPN2232, GE Healthcare) according to the manufacturer’s 
instructions. 
  
 
 
 
 
 
 
 
 
 
CHAPTER 3 – Investigation of the role of Mbd3/ NuRD 
complex in the initiation of reprogramming 
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3.1 – Introduction 
3.1.1 – NuRD complex during the initiation of reprogramming 
Our laboratory has recently discovered that Oct4 is of extreme importance for somatic 
cell reprogramming, and Oct4
-/-
 somatic cells fail to be reprogrammed to naïve pluripotency if 
no exogenous source of Oct4 expression is provided (Radzisheuskaya et al., 2013). 
Furthermore, Oct4 interactome studies in ESCs revealed members of NuRD complex, an 
essential chromatin complex for embryo development and pluripotent cell differentiation, as 
its highest confidence interactors (Ding et al., 2012; Liang et al., 2008; Pardo et al., 2010; van 
den Berg et al., 2010). Taking these observations into account, we decided to assess the role 
of the NuRD complex during transcription-factor induced pluripotency. 
To study the role of the NuRD complex in nuclear reprogramming, we have made use of 
the biochemical phenomena described by the Hendrich laboratory where the NuRD complex 
fails to assemble, if the 32kD subunit Mbd3 is deleted, as Mbd3 acts as an essential scaffold 
protein of the NuRD complex (Kaji et al., 2006). The process of somatic cell reprogramming 
mediated by the retroviral-delivery of transcription factors can be divided into two distinct 
and sequential phases: initiation and establishment of reprogramming. To better dissect the 
role that the NuRD complex plays during the process of reprogramming, I have looked 
closely at the impact of Mbd3 removal during both phases of reprogramming. In this chapter, 
I focused my attention to the role of the NuRD in the initial phase of reprogramming. The role 
of the NuRD complex in the establishment of reprogramming will be addressed in the chapter 
4.  
The initiation phase of reprogramming consists of the transduction of somatic cells with 
retroviruses (pMXs) encoding the reprogramming factors Oct4, Klf4 c-Myc and Sox2 (Figure 
3.1.1). If Neural Stem cells are used, Sox2 is not necessary since this cell type already 
expresses it (Silva et al., 2008). If transduced cells are maintained in serum-containing 
conditions (S+LIF), highly-proliferative reprogramming intermediates (pre-induced 
Pluripotent Stem cells, preiPSCs) start to emerge and take over the culture. The preiPSCs 
show downregulation of lineage specific genes from the original somatic cell type and express 
alkaline phosphatase, amongst other pluripotency markers, but are dependent on the 
continuous expression of the transgenes (Silva et al., 2008). PreiPSCs do not express key 
pluripotency genes, such as Nanog and Esrr and do not exhibit full differentiation potential 
(Okita et al., 2007; Silva et al., 2008; Wernig et al., 2007). This system allows the detailed 
study of the impact of the NuRD complex during the initial stages of reprogramming, since its 
readout (the amount of preiPSC colonies) is a direct measure of this phase and not of the 
overall process. 
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Figure 3.1.1 – Initiation phase of reprogramming. 
Schematic representation of the experimental design used to assess the requirement of the NuRD 
complex in the initiation of reprogramming. During this phase, downregulation of genes from the 
original somatic cell type is observed, but resulting preiPSCs fail to activate endogenous naïve 
pluripotency transcriptional programming, being dependent on transgene expression (Silva et al., 
2008). 
 
3.1.2 – Aim of the chapter 
Since chromatin remodelling plays an important role in reprogramming to naïve 
pluripotency (Apostolou and Hochedlinger, 2013; Papp and Plath, 2013) and, as the NuRD 
complex is a high confidence interactor of Oct4 and a key regulator of developmental cell 
state transitions, I investigated if NuRD is also involved in the reverse biological process of 
the induction of pluripotency. I aimed to address not only whether NuRD is required for 
somatic cell reprogramming to pluripotency, but also if the initiation of reprogramming 
kinetics is altered after the disruption of the complex.  
  
• Downregulation of genes from original cell
• Expression of some pluripotency markers 
(SSEA1, E-cad, Fgf4, Nr0b1)
• Dependency on transgene expression
• Inactive X chromosome
• No chimerism
pMXs-Oct4 
pMXs-Klf4
pMXs-cMyc
± pMXs-Sox2
Somatic cell preiPS Cell
S+LIF
Initiation
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3.2 – Results 
3.2.1 – Mbd3/NuRD complex is required for efficient initiation of reprogramming 
To study the impact of Mbd3/NuRD deletion during somatic cell reprogramming, Mbd3-
null somatic cells had to be generated. Since the NuRD complex is required for embryo 
development and in vitro differentiation of ESCs, I employed a strategy where Mbd3 could be 
conditionally deleted after differentiation. For that, Mbd3 alleles were targeted in ESCs in 
order to flank them with loxP sites, which allowed future excision induced by Cre 
recombination (Ramirez-Solis et al., 1995; Zheng et al., 2001). After targeting, selection and 
clonal expansion, Mbd3
fl/-
 (one allele floxed; one allele removed) ESCs were generated (Kaji 
et al., 2006). Upon Cre-mediated excision of loxP-flanked Mbd3 allele, Mbd3
-/-
 ESCs were 
established containing no Mbd3 protein (none of the isoforms were detected, Figure 3.2.1A). 
Phenotypically, Mbd3
fl/-
 ESCs are indistinguishable from their wild type parental ESC line, 
showing the same level of Mbd3 protein as assessed using western blot analysis (Figure 
3.2.1B). The same cell line was used in different published reports as a control for Mbd3-
deleted line (Kaji et al., 2006; Reynolds et al., 2012a; Reynolds et al., 2012b). A different 
genetic targeting was also designed, where only Mbd3 exon1 (ex1) was loxP-flanked 
(Mbd3
ex1fl/-
 ESCs; Figure 3.2.1C), resulting in a loss of Mbd3a and Mbd3b, but retaining 
residual hypomorphic Mbd3c expression (Figure 3.2.1D) (Kaji et al., 2006). 
Since NSCs constitute a somatic cell system that can grow clonally and be maintained for 
long periods in culture, enabling efficient and quick gene targeting and manipulation, they 
were chosen as a model to study the role of Mbd3/ NuRD in reprogramming (Silva et al., 
2008). These features of NSCs make them an optimal cell type for my studies, allowing the 
generation of expandable Mbd3-null clonal lines. For the establishment of Mbd3
-/-
 NSCs, 
Mbd3
fl/-
 ESCs were subjected to an adherent monolayer differentiation protocol (Pollard et al., 
2006), and resulting NSCs were treated with Cre-recombinase to induce the deletion of the 
floxed-Mbd3 allele (Figure 3.2.1E). The gene targeting strategies and cell lines described 
above were generated and kindly provided by the Hendrich laboratory.  
In order to establish an Mbd3 rescue NSC line, Mbd3
-/-
 NSCs were stably transfected 
with an Mbd3 transgene. As stated above, there are three Mbd3 isoforms, which differ in their 
N-terminus: Mbd3a is 32 amino acids bigger than Mbd3b, and the latter is 8 amino acids 
bigger than Mbd3c (Figure 3.2.1F). Mbd3b is the most abundant Mbd3 isoform in ESCs 
(Figure 3.2.1B), and this was the isoform used to generate the rescue Mbd3
-/-
:Mbd3 NSC line 
(Figure 3.2.1G). For ease of reading, Mbd3b will be referred as Mbd3 throughout the rest of 
the thesis, unless stated otherwise. 
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(figure on next  page) 
Figure 3.2.1 – Generation of Mbd3-/- Neural Stem Cells. 
(A) Schematic representation of Mbd3 loci in ESCs Mbd3fl/- and Mbd3-/-. Exons are indicated as 
dark grey boxes, non-coding sequences are indicated as unfilled boxes, and light grey triangles 
represent loxP sites. (B) Western blot analysis of Mbd3 and -Tubulin (tub) protein levels in ESC 
lines with different Mbd3 genotypes cultured in 2i/LIF conditions: Mbd3+/+, Mbd3fl/-, and Mbd3-/- 
(derived from Mbd3fl/- after Cre-mediated deletion). Mbd3 isoforms a, b and c are indicated. (C) 
Schematic representation of Mbd3 loci in Mbd3ex1fl/- and Mbd3Δex1/- ESCs. Exons are indicated as dark 
grey boxes, non-coding sequences as unfilled boxes and light grey triangles represent loxP sites. Exon 
1 deletion creates a hypomorphic Mbd3 protein, with lower molecular weight. (D) Western blot 
analysis of Mbd3 and -Tubulin (tub) protein levels in ESC lines with different Mbd3 genotypes 
cultured in 2i/LIF conditions: Mbd3+/+, Mbd3ex1fl/- and Mbd3Δex1/- (derived from Mbd3ex1fl/- after Cre-
mediated deletion). (E) Schematic representation of the strategy used for generation of Mbd3-/- NSCs. 
Mbd3fl/- ESCs were differentiated in vitro in Mbd3fl/- NSCs. Mbd3-/- NSCs were clonally generated 
from the latter after Cre treatment. An Mbd3-/- rescue NSC line (Mbd3-/-:Mbd3) was generated by 
stable transfection of an Mbd3b transgene. (F) ClustalW2 sequence alignment between Mbd3a, 
Mbd3b (cDNA used this study unless otherwise stated) and Mbd3c isoforms 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). Phenylalanine 34 (F34) is indicated in red. (G) Western 
blot analysis of Mbd3 and tub protein levels in the Mbd3fl/-, Mbd3-/- and Mbd3-/-:Mbd3 (rescue) NSCs 
used for reprogramming experiments. 
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2 3 4 5 6
1 -geo
Monolayer 
differentiation
Mbd3fl/- ESCs Mbd3fl/- NSCs
Mbd3-/- NSCsMbd3-/-:Mbd3 NSCs
+Cre
+Mbd3
Mbd3a MERKRWECPALPQGWEREEVPRRSGLSAGHRDVFYYSPSGKKFRSKPQLARYLGGSMDLSTFDFRTGKML 70
Mbd3b MERK--------------------------------SPSGKKFRSKPQLARYLGGSMDLSTFDFRTGKML 38
Mbd3c MARIWFGG-------------------------WEISVPDRPPATIQALAKHLPGPSNPP---------- 35
* *                                 * ..:   :   **::* *. : .
Mbd3a MNKMNKSRQRVRYDSSNQVKGKPDLNTALPVRQTASIFKQPVTKITNHPSNKVKSDPQKAVDQPRQLFWE 130
Mbd3b MNKMNKSRQRVRYDSSNQVKGKPDLNTALPVRQTASIFKQPVTKITNHPSNKVKSDPQKAVDQPRQLFWE 98
Mbd3c WTPVGAARCRVFSP-----QGKPDLNTALPVRQTASIFKQPVTKITNHPSNKVKSDPQKAVDQPRQLFWE 100
. :. :* **        :**************************************************
Mbd3a KKLSGLSAFDIAEELVRTMDLPKGLQGVGPGCTDETLLSAIASALHTSTLPITGQLSAAVEKNPGVWLNT 210
Mbd3b KKLSGLSAFDIAEELVRTMDLPKGLQGVGPGCTDETLLSAIASALHTSTLPITGQLSAAVEKNPGVWLNT 178
Mbd3c KKLSGLSAFDIAEELVRTMDLPKGLQGVGPGCTDETLLSAIASALHTSTLPITGQLSAAVEKNPGVWLNT 180
**********************************************************************
Mbd3a AQPLCKAFMVTDDDIRKQEELVQQVRKRLEEALMADMLAHVEELARDGEAPLDKACAEEEEEEEEEEEEPEPERV 285
Mbd3b AQPLCKAFMVTDDDIRKQEELVQQVRKRLEEALMADMLAHVEELARDGEAPLDKACAEEEEEEEEEEEEPEPERV 253
Mbd3c AQPLCKAFMVTDDDIRKQEELVQQVRKRLEEALMADMLAHVEELARDGEAPLDKACAEEEEEEEEEEEEPEPERV 245
***************************************************************************
F
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Morphologically, Mbd3
fl/-
, Mbd3
-/-
 and Mbd3
-/-:
Mbd3 rescue NSCs were indistinguishable 
(Figure 3.2.2A), expressing normal levels of three canonical NSC markers, Olig2, Blbp, and 
Sox2 (Figure 3.2.2B). I observed that Mbd3
-/-
 NSCs, which are robustly self-renewing, 
proliferate 1.5 fold slower than Mbd3
fl/-
 and Mbd3
-/-
:Mbd3 NSCs, consistent with previous 
reports in Mbd3
-/-
 ES cells (Kaji et al., 2006) (Figure 3.2.2C). In fact, it has previously been 
shown that the Mbd3/NuRD complex function is required for normal S phase progression in 
Human Burkitt's lymphoma cell lines (Sims and Wade, 2011). 
 
 
Figure 3.2.2 – Characterization of generated Mbd3-/- Neural Stem Cells. 
(A) Phase images of the Mbd3fl/-, Mbd3-/- and Mbd3-/-:Mbd3 (rescue) NSCs used for 
reprogramming experiments. (B) qRT-PCR analysis of NSC markers (Sox2, Olig2, Blbp) and Mbd3 
expression levels in NSCs. qRT-PCR values are normalized to Gapdh value and shown as relative to 
the highest value. (C) Cell proliferation analysis of Mbd3fl/-, Mbd3-/- and rescue NSC lines. The error 
bars indicate STDEV. 
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To initiate reprogramming, the generated NSC lines were transduced with retroviruses 
encoding cMyc, Klf4 and Oct4 (rMKO), kept in NSCs conditions (Egf+Fgf2) for 3 days and 
then switched to serum plus LIF (S+LIF) conditions (Figure 3.2.3A), which typically results 
in the formation of highly proliferative reprogramming intermediates, or preiPSCs (Silva et 
al., 2008). To assess the transduction efficiency after Mbd3 deletion, Mbd3
fl/-
 and Mbd3
-/-
 
NSCs were transduced with retroviruses encoding green fluorescent protein (rGFP; Figure 
3.2.3B). Equal percentages (~60%) of GFP
+
 cells were observed 72h after transduction in 
both conditions (Figure 3.2.3C). Mbd3
-/-
 NSCs showed higher mean expression of GFP 
(86944, compared to 78640 in the case of Mbd3
fl/-
 NSCs) (Figure 3.2.3D), indicating that 
Mbd3 deletion does not affect transduction efficiency. 
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Figure 3.2.3 – Transduction efficiency of Mbd3-/- NSCs. 
(A) Experimental design used to address the kinetics and efficiency of initiation of 
reprogramming in NSCs with different Mbd3 genotypes. NSCs were transduced with retroviruses 
(pMXs) encoding cMyc, Klf4, Oct4 (rMKO), maintained in Egf+Fgf2 medium for three days and then 
switched to S+LIF medium. (B) Phase and GFP images of Mbd3fl/- and Mbd3-/- NSCs 72h after 
transduction with retroviruses encoding GFP (pMX-GFP). (C) Retroviral GFP (rGFP) expression 72h 
after transduction of Mbd3fl/- or Mbd3-/- NSCs with pMX-GFP, assessed by flow cytometry. GFP+ 
gates are shown. (D) Table indicates the percentages of rGFP+ cells and rGFP mean 72h after 
transduction of Mbd3fl/- or Mbd3-/- NSCs with pMX-GFP. 
Mbd3fl/- NSCs Mbd3-/- NSCs 
rGFP (530/30 488nm-A)
6
1
0
/2
0
 5
6
1
n
m
-A Sample
rGFP+
cells
rGFP
mean
Mbd3fl/- NSCs 59.3% 78640
Mbd3-/- NSCs 60.4% 86944
B
C D
fl/- -/-
rG
FP
NSCs
500m
Reprogramming 
intermediates (preiPSCs)
rMKO
NSCs
S+LIFEgf+Fgf2
NSCs
A
65 
 
Strikingly, the kinetics of the preiPSC emergence after rMKO transduction was markedly 
delayed in the case of Mbd3
-/-
 cells. While Mbd3 expressing preiPSCs dominated the culture 
by day 4 post-transduction (d.p.t), Mbd3
-/-
 preiPSCs emerged only by 7-8 d.p.t (Figure 
3.2.4A). In addition, the number of emerging alkaline phosphatase positive (AP
+
) Mbd3
-/- 
preiPSC colonies was significantly reduced (65 fold less colonies) compared to parental and 
rescue cell lines (Figure 3.2.4B). Nevertheless, it was possible to establish and expand Mbd3
-/-
 
preiPSCs, although less efficiently and with delayed kinetics. Mbd3-null preiPSCs exhibit the 
same slower proliferation phenotype as the NSCs from which they were generated (they 
proliferate 1.5 fold slower than Mbd3
fl/-
 and rescue preiPSCs) (Figure 3.2.4C). All generated 
preiPSC lines exhibited expected downregulation of the original NSC marker genes, such as 
Olig2, Blbp and Sox2 (Figure 3.2.4D). Mbd3
-/- 
preiPSCs were found to express slightly higher 
levels of retroviral transgenes (up to 25% higher), assessed 12 days after transduction, 
compared to control cells (Figure 3.2.4E), suggesting that the dosage of reprogramming 
factors is not the reason for the observed reduced efficiency of reprogramming initiation.  
 
 
 
 
 
 
 
 
 
 
(figure on next page) 
Figure 3.2.4 – The absence of Mbd3/NuRD decreases the efficiency and kinetics of initiation 
of reprogramming. 
(A) Phase images of the reprogramming intermediates (preiPSCs) emerging from Mbd3fl/-,  
Mbd3-/- and Mbd3-/-:Mbd3 (rescue) NSCs at different days post-transduction (d.p.t). (B) Efficiency of 
preiPSC colony formation per 2.5 x 105 NSCs assessed by alkaline phosphatase (AP) staining at day 9 
post-transduction. Representative alkaline phosphatase (AP) stainings are shown. (C) Cell 
proliferation analysis of Mbd3fl/-, Mbd3-/- and Mbd3-/-:Mbd3 preiPSCs lines. (D) qRT-PCR analysis of 
NSC markers (Sox2, Olig2, Blbp) and Mbd3 expression levels in NSCs and corresponding preiPSCs. 
(E) qRT-PCR analysis of retroviral transgenes (rOct4, rKlf4 and rMyc) and Mbd3 expression in the 
obtained preiPSCs maintained in S+LIF. Three independent NSCs transductions were carried out and 
gene expression was assessed 12 days after transduction.  qRT-PCR values are normalized to Gapdh 
value and shown as relative to the highest value. The error bars indicate STDEV. 
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To further dissect the requirement of Mbd3 in the initiation of reprogramming, I analysed 
the effect of Mbd3 deletion at different experimental time-points. To do this, I made use of a 
NSC line derived from E13.5 embryos, where both Mbd3 alleles are flanked by loxP sites. 
These Mbd3
fl/fl
 NSCs were stably transfected with Cre-ERt2, which enabled Cre-mediated 
excision of the floxed Mbd3 alleles upon addition of tamoxifen (4-OHT; Figure 3.2.5A). 
Around 90% reduction in Mbd3 protein levels was observed 72h after 4-OHT treatment of 
Mbd3
fl/fl
:Cre-ERt2 NSCs (Figure 3.2.5B). As with Mbd3
-/-
 clonal NSCs, slower proliferation 
(up to 2 fold) was observed in cells when Mbd3 was deleted (Figure 3.2.5C). 4-OHT 
treatment, with the resulting deletion of Mbd3, did not alter the gene expression signature 
typical of NSCs (Figure 3.2.5D). Mbd3
fl/fl
 NSCs could be maintained in culture in the 
presence of 4-OHT (5 passages tested), excluding other effects (e.g. cytotoxicity) beyond Cre-
mediated Mbd3 excision. An Mbd3
ex1fl/ex1fl
 NSC line was also derived from E13.5 embryos, 
which exhibited similar phenotypes upon Cre-mediated Mbd3 exon 1 excision, resulting in 
the removal of all but a small amount of a truncated Mbd3 protein isoform (Aguilera et al., 
2011; Kaji et al., 2006) (Mbd3c; Figure 3.2.5E). 
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Figure 3.2.5 – Characterization of Mbd3fl/fl Neural Stem Cells 
(A) Schematic representation of Mbd3 loci in Mbd3fl/fl NSCs before and after the transfection with 
the pCAG-CreERt2 transgene and treatment with 4-OHT. Exons are indicated as dark grey boxes, 
non-coding sequences are indicated as unfilled boxes, and light grey triangles represent loxP sites. (B) 
Western blot analysis of Mbd3 and -Tubulin (tub) protein levels in the Mbd3fl/fl:Cre-ERt2 NSCs 
treated with tamoxifen (4-OHT) or ethanol (EtOH). (C) Cell proliferation analysis of NSC 
Mbd3fl/fl:Cre-ERt2, in the presence of 4-OHT or EtOH. (D) qRT-PCR analysis of NSC markers 
expression in Mbd3fl/fl:Cre-ERt2 NSCs treated with 4-OHT or EtOH. qRT-PCR values are normalized 
to Gapdh value and shown as relative to the highest value. The error bars indicate STDEV. (E) 
Schematic representation of Mbd3 loci in Mbd3ex1fl/ex1fl NSCs before and after transfection with pCAG-
Cre-ERt2 transgene and treated with 4-OHT. Exons are indicated as dark grey boxes, non-coding 
sequences are indicated as unfilled boxes, and light grey triangles represent loxP sites. 
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To study the impact of Cre-mediated Mbd3 deletion at different time-points, 
Mbd3
fl/fl
:Cre-ERt2 or Mbd3
ex1fl/ex1fl
:Cre-ERt2 NSCs were transduced with rMKO and 4-OHT 
was added to the media for different periods. 4-OHT was applied two days before 
transduction and kept throughout in the condition #1, or just applied six days after 
transduction in the condition #6 (Figure 3.2.6). Since 4-OHT is ethanol-based (EtOH), EtOH-
only was used as a control for the experiment. As a result, I observed that the earlier Mbd3 
was removed, the fewer preiPSC colonies were formed. An average of 40 colonies could be 
scored when 4-OHT was applied at the time of transduction, compared to an average of 1200, 
when 4-OHT was not applied. Similar results were obtained upon the conditional deletion of 
the Mbd3 exon1. By timely removal of Mbd3 during the initiation of reprogramming process, 
I was able to recapitulate the reprogramming phenotype observed in the KO cells.  
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Figure 3.2.6 – Time-course of Mbd3 requirement during the initiation of reprogramming. 
Mbd3fl/fl and Mbd3ex1fl/ex1fl NSCs were stably transfected with pCAG-CreERt2 transgene, 
transduced with retroviral transgenes MKO and treated with 4-OHT at indicated time points to induce 
Cre-mediated deletion of the floxed alleles during reprogramming. Ethanol (EtOH) was used as a 
control. The encircled numbers correspond to different conditions. PreiPSC colony formation was 
assessed by AP staining at day 10 post-transduction and is presented as the number of colonies per 7.5 
x 104 NSCs. The error bars indicate STDEV. 
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lower 5-hmC levels, leading to reduced expression of 5-hmC marked genes in ESCs (Yildirim 
et al., 2011). I observed that the Mbd3
-/-
 NSCs have 2 fold higher expression of Tet1/2 
compared to Mbd3
fl/-
 or the rescue line, a feature that is lost after the transition to a preiPSC 
state (Figure 3.2.7A). Those apparently higher levels of Tet1/2 are not translated into the 
higher bulk 5-hmC levels. Mbd3
-/-
 NSCs exhibit lower levels of 5-hmC than the parental or 
rescue cell line (Figure 3.2.7B), a feature that is maintained in their corresponding preiPSCs 
(Figure 3.2.7C). To test if increased levels of Tet1/2 could rescue the Mbd3-null 
reprogramming phenotype, Mbd3
-/-
 NSCs were stably transfected with Tet1 or/and Tet2. By 
scoring the amount of AP
+
 preiPSC colonies formed 9 days after the transduction with rMKO, 
I observed that the initiation of reprogramming was not rescued by the overexpression of 
either Tet1 or Tet2, alone or in combination (Figure 3.2.7D). This indicates that although the 
5-hmC levels are lower in Mbd3
-/-
 NSCs, overexpressing of Tet enzymes is not sufficient to 
alleviate their reprogramming block. 
Taken together, these results demonstrate that lack of a functional NuRD complex 
strongly impairs the initiation of reprogramming from NSCs. 
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Figure 3.2.7 – Lack of NuRD complex leads to loss of 5-hydroxymethylation. 
(A) qRT-PCR analysis of Tet1/2 expression levels in Mbd3fl/-, Mbd3-/- and Mbd3-/-:Mbd3 NSCs 
and corresponding preiPSCs. qRT-PCR values are normalized to Gapdh value and shown as relative 
to the highest value. The error bars indicate STDEV. (B-C) DNA dot blot analysis of 5-
hydroxymethylation (5-hmC) bulk levels in (B) NSCs and (C) corresponding preiPSCs. (D) 
Quantification of AP+ preiPSC colonies formed 9 days post-transduction of Mbd3-/- NSCs transfected 
with the indicated transgenes with MKO and culture in S+LIF conditions. Colony number is per 2.5 x 
105 NSCs. Representative alkaline phosphatase (AP) staining are shown. The error bars indicate 
STDEV.  
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3.3 – Discussion 
3.3.1 – Mbd3 facilitates the initiation of reprogramming from neural stem cells 
In this chapter I analysed the role of the NuRD complex during transcription-factor 
mediated reprogramming of NSCs to naïve pluripotency. I demonstrated that the lack of a 
functional NuRD complex not only strongly impairs the initiation of reprogramming resulting 
in up to 65 fold less AP
+
 colonies, but also reduces the kinetics of this process, phenotypes 
that are not due to a different dosage of reprogramming factors between the cell lines used 
(Figure 3.2.4). I also found that depletion of Mbd3/NuRD leads to decreased global 5-hmC 
levels in Mbd3
-/-
 NSCs and preiPSCs compared to Mbd3
fl/-
 and rescue cell lines (Figures 
3.2.7B-C). This is in agreement with a recent report where it was shown that Mbd3 KD results 
in reduction of bulk levels of 5-hmC in ESCs, and that Tet1 KD impairs Mbd3 recruitment to 
target genes (Yildirim et al., 2011). This shows that Mbd3 is both dependent upon 5-hmC for 
DNA binding and is necessary for normal levels of 5-hmC within the genome. How this 
relationship between NuRD and Tet1 could occur is not understood, but it is possible that 
Mbd3 could bind to a 5-hmC rich region and recruit Tet enzymes to oxidate adjacent 
methylcytosines, or Mbd3 could bind to 5-hmC loci and protect them from further steps in a 
demethylation pathway. Both these mechanisms conjecture that Mbd3 can bind to 
hydroxymethylated DNA, although Mbd3 is not capable of binding methylated DNA 
(Hendrich and Bird, 1998; Zhang et al., 1999). Comparison between the methyl binding 
domain sequences of Mbd3 and remaining methyl binding domain family members revealed 
that one of the few differences is a substitution of tyrosine (Y) for phenylalanine (F) residue 
(Y34/F34 in Mbd/Mbd3) (Figure 3.2.1F) (Yildirim et al., 2011). Since the structural 
difference between phenylalanine and tyrosine is the absence of a hydroxyl group in the 
former, the additional hydroxyl group in 5-hmC relative to 5-mC may allow a direct binding 
of Mbd3 to hydroxymethylated DNA in a manner structurally analogous to the binding of 
remaining Mbd members to 5mC. Although I also observed a correlation between the lack of 
the NuRD complex and lower global 5-hmC levels, this observation does not seem to be due 
to a direct binding of Mbd3 to 5-hmC through the methyl binding domain. I observed that the 
levels of 5-hmC in Mbd3
-/-
 NSCs and preiPSCs could be rescued by the expression of Mbd3b, 
an Mbd3 isoform that lacks part of the annotated methyl binding domain, including the 
phenylalanine 34 (Y34) (Figure 3.2.1F and Figures 3.2.7B-C). Irrespectively of the 
mechanism through which NuRD and Tet1 interact, Mbd3 depletion results in lower global 
hydroxymethylation. This epigenetic mark has been previously associated with primed 
expression of key pluripotency genes before reprogramming to naïve pluripotency (Costa et 
al., 2013). Taking all these data into account, I hypothesize that the NuRD complex might act 
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as a mediator of 5-hmC’s effects on gene expression, enabling gene expression priming, 
acting as a facilitator of the induction of pluripotency. This would explain, at least in part, the 
observed Mbd3 deletion phenotype, since key genes might fail to become hydroxymethylated, 
repressing the specific gene activation signature that is required for efficient reprogramming.  
 
3.3.2 – Conclusions 
In this chapter, I demonstrated that disruption of the NuRD complex strongly impairs the 
initiation of reprogramming from NSCs, both in rate and extent. I also show that the earlier 
Mbd3 is deleted, the lower the number of preiPSC colonies formed. Although further 
molecular mechanistic information about the role of the NuRD complex during 
reprogramming is necessary, our data indicates that the hydroxymethylation of chromatin may 
play a part in NuRD-mediated genome-wide reprogramming. 
  
 
 
 
 
 
 
 
 
 
CHAPTER 4 - Dissection of the requirement of Mbd3/ NuRD 
complex for iPSC generation  
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4.1 – Introduction 
4.1.1 – NuRD complex in the establishment of naïve pluripotency 
In the previous chapter I analysed the role of the NuRD complex in the initiation of 
reprogramming using retroviral delivery of transcription factors. In this chapter I will assess 
the requirement for Mbd3 at the later stages of reprogramming, as well as its overall role in 
reprogramming using different cell systems. 
PreiPSCs are generated after the transduction of somatic cells and their culture in serum 
plus LIF containing medium. PreiPSCs can undergo full conversion to naïve pluripotency by 
their culture in serum-free medium containing LIF and inhibitors of both mitogen-activated 
protein kinase (Mek/Erk signalling – PD0325901) and glycogen synthase kinase-3 signalling 
(GSK3 - CHIR99021) - 2i/LIF media (Silva et al., 2008; Ying et al., 2008). This phase is 
termed the establishment phase of reprogramming. During this phase retroviral transgenes 
become silenced and the endogenous naïve pluripotent transcriptional program gets fully 
reactivated (Silva et al., 2008) (Figure 4.1.1). The generated iPSCs are now capable of re-
entering embryonic development, and contributing to all the tissues in the generated chimeras, 
including the germline (Okita et al., 2007; Silva et al., 2008; Silva et al., 2009). 
 
 
Figure 4.1.1 – Establishment of reprogramming. 
Schematic representation of the experimental design used to assess the requirement of the NuRD 
complex during the establishment of reprogramming. Upon transduction of somatic cells with the 
reprogramming factors Oct4, Klf4 and c-Myc (and Sox2) and culture in serum-containing media 
(S+LIF), preiPSCs are generated, being characterized for their exogenous retroviral transgene 
dependency. Exposure to serum-free medium containing LIF and inhibitors of both Mek/Erk and 
GSK3 (2i/LIF) leads to the establishment of iPSCs, which are capable to re-enter embryo 
development and contribute that all germ layers (Silva et al., 2008). 
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Other cell systems can be used to study nuclear reprogramming, such as the 
reprogramming to naïve pluripotency of primed pluripotent stem cells, termed epiblast-
derived stem cells (EpiSCs) (Brons et al., 2007; Tesar et al., 2007). As discussed in section 
1.1.5, EpiSCs are isolated from the post-implantation epiblast (E5.5) and constitute a primed 
pluripotent state that fail to re-enter development when injected into a blastocyst (Nichols and 
Smith, 2009). EpiSCs can be obtained by the culture of the post-implantation Epiblast in 
medium containing Fgf2 and Actinin A (Brons et al., 2007; Tesar et al., 2007), and also 
obtained by the direct differentiation of ESCs, by culture of these in Fgf2 and Activin A (Guo 
et al., 2009). Conversely, they can be reprogrammed to naïve pluripotency by combining the 
overexpression of at least one transcription factor, such as Klf4, Klf2 or Nanog, with the use 
of serum-free 2i/LIF medium which not only promotes the reprogramming of EpiSCs but also 
blocks their self-renewal (Guo et al., 2009; Silva et al., 2009). Forced activation of the LIF 
signalling pathway in EpiSCs is also capable of inducing their reprogramming to naïve 
pluripotency (Stuart et al., 2014; van Oosten et al., 2012; Yang et al., 2010). The resulting 
iPSCs are able to be injected into the blastocyst and to re-enter embryo development (Guo et 
al., 2009; Silva et al., 2009). A complete comparison of naïve pluripotency (ESCs/ iPSCs) and 
primed pluripotency (EpiSCs) can be found in Figure 1.1.3. 
A third system used in this chapter to address the role of the NuRD complex during 
induced pluripotency involves the use of piggyBac (PB) transposon/ transposase vectors to 
deliver the required transcription factors into mouse embryonic fibroblasts (MEFs) (Kaji et 
al., 2009; Woltjen et al., 2009). Taking into account that PB vectors remain active throughout 
the reprogramming process, including in the generated iPSCs, this system can allow the study 
of somatic cell reprogramming as a whole (Kaji et al., 2009; O'Malley et al., 2009; Woltjen et 
al., 2009). 
 
4.1.2 – Aim of the chapter 
In the previous chapter I showed that the lack of a functional NuRD complex strongly 
impairs the efficiency and kinetics of the initiation of reprogramming from NSCs. In this 
chapter I aimed to address whether NuRD is required for the later stages of reprogramming, 
and whether the deletion of Mbd3 at later stages of the reprogramming process mimics its 
removal at earlier stages. I also aimed to assess the role of the NuRD complex in the 
reprogramming of other cells types, namely EpiSCs and MEFs. 
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4.2 – Results 
4.2.1 – Mbd3/NuRD complex requirement to the establishment of pluripotency  
To induce the completion of the reprogramming process, Mbd3
fl/-
, Mbd3
-/-
 and rescue 
Mbd3
-/-
:Mbd3 preiPSCs obtained after MKO transduction (Figure 3.2.4) were cultured in 
serum-free 2i/LIF medium, and the resulting iPSC colonies were scored 12 days afterwards 
(Figure 4.2.1A). I observed that the efficiency of the conversion to naïve pluripotency of 
Mbd3
-/-
 preiPSCs is strongly reduced (20 fold) compared to Mbd3
fl/-
 and Mbd3
-/-
:Mbd3 
preiPSCs. The obtained Mbd3
fl/-
, Mbd3
-/-
 and Mbd3
-/-
:Mbd3 iPSCs could be clonally expanded 
in 2i/LIF conditions, exhibiting the expected reactivation of the pluripotency-associated 
transcriptional program and the silencing of retroviral reprogramming promoters (Figure 
4.2.1B). From this experiment it is unclear whether the lower efficiency of iPSC generation 
from Mbd3
-/-
 preiPSCs was due to the requirement for the NuRD complex in those 
reprogramming intermediates or if they were epigenetically disturbed due to the lack of the 
NuRD complex during their generation. To answer this question, Mbd3
fl/-
 preiPSCs were 
stably transfected with Cre-ERt2 and treated for 12 days (3-4 passages) with 4-OHT in EtOH, 
which results in the depletion of Mbd3 protein levels, or EtOH only (Figure 4.2.1C). I plated 
the same number of Mbd3
fl/-
 preiPSCs in 2i/LIF medium and scored the resulting iPSCs 
colonies 12 days later (Figure 4.2.1D). I observed that Mbd3 deletion in this established 
preiPSC line, prior to 2i/LIF medium switch, decreases reprogramming efficiency by up to 80 
fold, indicating that Mbd3 affects both the initiation and the intermediate stages of 
reprogramming. iPSCs generated from both Mbd3
fl/-
 preiPSC pre-treated with 4-OHT or 
EtOH showed a strong down-regulation of the retroviral transgenes and an up-regulation of 
pluripotency markers (Figure 4.2.1E).                   
(figure on next page) 
Figure 4.2.1 – Conversion to naïve pluripotency of Mbd3-/- preiPSCs is strongly impaired. 
(A) Quantification of iPSCs colonies generated from Mbd3fl/-, Mbd3-/- and Mbd3-/-:Mbd3 (rescue) 
preiPSCs after 2i/LIF culture for 12 days. Colony number is per 1.0 x 105 preiPSCs. (B) qRT-PCR 
analysis of retroviral transgenes, Mbd3, and pluripotency-associated in preiPSCs and corresponding 
derived iPSCs. (C) Western blot analysis of Mbd3 and -Tubulin (tub) protein levels in the Mbd3fl/-
:Cre-ERt2 preiPSC treated with 4-OHT or EtOH for 12 days. (D) Quantification of iPSCs colonies 
generated from preiPSCs Mbd3fl/- preiPSCs stably transformed with pCAG-Cre-ERt2 and treated with 
4-OHT or EtOH for 12 days while cultured in S+LIF. Medium was switched from S+LIF to 2i/LIF 
24h after plating. No 4-OHT or EtOH was added during 2i/LIF culture. Colony number is per 1.0 x 
105 preiPSCs. (E) qRT-PCR analysis in Mbd3fl/-:Cre-ERt2 preiPSCs treated with 4-OHT (or EtOH 
control) and corresponding derived iPSCs. qRT-PCR values are normalized to Gapdh value and 
shown as relative to the highest value. The error bars indicate STDEV. 
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I previously observed that the earlier Mbd3 was removed during the initiation of 
reprogramming, the fewer preiPSC colonies were formed (Figure 3.2.6). To determine if a 
similar relationship was also observed during the establishment phase of reprogramming, I 
performed a time-course experiment to define the time window for Mbd3 requirement in NSC 
reprogramming. For that, Mbd3
fl/fl
:Cre-ERt2 NSCs were transduced with rMKO and also with 
retroviruses encoding GFP and treated with 4-OHT at different experimental time points 
(Figure 4.2.2). Media was changed to S+LIF 4 days after transduction and, 4 days later, to 
2i/LIF. The number of iPSC colonies exhibiting silencing of retroviral GFP expression was 
assessed 12 days after 2i/LIF medium switch. 
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Figure 4.2.2 – Mbd3 is specifically required for the initiation of pluripotency. 
Mbd3fl/fl:Cre-ERt2 NSCs were transduced with rMKO and rGFP, maintained in Egf+Fgf2 
medium for three days, switched to S+LIF for more four days to allow preiPSC emergence and then 
switched to 2i/LIF conditions to induce iPSC formation. 4-OHT was added at different time-points 
(before or after preiPSC emergence) to induce Mbd3-floxed alleles excision. The encircled numbers 
correspond to different conditions. At day 20 after transfection, GFP- iPSC colonies were counted and 
subsequently stained for AP. The number of colonies is presented per 7.5 x 104 NSCs. The error bars 
indicate STDEV. 
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Although retroviral GFP silencing is not a mainstream pluripotency readout, its 
combination with stringent culture conditions, serum-free 2i/LIF medium, makes it a valuable 
marker to study reprogramming. In this experimental setup, only cells undergoing 
reprogramming and already reprogrammed ones survive. This explains why no GFP is visible 
in Figure 4.2.2, despite flow cytometry analysis showing that more than 80% of emerging 
preiPSCs 8 days after transduction are rGFP
+
 (Figure 4.2.3A-C). I observed that the number 
of rGFP
-
 iPSC colonies formed was proportional to the amount of time cells had expressed 
Mbd3 during the initiation phase of reprogramming (prior to 2i/LIF culture). The control 
condition had an average of 230 colonies, a number that dropped down to 1 colony when 4-
OHT was applied at the time of transduction. I observed neither a reduction nor a gain of 
reprogramming efficiency when Mbd3 was deleted at the 2i/LIF stage. Regardless of the stage 
of Mbd3 deletion, the generated iPSCs presented a pluripotency-associated transcriptional 
signature similar to wild type ESCs (Figure 4.2.3D). Analyses were performed after one 
passage on a pool of colonies from the entire well, preventing further culture enrichment for 
naïve pluripotent cells. Since transduction efficiency is maintained upon Mbd3 deletion 
(Figure 3.2.3B-D), and similar retroviral expression of reprogramming transgenes is observed 
between cells expressing or not Mbd3 (Figure 3.2.4E), I can conclude that the indicated 
results are a direct measure of the impact of Mbd3 excision on reprogramming.  
Together, these results indicate that Mbd3 specifically affects the initiation and 
intermediate stages, preiPSC formation, of reprogramming but not the 2i/LIF-mediated 
establishment of pluripotency.  
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Figure 4.2.3 – Characterization of the iPSCs generated from Mbd3fl/fl:Cre-ERT2 Neural 
Stem Cells. 
(A) Retroviral GFP (rGFP) expression 8 days post transduction of Mbd3fl/fl:Cre-ERt2 NSCs with 
rMKO or rMKO-rGFP. Percentage of rGFP+ cells was assessed by flow cytometry. GFP+ gates are 
shown. (B) Table indicates the percentage of rGFP+ cells 8 days post transduction of Mbd3fl/fl:Cre-
ERt2 NSCs with MKO or MKO-GFP. (C) Phase and GFP images of Mbd3fl/fl:Cre-ERt2 preiPSC 
colonies 8 days after transduction with rOKM + rGFP in presence of EtOH. Images acquired before 
medium switch to 2i/LIF, day 8. (D) qRT-PCR analysis of pluripotency-associated genes in iPSCs 
generated from Mbd3fl/fl:Cre-ERt2 NSCs with Mbd3 deletion at different time points of 
reprogramming, which conditions refer to Figure 2C. qRT-PCR values are normalized to Gapdh value 
and shown as relative to the highest value. The error bars indicate STDEV. 
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4.2.2 – Comparison of Mbd3-/- iPSCs to Mbd3-/- ESCs 
To address if Mbd3
-/-
 iPSCs, where Mbd3 has been removed at a somatic cell state, 
showed similar behaviour to Mbd3
-/-
 ESCs, where Mbd3 was removed at a pluripotent state, 
different phenotypic assays were employed. As previously reported, Mbd3
-/-
 ESCs can self-
renew in culture, expressing relatively normal levels of pluripotency markers (Kaji et al., 
2006; Reynolds et al., 2012a). However, Mbd3-null ESCs proliferate 2-times slower, a 
phenotype consistent with the known involvement of Mbd3 in cell cycle regulation (Kaji et 
al., 2006; Sims and Wade, 2011). Similar to Mbd3-null ESCs, different clonal Mbd3
-/-
 iPSC 
lines also proliferate 2-times slower than Mbd3
fl/-
 or rescue lines (Figure 4.2.4A). 
Another previously reported phenotype of Mbd3
-/-
 ESCs is their lack of differentiation 
potential. When seeded for in vitro differentiation, Mbd3
-/-
 ESCs fail to exit the self-renewing 
program, continuing to express high levels of pluripotency genes (Kaji et al., 2006). 
Moreover, when injected back into the embryo, they fail to contribute to the germ lineage 
(Kaji et al., 2006; Kaji et al., 2007). I have assessed if Mbd3
-/-
 iPSCs also fail to undergo in 
vitro differentiation using different differentiation assays. First, two clonal Mbd3
-/-
 iPSC lines, 
Mbd3
fl/-
 and rescue iPSC lines, and ESC controls were clonally seeded in LIF-depleted serum 
media (S-LIF). AP
+
 colonies could still be observed after seven days in S-LIF culture in the 
case Mbd3
-/-
 iPSCs/ESCs, but not in Mbd3-expressing lines (Figure 4.2.4B), indicating that 
although Mbd3-expressing cells fail to remain pluripotent when cultured in the absence of 
LIF, Mbd3-null cells can resist differentiation and clonally maintain a pluripotent status. 
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Figure 4.2.4 – iPSCs proliferation and clonal differentiation analysis. 
(A) Cell proliferation analysis of Mbd3fl/-, Mbd3-/- and Mbd3-/-:Mbd3 iPSCs clonal lines. (B) 
Alkaline phosphatase staining after culture in LIF-deprived serum-containing media (S-LIF) of clonal 
seeded ESCs or iPSCs. 2000 ESCs/iPSCs were seeded in the indicated media. 
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All above indicated cell lines were then cultured in S+LIF or S-LIF media to assess if 
Mbd3-deletion allows not only clonal growth in the absence of LIF but also extensive culture. 
Whereas Mbd3
fl/-
 iPSCs, rescue iPSCs, and Mbd3
fl/-
 ESCs were lost after two passages in S-
LIF, Mbd3
-/-
 iPSCs could be expanded in both conditions for more than four passages (Figure 
4.2.5A), exhibiting only a small reduction in pluripotency-associated gene expression (Figure 
4.2.5B).  
To further assess the lack of differentiation in Mbd3
-/-
 iPSCs when cultured in a 
monolayer culture in the absence of LIF, I measured the differentiation potential of all of the 
above cell lines during a time-course of 10 days using a pluripotency reporter. For that, I 
made use of a construct where GFP and puromycin resistance are expressed under the control 
of the Oct4 distal enhancer (EOS-GiP), meaning that only naïve pluripotent cells are GFP
+
. 
After stable transfection of the EOS-GiP construct into iPSCs/ ESCs and their culture in 
2i/LIF containing puromycin, I observed that 100% of the cells of all genotypes are GFP
+
 
(Figure 4.2.5C-D). Since only pluripotent cells are GFP
+
, I used these stably transfected cell 
lines to indirectly study the exit from pluripotency, since differentiated cells will become 
GFP
-
. 
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Figure 4.2.5 – Mbd3-/- ESCs/iPSCs can be cultured in the absence of pluripotency culture 
requisites. 
(A) Phase images of Mbd3-/- ESCs/iPSCs cultured in the presence or absence of LIF for 4 
passages (12 days). Mbd3fl/- ESCs/iPSCs and rescue cell lines were lost after 2 passages in S-LIF. (B) 
qRT-PCR analysis of pluripotency-associated in Mbd3-/- ESCs/iPSCs cultured in the presence or 
absence of LIF for 4 passages (12 days). qRT-PCR values are normalized to Gapdh value and shown 
as relative to the highest value. The error bars indicate STDEV. (C) ESCs/iPSCs with different 
genotypes were transfected with pB-EOS-GiP (GFPiresPuro under the control of early transposon 
promoter and Oct-4 and Sox2 enhancers) and selected using puromycin. Shown are merged phase and 
GFP images. (D) EOS-GiP levels in the different ESCs/iPSCs after stable transfection with pB-EOS-
GiP. Mbd3fl/- untransfected ESCs were used as GFP- control.  
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The generated EOS-GiP cell lines were then cultured in S-LIF media and GFP expression 
was analysed by flow cytometry every other day for 10 days (Figure 4.2.6A). More than 50% 
of Mbd3
-/-
 iPSCs/ ESCs remained EOS-GiP
+
 after 10 days of culture in the absence of LIF, 
whereas more than 80% of Mbd3
fl/-
 iPSCs/ ESCs exited self-renewal and differentiated, 
becoming EOS-GiP
-
. A time-course representation of all time points and duplicates collected 
can be found in Figure 4.2.6B. This indicates that although a minority of Mbd3
-/-
 iPSCs/ ESCs 
will eventually become EOS-GiP
- 
(around 30%), this process is very inefficient and exhibits 
delayed kinetics.  
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Figure 4.2.6 – Mbd3-/- iPSCs fail to down-regulate Oct4 reporter expression upon LIF-
withdrawal.  
(A) Time-course of Oct4-GFP (EOS-GiP) expression upon during culture in LIF-deprived 
serum-containing media. GFP expression was assessed by flow cytometry. GFP+ gates are shown. (B) 
Graphical representation of GFP+ gates from panels above. The error bars indicate STDEV. 
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The gold-standard of in vitro differentiation assays is the differentiation of pluripotent 
cells as embryoid bodies (EBs), the protocol that more closely resembles in vivo development 
(Doetschman et al., 1985). For the generation of EBs, ESCs are grown in low-attachment 
bacterial dishes in S-LIF, and after 3 to 8 days of culture the cells form complex EBs that are 
morphologically similar to morulas and early blastocysts (Doetschman et al., 1985), 
containing cells that are committed for differentiation into all germ lineages: endoderm, 
mesoderm and ectoderm. I tested how the iPSCs/ ESCs with different Mbd3 genotypes 
performed during EB differentiation, collecting samples for gene expression analysis at day 3, 
5 and 7 of culture in S-LIF. Key pluripotency-associated genes such a Nanog, Rex1, Esrr 
and Klf2 were found to be significantly down-regulated after 3 days in S-LIF in Mbd3
fl/-
 
iPSCs/ ESCs and Mbd3
-/-
:Mbd3 iPSCs (Figure 4.2.7A). Oct4 expression was kept high during 
the first 5 days of differentiation, and down-regulated only after 7 days, which is in 
accordance with the recently described role of Oct4 in the exit from pluripotency (Karwacki-
Neisius et al., 2013; Radzisheuskaya et al., 2013). All these pluripotency markers were found 
to be highly expressed throughout the EB differentiation protocol in Mbd3
-/-
 cells. Moreover, 
whereas key lineage specification genes such as Fgf5 (primitive ectoderm), Gata4 (endoderm) 
and T-brachyury (mesoderm) could be highly detected after 3 to 5 days of differentiation in 
Mbd3-expressing cells, these genes failed to be properly up-regulated during S-LIF culture of 
Mbd3-null cells. From our panel of differentiation genes, the only gene that was found to be 
up-regulated after EB differentiation of Mbd3
-/-
 cells was Pl-I (trophectoderm), a phenomena 
previously described during the differentiation of Mbd3
-/-
 ESCs (Kaji et al., 2006). Those 
results indicate that a lack of functional NuRD seems to be priming pluripotent cells to 
differentiate into trophectoderm, an extra-embryonic lineage that wild type ESCs cannot 
generate. The fact that disruption of the NuRD complex prompts cells to differentiate into 
trophectoderm might explain why ~30% of Mbd3
-/-
 iPSCs/ ESCs become EOS-GiP
-
 after 10 
days in culture in S-LIF (Figure 4.2.6B). Indeed, cells resembling trophoblast giant cells were 
visible after 6-8 days of culture of Mbd3
-/-
 iPSCs/ ESCs in S-LIF (data not shown). 
Additionally, beating cells were visible 3 to 4 days after plating the EBs generated from 
Mbd3
fl/-
 iPSCs/ ESCs and Mbd3
-/-
:Mbd3 iPSCs on gelatine, but not Mbd3-null cells. In fact, 
AP
+
 colonies could still be seen upon 4 days of S-LIF culture on gelatine of the Mbd3
-/- 
7 day-
old EBs on gelatine (Figure 4.2.7B), indicating how recalcitrant to differentiation these cells 
are. All together, the data presented above indicates that Mbd3
-/-
 iPSCs are phenotypically 
indistinguishable from previously reported Mbd3-null ESCs (Kaji et al., 2006), exhibiting 
slower proliferation and a lack of differentiation capacity, marked by impaired embryoid body 
differentiation.  
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Figure 4.2.7 – Mbd3-/- iPSCs exhibit impaired embryoid body differentiation. 
(A) qRT-PCR analysis of pluripotency- and differentiation-associated genes during differentiation 
as embryoid bodies of Mbd3fl/-, Mbd3-/-, Mbd3-/-:Mbd3 iPSCs or ESCs controls. The error bars indicate 
STDEV. (B) Alkaline phosphatase staining 4 days after plating of 7-day matured embryoid bodies in 
gelatine-coated dishes. Beating cells were observed after differentiation of Mbd3fl/- ESCs/iPSCs and 
rescue line, but not Mbd3-/- ESCs/iPSCs.  
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In the chapter 3, I showed that Mbd3
-/-
 NSCs and preiPSCs exhibit lower global levels of 
5-hmC compared to Mbd3-expressing cells (Figure 3.2.7). Since this relationship between 
Mbd3 and 5-hmC levels was first reported in ESCs (Yildirim et al., 2011), I tested if a similar 
phenotype is observed in iPSCs. As seen before in the case of NSCs and preiPSCs, similar 
Tet1/2 expression levels were detected in both Mbd3
fl/-
 and Mbd3
-/-
 iPSCs (Figure 4.2.8A). 
Yet, Mbd3
-/-
 iPSCs display lower levels of 5-hmC, to a similar extent than observed in Mbd3-
null ESCs (Figure 4.2.8B), revealing that, although Mbd3
-/-
 iPSCs could be established, these 
maintain a lower level of 5-hmC, which might explain, at least in part, the requirement for 
NuRD in somatic cell reprogramming (discussed in section 3.3.1).  
 
 
Figure 4.2.8 – Mbd3-/- ESCs/iPSCs show impaired levels of 5-hydroxymethylation. 
(A) qRT-PCR analysis of Tet1/2 expression levels in Mbd3fl/- and Mbd3-/- ESCs/iPSCs. qRT-PCR 
values are normalized to Gapdh value and shown as relative to the highest value. The error bars 
indicate STDEV. (B) DNA dot blot analysis of 5-hydroxymethylation (5-hmC) global levels in 
Mbd3fl/- and Mbd3-/- ESCs/iPSCs. 
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4.2.3 – The NuRD complex is required for Epiblast Stem Cell reprogramming 
Next, I tested the impact of Mbd3 deletion during EpiSC reprogramming to naïve 
pluripotency. For this, two approaches were used: siRNA mediated Mbd3 depletion or genetic 
deletion. 
To study the impact of Mbd3 knockdown (KD) in the reprogramming of EpiSCs, wild 
type EpiSCs carrying an Oct4-GFP reporter were stably transfected with piggyBac (PB) 
vectors constitutively expressing Klf2 and Nanog (K2N) or Klf4 and transfected with either 
small interference RNA (siRNA) against Mbd3 or control siRNA (siCtrl) (Figure 4.2.9A). To 
test which siRNA resulted in higher Mbd3 silencing, EpiSCs were transfected with four 
different siRNAs, independently or pooled, and both Mbd3 transcript and protein expression 
were analysed 48 or 72 hours latter (Figure 4.2.9B). Since the highest KD efficiency was 
achieved using siRNAs #1, #3 and #5, these were pooled and transfected together into EpiSCs 
for reprogramming experiments. Strikingly, Mbd3 KD led to a complete impairment of Klf4-
mediated reprogramming and up to a 6 fold reduction in the reprogramming ability of K2N 
(Figure 4.2.9C). Although with less efficiency, iPSCs could be generated after Mbd3 KD, 
exhibiting a gene expressing profile similar to wild type ESCs (Figure 4.2.9D).  
 
 
 
 
 
 
(figure on next page) 
Figure 4.2.9 – Mbd3 knockdown impairs Epiblast Stem Cell reprogramming. 
(A) Experimental design used to analyse the effect of Mbd3 knockdown (KD) on EpiSC 
reprogramming. Wild type EpiSCs (carrying an Oct4-GFP cassette), stably transfected with pPB-
CAG-Klf2.2A.Nanog (K2N) or pPB-CAG-Klf4, were transfected with either siMbd3 or siControl 
(siCtrl) and after 24h plated in 2i/LIF for 12 days. (B) qRT-PCR and western blot analysis of Mbd3 
transcript and protein levels, respectively, 48h and 72h after siRNA-mediated KD. tub indicates -
Tubulin. siRNAs were tested independently or pooled. A pool of si#1, #3 and #5 was used for future 
experiments. (C) The efficiency of EpiSC reprogramming after Mbd3 KD assessed by counting Oct4-
GFP+ iPSC colonies. Representative AP stained plates are also indicated. Colony number is per 1.0 x 
104 EpiSCs. (D) qRT-PCR analysis of Oct4, total Nanog, Rex1, Esrr, total Klf2 and Nr0b1 
expression in Klf2-2A-Nanog transfected Oct4-GFP EpiSCs and derived iPSCs with siCtrl and 
siMbd3 transfection in 2i/LIF. qRT-PCR values are normalized to Gapdh value and shown as relative 
to the highest value. The error bars indicate STDEV. 
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Since Mbd3 KD decreased the reprogramming efficiency of EpiSCs, I decided to test if 
the same finding could be achieved after genetic ablation of Mbd3. As described in the section 
1.4.2, Mbd3
-/-
 blastocysts die early post-implantation (Kaji et al., 2007), and since EpiSCs are 
derived from the post-implantation epiblast, Mbd3
-/-
 EpiSCs could not be derived in vivo. 
However, EpiSCs can be derived in vitro by the culture of ESCs in Fgf2 and Activin A 
conditions (Fgf2/Act.A) (Guo et al., 2009; Nichols and Smith, 2009). I tested if Mbd3
-/-
 ESCs 
could be differentiated into Mbd3
-/-
 EpiSCs by in vitro culture in Fgf2/Act.A (Figure 
4.2.10A). To follow differentiation into an EpiSC state, ESC lines stably transfected with the 
naïve pluripotency reporter EOS-GiP were used. As described above, the EOS promoter is 
only active in naïve pluripotent cells, being inactive in primed pluripotent cells, EpiSCs. 
Surprisingly, cells with EpiSC morphology could be seen after 2-3 passages in Fgf2/Act.A of 
Mbd3
-/-
 ESCs (Figure 4.2.10B). Flow cytometry analysis revealed that less than 5% of both 
Mbd3
fl/-
 and Mbd3
-/-
 cells were GFP
+
 after culture in Fgf2/Act.A conditions for 10 passages 
(Figure 4.2.10C). Moreover, both Mbd3
-/-
 and Mbd3
fl/-
 EpiSCs showed a downregulation of 
naïve pluripotency-associated genes (Nanog, Rex1, Klf2, Klf4 and Nr0b1) and an up 
regulation of primed pluripotency-associated genes (Lefty1 and T brachyury) (Figure 
4.2.10D). Although a functional NuRD complex is required for the generation of the post-
implantation epiblast in vivo, Mbd3-null EpiSCs can be generated in vitro by induced 
differentiation of naïve pluripotent Mbd3
-/-
 ESCs (Kaji et al., 2007). This indicates that the 
NuRD complex is not required for this transition between naïve and primed pluripotency in 
vitro. 
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Figure 4.2.10 – Lack of NuRD complex does not impair Epiblast Stem Cell differentiation.  
(A) Experimental design used to generate Mbd3-/- EpiSCs from Mbd3-/- ESCs by continuous 
culture in Fgf2 + Activin A (Fgf2/Act.A) conditions. The EOS-GiP reporter is only active in naïve 
pluripotent cells, becoming silent during EpiSCs differentiation. (B) Phase and GFP (merged) images 
of Mbd3fl/- and Mbd3-/- ESCs and EpiSCs derived from them. (C) EOS-GiP levels in Mbd3fl/- and 
Mbd3-/- ESCs and corresponding EpiSC derived after 10 passages in Fgf2/Act.A conditions. (D) qRT-
PCR analysis of Oct4, Nanog, Rex1, Klf2, Klf4, Nr0b1, Lefty1 and T brachyury expression in parental 
Mbd3fl/- and Mbd3-/- EOS-GiP ESCs and corresponding EOS-GiP EpiSCs. qRT-PCR values are 
normalized to Gapdh value and shown as relative to the highest value. The error bars indicate STDEV. 
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After establishing the above described EpiSC lines with a Klf2-Nanog construct  (K2N) 
these were plated in Fgf2/Act.A and switched next day to 2i/LIF conditions to minimize the 
possible impact of differences in cell proliferation (Figure 4.2.11A). Colonies showing 
reactivation of EOS-GiP transgene were observed 5-6 days after 2i/LIF application in cells 
from both genotypes, indicating that these ESC-derived EpiSCs could be reprogrammed back 
to full pluripotency (Figure 4.2.11B). Similarly to Mbd3 KD, Mbd3 genetic knockout (KO) 
led to a 20 fold reduction in K2N-mediated EpiSC reprogramming (Figure 4.2.11C).  
 
 
Figure 4.2.11 – Mbd3 knockout impairs Epiblast Stem Cell reprogramming. 
(A) Experimental design used to analyse the effect of Mbd3 knockout (KO) on EpiSC 
reprogramming. Mbd3-/- or Mbd3fl/- EpiSCs carrying an Oct4-GFP reporter (EOS-GiP), stably 
transfected with pPB-CAG-Klf2.2A.Nanog (K2N) or empty vector (EV), were plated in 2i/LIF for 12 
days. (B) Phase and EOS-GiP images of Mbd3
fl/-
 and Mbd3
-/-
 iPSCs generated from EpiSCs. (C) The 
efficiency of EpiSC reprogramming after Mbd3 KO was assessed by counting EOS-GFP+ iPSC 
colonies. Representative AP stained plates are also indicated. Colony number is per 1.5 x 104 EpiSCs. 
The error bars indicate STDEV. 
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The generated Mbd3
fl/-
 and Mbd3
-/-
 iPSCs maintained continuous GFP expression, 
allowing their culture in the presence of puromycin, a consequence of complete reactivation 
of the EOS-GiP reporter (Figure 4.2.12A-B). IPSCs from both genotypes reactivated the 
endogenous naïve pluripotency transcriptional program, exhibiting a gene expression profile 
similar to the original Mbd3
fl/-
 and Mbd3
-/-
 ESCs (Figure 4.2.12C).  
It has been reported that different populations of EpiSCs can be derived, exhibiting 
antagonistic levels of Oct4 and T brachyury (Han et al., 2010). Those different EpiSC lines 
display different behaviours. Oct4
high
/T brachyury
low
 are able to spontaneously convert to 
naïve pluripotency by culture in ESC media, without the use of exogenous transgenes (Han et 
al., 2010). To eliminate the possibility that the impaired EpiSC reprogramming after Mbd3 
deletion might be due to T brachyury levels, I used two independent EpiSC lines which 
differed in the expression levels of T Brachyury (Figure 4.2.12D). For the knockdown studies, 
the wild type EpiSC line chosen (OEC2) expresses very low levels of T brachyury, whereas 
for the knockout experiments I used Mbd3
-/-
, and their counterpart Mbd3
fl/-
, EpiSCs which 
express high levels of T-Brachyury. Moreover, I have never observed spontaneous 
reprogramming to naïve pluripotency of any EpiSC line (wild type or Mbd3
fl/-
 and Mbd3
-/-
 
transfected with empty vector) after culture in 2i/LIF conditions alone.  
Together, these results indicate that lack of a functional NuRD complex not only impairs 
NSC reprogramming but also transcription factor-mediated EpiSC reprograming. 
 
 
 
 
 
 
 
(figure on next page) 
Figure 4.2.12 – Characterization of the iPSCs generated from Mbd3-/- EpiSCs. 
(A) Phase and GFP (merged) images of Mbd3fl/- and Mbd3-/- iPSCs generated from corresponding 
EpiSCs. (B) EOS-GFP levels in Mbd3fl/- and Mbd3-/- EpiSCs after sorting for EOS-GFP- EpiSCs and 
corresponding iPSCs. (C) qRT-PCR analysis of Oct4, total Nanog, Rex1, total Klf2, Klf4, Nr0b1, 
Lefty1 and T (brachyury) expression in parental Mbd3fl/- and Mbd3-/- EOS-GiP ESCs, Mbd3fl/- and 
Mbd3
-/-
 EOS-GiP EpiSCs obtained from them and EpiSC-derived iPSCs. (D) qRT-PCR analysis of T 
brachyury in the EpiSCs lines used in this study: Oct4-GFP EpiSCs used for knockdown experiments 
and EOS-GiP EpiSCs used for knockout experiments. qRT-PCR values are normalized to Gapdh value 
and shown as relative to the highest value. 
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4.2.4 – The NuRD complex does not impact Mouse Embryonic Fibroblast 
reprogramming 
All the above described results indicate that Mbd3 is critical for efficient reprogramming. 
To check if similar results are observed when different reprogramming approaches are used, 
we performed piggyBac-mediated reprogramming of mouse embryonic fibroblasts (MEFs) 
combined with either Mbd3 depletion by KD or KO. The MEF piggyBac-mediated 
reprogramming experiments presented below were performed in collaboration with Luca 
Tosti and Keisuke Kaji from the MRC Centre for Regenerative Medicine, University of 
Edinburgh. 
First, we used an Mbd3 knockdown system (Figure 4.2.13A). For this, Nanog-GFP MEFs 
were treated with doxycycline (DOX) for the induction of the iMKOS polycistronic cassette 
which had been previously transfected into those MEFs (O'Malley et al., 2013). This 
polycistronic cassette encodes all four Yamanaka factors which are expressed from a single 
promoter and are linked by self-processing 2A peptides (Carey et al., 2009), and is only active 
when DOX is added to the culture (O'Malley et al., 2013). After addition of DOX, MEFs were 
cultured in S+LIF medium supplemented with vitamin C and Alki (Tgf signalling inhibitor). 
24h afterwards they were transduced with lentiviruses expressing shRNA against Mbd3. 80-
90% Mbd3 KD was observed 6 days after transduction of the MEFs with shMbd3, which 
corresponds to day 7 of reprogramming (Figure 4.2.13B). Reactivation of the Nanog-GFP 
reporter was observed 10-12 days after the induction of the iMOKS cassette (Figure 4.2.13C), 
and the Nanog-GFP
+
 iPSC colonies generated were scored at day 13 of reprogramming 
(Figure 4.2.13D). No significant differences were found between MEFs transduced with two 
different shRNAs against Mbd3 or shControls (around 100 colonies were scored in all cases). 
To test if this difference could be due to the reprogramming cassette used, we tested two 
reprogramming cassettes side-by-side: the iMKOS used above (O'Malley et al., 2013) and the 
iOKSM cassette (O'Malley et al., 2013; Sommer et al., 2009). The only difference between 
these two cassettes is the order in which the factors were cloned. Once again, no impact on the 
amount of Nanog-GFP
+
 iPSC colonies generated using either cassette was observed (Figure 
4.2.13E). Interestingly, we observed a 2 fold increase in the amount of Nanog-GFP
-
 colonies, 
which corresponds to partially reprogrammed colonies, after reprogramming of the MEFs 
transduced with shMbd3. 
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Figure 4.2.13 – Mbd3 knockdown does not impact Mouse Embryonic Fibroblasts piggyBac-
mediated reprogramming. 
(A) Experimental designs used to analyse the effect of Mbd3 KD. Nanog-GFP MEFs transfected 
with doxycycline-inducible MKOS piggyback transposon (iMKOS) were cultured in S+LIF + DOX + 
vitamin C (vitC) + Alki 24 hours before lentiviral infections of shMbd3 or shControls. (B) Western 
blot analysis of Mbd3 and -Tubulin (tub) protein levels at day 7 of reprogramming MEFs infected 
with shMbd3 or control shRNA against Hygromycin or Zeocin resistant genes (shHyg or shZeo). Over 
90% of Mbd3 knockdown was observed. (C) Phase and Nanog-GFP images of iPSCs derived from 
MEFs transduced with lentiviruses encoding shHyg or shMbd3.5. (D) Number of Nanog-GFP+ iPSC 
colonies at day 13 of reprogramming upon infection of indicated shRNAs. (E) Quantification of 
Nanog-GFP+ iPSCs colonies and Nanog-GFP- colonies generated by piggybac MEF reprogramming 
using two different reprogramming cassettes, iMKOS and iOKSM. Mbd3 KD using shRNA was 
carried out 24h after induction of reprogramming cassettes. shMbd3.5 was used for this experiment. 
Typical iMKOS positive cell number at day 2 of reprogramming is 1.0-3.0 x 104 cells per well, 
providing 1-2% reprogramming efficiency. The error bars indicate STDEV. 
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We also tested Mbd3 depletion by KO, by treating Cre-ERt2 transduced Mbd3
ex1fl/ex1fl
 
MEFs with 4-OHT at 0h or 48hrs after the induction of reprogramming factor expression 
(Figure 4.2.14A). Mbd3 exon 1 excision results in a loss of Mbd3a and Mbd3b isoforms, but a 
hypomorphic Mbd3c residual expression is observed (Figure 4.2.12B and Figure 3.2.1D). 
Since Mbd3
ex1fl/ex1fl
 MEFs do not contain a reprogramming reporter, the resulting colonies 
were stained for Nanog protein 13 days after induction of the iMKOS cassette (Figure 
4.2.14C). Although Mbd3 protein was found to be down-regulated, no impact on piggyBac-
mediated MEF reprogramming was observed after Mbd3 exon 1 deletion (Figure 4.2.14D), 
recapitulating the result obtained from Mbd3 KD during MEF reprogramming. 
Together, the above results show that Mbd3 depletion after the induction of 
reprogramming cassettes in a piggyBac-mediated MEF reprogramming system leads to no 
effect on transcription factor-induced naïve pluripotency.  
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Figure 4.2.14 – Mbd3 knockout does not impact Mouse Embryonic Fibroblasts piggyBac-
mediated reprogramming. 
(A) Experimental designs used to analyse the effect of Mbd3 exon 1 KO. Mbd3ex1fl/ex1fl MEFs 
transfected with iMKOS were infected with pMX-Cre-ERt2. Reprogramming was carried out in 
S+LIF + DOX + vitC + Alki, and 4-OHT was added either at the time of DOX administration (0h) or 
48h later (48h). (B) Western blot analysis of Mbd3 and tub protein at day 7 during reprogramming of 
Mbd3ex1fl/ex1fl:Cre-ERt2 MEFs treated 4-OHT 0h or 48h after induction of reprogramming cassettes. 
About 80% of Mbd3 knockdown was observed. (C) Phase and Nanog immunofluorescence positive 
colonies images of iPSCs derived from Mbd3ex1fl/ex1fl:Cre-ERt2 treated 4-OHT 0h or 48h after induction 
of reprogramming cassettes. (D) Number of Nanog positive colony numbers determined by 
immunofluorescence after 13 days of reprogramming of Mbd3ex1fl/ex1fl:Cre-ERt2 MEFs. Typical 
iMKOS positive cell number at day 2 of reprogramming is 1.0-3.0 x 104 cells per well, providing 1-
2% reprogramming efficiency. The error bars indicate STDEV.   
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4.3 – Discussion 
4.3.1 – Mbd3 is required for efficient iPSC generation 
In this chapter I dissected the requirement for the Mbd3/ NuRD complex during iPSC 
generation. Using genetic or siRNA mediated Mbd3 depletion, as well as different cell 
systems and experimental designs, I observed an impairment of reprogramming which is 
proportional to the amount of time cells express Mbd3 during the initiation of reprogramming. 
I observed that depending on the reprogramming context, Mbd3/ NuRD depletion leads to 
two possible outcomes: no effect, in case of piggyBac-mediated MEF reprogramming; or a 
significant impairment in transcription factor-induced naïve pluripotency, in the case of NSC 
or EpiSC reprogramming. PiggyBac-mediated MEF reprogramming might not be affected 
due to the fact that Mbd3 is only deleted after the induction of the reprogramming factors. 
Since the loss of Mbd3 protein requires a few days from the time 4-OHT is administrated, and 
shMbd3 is transduced, it is possible that in this MEF reprogramming system cells go through 
the critical stage of reprogramming with Mbd3 protein still present. Indeed, the treatment of 
human fibroblasts with shRNAs against Mbd3 prior to OSKM expression led to a 2 fold 
reduction in reprogramming efficiency (Onder et al., 2012), reinforcing the idea that the 
induction of the reprogramming factors before Mbd3 deletion during MEF reprogramming 
may overcome the requirement for the NuRD complex. Importantly, regardless of the system 
used, Mbd3 deletion never resulted in the enhancement of reprogramming efficiency. My 
results identify a key role of the NuRD complex in reprogramming and show that, in a context 
dependent manner, a chromatin modifying complex required for cell differentiation also 
promotes reversion back to a naïve pluripotent cell state, acting as a facilitator of transcription 
factor-mediated induced pluripotency (Figure 4.3.1) 
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Figure 4.3.1 – Role of Mbd3/NuRD during the reprogramming. 
The NuRD complex is essential for embryonic development. Its absence causes early embryo 
lethality (Hendrich et al., 2001; Kaji et al., 2007) and inability of ESCs to differentiate in vitro (Kaji et 
al., 2006). As demonstrated here, the NuRD complex is also critical for efficient reprogramming of 
NSCs, preiPSCs and EpiSCs (1), highlighting the complex as an important facilitator of cell state 
transitions. In my experimental setting where Mbd3 is depleted only after MKOS induction, no effect 
on reprogramming was observed (2). 
 
My results are in apparent disagreement with the two reports which were published 
during the execution of this project (Luo et al., 2013; Rais et al., 2013). In both studies it was 
reported that Mbd3/ NuRD constitutes a barrier for somatic cell reprogramming. Particularly, 
the abrogation of Mbd3 expression led to higher reprogramming efficiencies, but the extent of 
this increase was different between those two studies (Luo et al., 2013; Rais et al., 2013). 
In the Luo et al report, the system used to address the impact of the NuRD complex in 
reprogramming was Mbd3 KD in MEF reprogramming system based on lentiviral-MKOS 
delivery (Luo et al., 2013). It was observed the shMbd3 transduction during MEF 
reprogramming leads to a 4 fold increase in the Oct4-GFP
+
 colonies generated. In our hands, 
while both Mbd3 KD and KO during MEF reprogramming demonstrated about 80% 
downregulation of Mbd3 protein levels, neither impacted on the efficiency of MEF 
reprogramming. Potential explanations for the differences between Luo et al and our MEF 
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reprogramming results could be the means of reprogramming factor delivery used (4 viruses 
vs MKOS piggybac) and/or the reprogramming readout (alkaline phosphatase staining or 
Oct4-GFP vs Nanog-GFP). We addressed how reprogramming cassettes or the readout affect 
the results by performing Mbd3 KD during piggyBac reprogramming using a different 
reprogramming cassette, iOKSM, which was reported to generate iPSC lines with abnormal 
imprinting patterns due to suboptimal stoichiometry of the 4 factors, unless Vitamin C is 
present (Carey et al., 2011; Stadtfeld et al., 2012). This iOKSM cassette was used in Rais et al 
study as well (Rais et al., 2013). Interestingly, while Nanog-GFP
+
 colony number was not 
affected by Mbd3 KD when using either iMKOS or iOKSM reprogramming cassettes, the 
total colony number was increased up to 2 fold in the presence of shMbd3 in the case of the 
iOKSM cassette (Figure 4.2.13E). Previous reports have demonstrated that endogenous Oct4 
expression occurs in the early stages of reprogramming and is not a good predictor of 
successful reprogramming (Buganim et al., 2012; O'Malley et al., 2013; Silva et al., 2008; 
Theunissen et al., 2011b), especially if a stringent culture medium such as serum-free, KSR 
(knockout serum replacement)-free, 2i/LIF is not used. This is of relevance since for iPSC 
induction Luo et al used medium supplemented with 10% KSR. While further investigation is 
necessary, differences between Luo et al and our work might be due to different stoichiometry 
of the 4 factors and the criteria used for scoring iPSC colonies.  
More recently, another report was published claiming that low levels or deletion of Mbd3 
leads to rapid deterministic reprogramming with 100% efficiency (Rais et al., 2013). The 
conclusions by Rais et al were founded on two key findings. First, they identified Mbd3 as a 
barrier to reprogramming by an RNAi screen in EpiSCs. Second, they showed that MEFs 
derived from Mbd3
fl/-
 ESCs reportedly expressing 20% of wild type Mbd3 levels, exhibit 
100% reprogramming efficiency judging by the upregulation of an Oct4-GFP (genomic Oct4 
fragment 18 kb, GOF-18) reporter transgene. There are, however, issues with Rais et al’s 
experiments. Firstly, the EpiSCs used exhibit high expression of the naïve pluripotency 
marker Klf4, which is usually negligible in EpiSCs compared to ESCs cultured in 2i/LIF (Guo 
et al., 2009; Silva et al., 2009; Yang et al., 2010) (Figure 4.2.10D) and ectopic expression of 
Klf4 induces reprogramming to naïve pluripotency (Guo et al., 2009). This questions the 
reliability of their EpiSCs as an RNAi screening system for reprogramming. Secondly, the 
Mbd3
fl/-
 heterozygous ESC line, which was generated by the Hendrich laboratory (University 
of Cambridge) and used in the study by Rais et al to derive Mbd3
fl/-
 MEFs, actually express 
Mbd3 protein at nearly wild type levels (Reynolds et al., 2012b) (Figure 3.2.1B), in contrast 
to the 20% shown in Rais et al. Thus, MEFs derived from this line cannot be used to describe 
the effects of lower levels of Mbd3 in reprogramming, nor is it clear why the cells used by 
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Rais et al show such low levels of Mbd3. Surprisingly, analysis of whole cell extracts input 
(WCE) ChIP-seq (chromatin immunoprecipitation followed by massively parallel sequencing) 
tracks of Mbd3
fl/-
 MEFs and derived iPS cells published by Rais et al revealed a striking over-
representation of Pou5f1/Oct4 regulatory sequences, indicative of a large number of copies of 
the Oct4 reporter transgene (GOF-18) in the genome (Figure 4.3.2, top panel). For this reason, 
reactivation of the reporter transgene could occur more readily than endogenous pluripotency-
associated gene activation, leading to inappropriately inflated measures of reprogramming 
efficiency. Furthermore, closer inspection of the same input ChIP-seq tracks at the Pou5f1 
regulatory sequences also revealed that the 18kb Oct4 reporter transgene used by Rais et al in 
control Mbd3
+/+
 MEFs was different from that in Mbd3
fl/-
 MEFs. The key Pou5f1 regulatory 
sequence, the proximal enhancer (PE), responsible for driving GFP expression, is found to be 
missing in the Oct4-GFP reporter of control MEFs, indicative of GOF-18ΔPE (Yeom et al., 
1996; Yoshimizu et al., 1999) (Figure 4.3.2, middle and bottom panels). Thus, the intact 
versus the defective Oct4-GFP reporter transgene could easily explain the difference in Oct4-
GFP
+
 colony numbers observed between Mbd3
+/+
 and Mbd3
fl/- 
in Rais et al’s study. While the 
impact of the loss of Mbd3 on reprogramming may differ depending on cell type or 
reprogramming strategy (e.g. viral vs transposon, culture conditions, etc…), the claim made in 
the Rais et al study of deterministic 100% reprogramming efficiency upon Mbd3 KO or KD is 
likely to be an experimental artefact. 
Despite observing an important role for Mbd3 in various reprogramming contexts, I do 
not exclude the possibility that these opposing results could be due to some other technical 
differences between the studies, such as culture media, reprogramming cassettes and 
pluripotency reporters used. 
In this chapter I also described that both Mbd3-null ESCs and iPSCs show globally 
reduced 5-hmC levels, once again raising the hypothesis that the NuRD complex might be 
controlling 5-hmC levels in the genome, by direct shielding of this mark from further 
oxidation by recruitment of Tet enzymes for 5-hmC generation. Regardless of the mechanism, 
this reduction in hydroxymethylation might be responsible for the decreased efficiency of 
Mbd3-null cell reprogramming. 
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(figure on next page) 
Figure 4.3.2 – WT cells, but not Mbd3fl/-, show deletion of GOF reporter transgene. 
Shown is Rais et al whole-cell extracts (WCE) input control ChIP-seq data of wild type (WT) 
MEFs, WT iPSCs, Mbd3fl/- MEFs and Mbd3fl/- iPSCs. Upper panel shows a 400Mb region of 
chromosome 17 which contains the Pou5f1 (Oct4) locus. Please note the strong signal surrounding the 
Pou5f1 locus. This potentially indicates the presence of multiple genomic integrations of the 18Kb 
Oct4-GFP (GOF-18) (Yeom et al., 1996) reporter transgene in the genome, which could lead to 
unspecific reporter activation during reprogramming. Middle panel shows a closer magnification of 
the region exhibiting the strong signal at the Pou5f1 locus. This reveals a deletion (red box) within the 
GOF-18 reporter transgene in WT MEFs and derived from them iPSCs. However, this deletion seems 
not to be present in Mbd3fl/- cells. Lower panel indicates that deleted region corresponds to the highly 
conserved Pou5f1 regulatory sequence known as the proximal enhancer (PE), lack of which makes the 
expression of the reporter exclusive to the naïve pluripotent and germ cells  (Yoshimizu et al., 1999). 
ChIP-seq data for Nanog (GSM288345) is indicated as an example for transcription factor occupancy 
at the Pou5f1 regulatory sequences (peak on the left corresponds to the distal enhancer, peak on the 
right – to the proximal enhancer). 
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4.3.2 – Conclusions 
In this chapter, by manipulating Mbd3 levels using genetics or shRNA/siRNA in a 
number of biological systems, I demonstrated that the NuRD complex facilitates the ability of 
cells to reprogram to naïve pluripotency. This leads to the hypothesis that in a context 
dependent manner, the NuRD complex might act as a gene expression activator, and that 
NuRD’s function expands beyond simple gene repression as previously claimed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
CHAPTER 5 – Functional investigation of the effect of Mbd3 
overexpression during the induction of pluripotency  
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5.1 – Introduction 
5.1.1 – Mbd3/ NuRD acting as facilitator of genome-wide reprogramming 
In the previous chapters I observed that the complete removal of Mbd3 or a decrease in 
its expression can significantly impair the generation of both preiPSCs (chapter 3) and iPSCs 
(chapter 4). Those observations made us postulate that Mbd3/ NuRD might act as a facilitator 
of transcription-factor induced pluripotency, probably by interacting with transcription factors 
to assist genome-wide reprogramming. I hypothesized that the NuRD complex might be 
recruited to key genes during nuclear reprogramming through interactions with 
reprogramming factors, facilitating reprogramming, perhaps by enabling the repression of 
lineage specific genes or by alleviating the repression of key pluripotency genes.  
Since loss of NuRD function reduces reprogramming efficiency, I set out to determine 
the effect of higher Mbd3 and/ or NuRD complex levels on reprogramming (Figure 5.1.1). 
 
 
Figure 5.1.1 – Effect of Mbd3 overexpression on reprograming. 
In the previous chapters we described that Mbd3/ NuRD depletion decreases reprogramming 
efficiency of NSCs, preiPSCs and EpiSCs. In this chapter 5 we assessed the effect of Mbd3 
overexpression reprogramming of these cell types. 
 
5.1.2 – Aim of the chapter 
Previously I observed that Mbd3 depletion can significantly impair nuclear 
reprogramming. In this chapter I aimed to test whether Mbd3 levels are limiting for 
reprogramming, and weather Mbd3 might enhance transcription-factor mediated 
reprogramming. For that, I used different reprogramming systems, namely NSCs, preiPSCs 
and EpiSCs.  
EpiSCs
NSCs
preiPSCs
iPSCs
Mbd3 depletion
Mbd3 
overexpression
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5.2 – Results 
5.2.1 – Overexpression of Mbd3/NuRD facilitates Nanog-mediated reprogramming 
To test whether Mbd3 levels are limiting for reprogramming, Oct4-GFP reporter NSCs 
were stably transfected with Mbd3. Stable lines were subsequently transduced with rOKM, 
cultured in Egf+Fgf2 medium for three days, cultured in S+LIF medium for 6 days and finally 
switched to 2i/LIF conditions (Figure 5.2.1A). Mbd3 overexpression had neither a positive 
nor a detrimental effect on the efficiency of Oct4-GFP
+
 iPSC formation during NSC 
reprogramming (Figure 5.2.1B-C). Our laboratory has previously reported that Nanog 
overexpression enhances reprogramming efficiency in combination with 2i/LIF culture 
(Theunissen et al., 2011b). I used Nanog overexpression as a control for the enhancement of 
reprogramming, observing a 5 fold increase in NSC reprogramming. Interestingly, combined 
overexpression of Nanog and Mbd3 synergistically induced a 10 fold increase in 
reprogramming efficiency, twice the efficiency of Nanog alone (Figure 5.2.1B). Interestingly, 
Mbd3 overexpression in these cell lines caused an increase in the protein levels of Mta2, a 
core subunit of the NuRD complex which is degraded in the absence of Mbd3 (Figure 5.2.1B) 
(Kaji et al., 2006). This suggests that the effects of Mbd3 overexpression are potentially 
attributable to the total amount, and, subsequently, the total activity, of the NuRD complex. 
iPSCs generated from NSCs transfected with any transgene combination showed a gene 
expression signature typical of naïve pluripotent cells (Figure 5.2.1E). 
 
 
 
 
(figure on next page) 
Figure 5.2.1 – Mbd3 overexpression does not affect Neural Stem Cell reprogramming. 
(A) Experimental design used to address the effect of Mbd3 overexpression on NSC 
reprogramming. NSCs carrying an Oct4-GFP cassette were stably transfected with pPB-CAG-Nanog 
and pPB-CAG-Mbd3b or pPB-CAG-empty controls, transduced with rOKM, cultured in Egf+Fgf2 
medium for three days, switched to S+LIF medium for 6 days and then switched to 2i/LIF conditions. 
(B) Quantification of Oct4-GFP+ colonies after 12 days in 2i/LIF conditions. Colony number is per 1.0 
x 105 NSCs. (C) Phase and GFP images and AP staining of the iPSCs obtained from NSCs 
overexpressing respective transgenes. (D) Western blot analysis of Nanog, Mbd3, Mta2 and -Tubulin 
(tub) protein expression in NSCs overexpressing the indicated transgene combinations. (E) qRT-
PCR analysis of NSC- and pluripotency-associated genes, and Mbd3 in transgenic NSCs and 
corresponding derived iPSCs. qRT-PCR values are normalized to Gapdh value and shown as relative 
to the highest value. The error bars indicate STDEV. 
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I then assessed the impact of Mbd3 overexpression in other reprograming systems. First, I 
tested if Mbd3 expression could overcome the reprogramming block of preiPSCs. For that, 
Nanog-GFP preiPSCs were stably transfected with the same transgene combinations as the 
NSCs above (Figure 5.2.2A). Since I wanted to evaluate the ability of Mbd3 to enhance 
reprogramming efficiency, I chose a particular preiPSC line which was derived from MEFs 
and that shows inefficient conversion rate to naïve pluripotency in 2i/LIF conditions. This is a 
suitable cell system for gain-of-function studies and this cell line has previously been used in 
our laboratory to dissect the Nanog-Tet1/2 synergistic effect on reprogramming (Costa et al., 
2013). As observed for NSCs, Mbd3 overexpression in preiPSCs also caused an increase in 
the protein levels of Mta2 (Figure 5.2.2B). 
 
 
Figure 5.2.2 – Mbd3 overexpression in preiPSCs leads to increased levels of other NuRD 
subunits.  
(A) Experimental design used to address the effect of Mbd3/NuRD overexpression on the 
conversion of preiPSCs to iPSCs. PreiPSCs (carrying a Nanog-GFP) were stably transfected with 
pPB-CAG-Nanog and pPB-CAG-Mbd3b or pPB-CAG-empty controls and plated in 2i/LIF conditions 
for 12 days. (B) Western blot analysis of Nanog, Mbd3, Mta2 and -Tubulin (tub) protein expression 
in preiPSCs overexpressing Nanog or Nanog and Mbd3. 
 
To study the conversion of the established transgenic preiPSC lines to naïve pluripotency, 
these were plated in S+LIF medium, and switched to 2i/LIF conditions 2-3 days afterwards. 
Interestingly, the combined overexpression of Mbd3 and Nanog in MEF-derived preiPSCs led 
to accelerated reprogramming kinetics, and Nanog-GFP
+
 colonies were visible as early as 24h 
after the beginning of 2i/LIF culture (Figure 5.2.3).  
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Figure 5.2.3 – Nanog-Mbd3 preiPSCs show increased reprogramming.  
Phase and GFP images acquired before and after medium switch to 2i/LIF of the different 
transgenic Nanog-GFP preiPSCs lines. Images were taken every day during the 12 days of the 
experiment. The field of vision is not the same in the different images correspondent to the same 
transgenic line. 
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I observed that the combined forced expression of Nanog-Mbd3 not only facilitated 
preiPSC’s conversion to naïve pluripotency in rate but also in extent (Figure 5.2.4A), and 
reprogramming efficiency was up to 30 fold higher compared to the Nanog-Empty vector 
(EV) control (Figure 5.2.4B). As expected, this preiPSC line, which was recalcitrant to 
reprogramming, failed to convert to naïve pluripotency after its transfection with EV controls 
(Figure 5.2.4C), since preiPSC were not allowed to expand for more than 3 days before 2i/LIF 
switch. Moreover, the overexpression of Mbd3 alone was not sufficient to overcome this 
reprogramming block, showing that NuRD alone is not sufficient to induce reprogramming 
and only acts as a facilitator of Nanog-mediated reprogramming. Importantly, the iPSCs 
generated from preiPSCs by the overexpression of Nanog and Mbd3, exhibited the molecular 
properties of naïve pluripotent cells (Figure 5.2.4D), as well as the capacity for chimera 
contribution (Figure 5.2.4E) and germline competence (Figure 5.2.4F) after the excision of 
the reprogramming transgenes. 
 
 
 
 
 
 
 
 
 
 
(figure on next page) 
Figure 5.2.4 – Overexpression of Mbd3/NuRD facilitates Nanog-mediated preiPSC 
reprogramming. 
(A) The kinetics of the emergence of Nanog-GFP+ colonies from the transgenic preiPSCs during 
a 12-day culture in 2i/LIF conditions (y-axis scale changes at day 7). Colony number is per 1.0 x 105 
preiPSCs. Representative field of vision of each time point can be seen in Figure 5.2.2. (B) 
Quantification of Nanog-GFP+ colonies after 12 days of 2i/LIF culture. Colony numbers are per 1.0 x 
105 preiPSCs.  (C) Phase and GFP images and AP staining of the iPSCs formed from preiPSCs 
overexpressing respective transgenes. (D) qRT-PCR analysis of retroviral transgenes, pluripotency-
associated, and Mbd3 in preiPSCs and corresponding derived iPSCs. (E) Male chimera showing 
contribution from Nanog-Mbd3 iPSCs generated from preiPSCs (brown colour). (F) Germline 
contribution of Nanog-Mbd3 iPSCs. Cells were treated with TAT-Cre for reprogramming transgene 
excision prior to blastocyst injection. Chimeric father, C57BL/6 mother and pups resulting from cross 
can be viewed. 
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After careful analysis of the Nanog transcript (Figure 5.2.4D) and protein levels (Figure 
5.2.2B) in the different transgenic preiPSC lines, I detected that Nanog transgenic levels were 
2 fold higher in Nanog-Mbd3 preiPSCs compared to Nanog-EV preiPSCs. To exclude the 
possibility of this affecting the results, I generated new Nanog-EV and Nanog-Mbd3 preiPSC 
lines with similar transgenic Nanog levels (Figure 5.2.5A). As with the previous preiPSC 
lines, higher amounts of Mta2 were observed in the Nanog-Mbd3 preiPSC line (Figure 
5.2.5A), and the synergistic gain-of-function reprogramming phenotype after combined 
forced expression of Nanog and Mbd3 was again observed (Figures 5.2.5B-C). The iPSCs 
generated from these new preiPSC lines expressed similar levels of transgenic Nanog were 
molecularly indistinguishable from the iPSCs generated in Figure 5.2.4, displaying the 
expected molecular properties of naïve pluripotent cells (Figures 5.2.5D). 
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Figure 5.2.5 – Nanog/Mbd3 synergy is independent of Nanog transgenic levels. 
(A) Western blot analysis of Nanog, Mbd3, Mta2 and -Tubulin (tub) protein expression in 
preiPSCs overexpressing Nanog or Nanog and Mbd3. It is notable that expression level of Nanog 
transgene in the cell lines are similar (refer to Figure 5.2.5 D). (B) Quantification of Nanog-GFP+ after 
12 days of 2i/LIF culture. Colony numbers are per 1.0 x 105 preiPSCs. (C) Phase and GFP images and 
AP staining of the iPSCs formed from preiPSCs overexpressing respective transgenes. (D) qRT-PCR 
analysis of pluripotency-associated genes and Mbd3 in transgenic preiPSCs and corresponding derived 
iPSCs. qRT-PCR values are normalized to Gapdh value and shown as relative to the highest value. 
The error bars indicate STDEV. 
 
To gain some insights into the mechanism of the synergy between Nanog and Mbd3, I 
looked for signs of the expression of naïve pluripotency genes in these established preiPSC 
lines, which could explain the gain-of-function reprogramming phenotype. These analyses of 
primed expression were carried out 12 days after stable transfection of the preiPSCs which are 
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plus transgenic) and endogenous Nanog, I observed that all the transgenic preiPSC lines 
express only background levels of endogenous Nanog prior to the induction of pluripotency 
by 2i/LIF medium switch (Figure 5.2.6A), indicating no priming of endogenous Nanog 
expression. However, I observed a significant primed expression of the key pluripotency 
genes Esrr and endogenous Oct4 (Figure 5.2.6B). I noticed that the expression levels of 
Esrr and endogenous Oct4 in the Nanog-Mbd3 preiPSCs are already 5% and 3% of wild 
type ESC levels in 2i/LIF, respectively. The expression level of Esrris also approximately 
80 times greater than that of Nanog-EV preiPSCs and 700 times greater than that of Mbd3-EV 
and EV-EV preiPSCs. The expression level of endogenous Oct4 is approximately 2000 times 
greater than that of Nanog-EV preiPSCs and 3000 times greater than that of Mbd3-EV and 
EV-EV preiPSCs. The Esrr and endogenous Oct4 expression levels continued to be higher in 
Nanog-Mbd3 than Nanog-EV preiPSCs after the medium switch to 2i/LIF (Figure 5.2.6C). 
After only 4 days of 2i/LIF culture the levels of Esrr and endogenous Oct4 in Nanog-EV 
transgenic lines matched the levels of these genes in the Nanog-Mbd3 preiPSCs cultured in 
S+LIF, indicating clear priming for conversion to naïve pluripotency. I have also observed a 2 
fold increase in Tet1/2 expression in Nanog-Mbd3 preiPSCs in comparison to Nanog-EV 
preiPSCs, and 4 fold increase compared to Mbd3-EV or EV-EV preiPSC lines (Figure 5.2.6D). 
This is of extreme importance, since both Oct4 and Esrr are genes are known to mark cells 
that are on a route to become fully reprogrammed (Buganim et al., 2012). Strikingly, Nanog-
Mbd3 preiPSCs exhibited profoundly higher levels of 5-hmC than Nanog-EV or Mbd3-EV 
preiPSCs (Figure 5.2.6E), a phenomena previously observed in preiPSCs overexpressing 
Nanog and Tet1/2 (Costa et al., 2013). This genome-wide increase in 5-hmC, a marker 
assumed to be associated with gene activation, could explain Esrr and endogenous Oct4 
primed expression with the concomitant gain-of-function reprogramming phenotype of 
Nanog-Mbd3 preiPSCs. 
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(figure on next page) 
Figure 5.2.6 – Nanog/Mbd3 overexpression primes preiPSCs to reprogram to naïve 
pluripotency. 
(A) qRT-PCR analysis of endogenous Nanog and Total Nanog in transgenic preiPSCs and 
respective generated iPSCs. (B) qRT-PCR analysis of Esrr and endogenous (end) Oct4 expression in 
preiPSC 12 days after stable transgene transfection and culture in S+LIF (y-axes in log10 scale). The 
expression levels of Esrr and endogenous Oct4 in these Nanog-Mbd3 preiPSC are 5% and 3%, 
respectively, of the expression levels of WT ESCs in 2i/LIF. (C) Time course qRT-PCR analysis of 
Esrr and endogenous Oct4 expression after medium switch to 2i/LIF of the indicated preiPSCs lines. 
(D) qRT-PCR analysis of Tet1/2 expression levels in transgenic preiPSCs. qRT-PCR values are 
normalized to Gapdh value and shown as relative to the highest value. The error bars indicate STDEV. 
(E) DNA dot blot analysis of 5-hydroxymethylation (5-hmC) bulk levels in transgenic preiPSCs. 
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Above I showed that preiPSC reprogramming to naïve pluripotency is greatly enhanced 
by Nanog-Mbd3 overexpression. I then decided to test if similar synergy could be observed in 
EpiSC reprogramming. For that, Oct4-GFP EpiSCs were stably transfected with the same 
transgene combinations as the NSCs and preiPSCs above (Figure 5.2.7A). Similarly to 
preiPSCs, EpiSCs overexpressing both Nanog and Mbd3 showed also higher levels of the 
NuRD subunit Mta2 (Figure 5.2.7B), and a 30 fold increase in the ability to generate iPSCs 
relative to a Nanog-EV control (Figures 5.2.7C-D). iPSCs generated from EpiSCs reactivated 
the naïve pluripotency-associated transcriptional program (Figure 5.2.7E), and the iPSCs 
obtained by the overexpression of Nanog and Mbd3 were able to contribute to chimeras upon 
blastocyst injection (Figure 5.2.7F).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 (figure on next page) 
Figure 5.2.7 – Overexpression of Mbd3/NuRD facilitates Nanog-mediated EpiSC 
reprogramming. 
(A) Experimental design used to address the effect of Mbd3/NuRD overexpression on EpiSC 
reprogramming. EpiSCs (carrying an Oct4-GFP) were stably transfected with pPB-CAG-Nanog and 
pPB-CAG-Mbd3b or pPB-CAG-empty controls and plated in 2i/LIF conditions for 12 days. (B) 
Western blot analysis of Nanog, Mbd3, Mta2 and -Tubulin (tub) protein expression in EpiSCs 
overexpressing Nanog or Nanog and Mbd3. (C) Quantification of Oct4-GFP+ colonies after 12 days of 
2i/LIF culture. Colony numbers are per 2.0 x 104 EpiSCs. (D) Phase and GFP images and AP staining 
of the iPSCs formed from EpiSCs overexpressing respective transgenes. (E) qRT-PCR analysis of 
pluripotency-associated genes and Mbd3 in transgenic EpiSCs and corresponding derived iPSCs. qRT-
PCR values are normalized to Gapdh value and shown as relative to the highest value. The error bars 
indicate STDEV. (F) Chimera of Nanog-Mbd3 iPSCs generated from EpiSCs (brown colour). 
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5.2.2 – Synergy is specific to Nanog-driven reprogramming 
I observed that increased Mbd3/NuRD levels can enhance reprogramming efficiency 
when co-overexpressed with the reprogramming factor Nanog. But is this synergy unique to 
Nanog? I showed that Mbd3 overexpression alone failed to alleviate the reprogramming block 
of MEF-derived preiPSCs that express high amounts of retroviral Oct4, Klf4, cMyc and Sox2 
(Figures 5.2.4A-C). This is suggestive that increased levels of Mbd3 do not synergise with 
these reprogramming factors. I checked if Mbd3 overexpression could enhance 
reprogramming efficiency during Klf4 and Nr5a2 induced reprogramming. These are two well 
characterized EpiSC reprogramming factors (Guo and Smith, 2010; Guo et al., 2009). For 
that, Oct4-GFP EpiSCs were stably transfected with those transcription-factors alone or in 
combination with Mbd3, and plated in 2i/LIF conditions for conversion to naïve pluripotency. 
I found that combined overexpression of Mbd3 with Klf4 or Nr5a2 in EpiSCs does not confer 
an increase in reprogramming efficiency (Figures 5.2.8A-B), although the reprogramming 
factors are expressed under all conditions at similar levels (Figure 5.2.8C). Thus, the observed 
synergy with Mbd3 overexpression seemed to be specific to Nanog-mediated reprogramming.  
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Figure 5.2.8 – The reprogramming synergy with the NuRD complex is specific to Nanog. 
(A) Quantification of Oct4-GFP+ colonies after 12 days of 2i/LIF culture, generated from EpiSCs 
transfected with the indicated transgene combinations. Colony numbers are per 2.0 x 104 EpiSCs. (B) 
Phase and GFP images and AP staining of the iPSCs formed from EpiSCs overexpressing respective 
transgenes. (C) qRT-PCR analysis of pluripotency-associated genes and Mbd3 in transgenic EpiSCs 
and corresponding derived iPSCs. qRT-PCR values are normalized to Gapdh value and shown as 
relative to the highest value. The error bars indicate STDEV. 
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Having identified Nanog as a unique factor that synergises with Mbd3 during 
reprogramming, I next aimed to understand how this synergy occurs. I performed some 
structure-function experiments to understand which domains of Mbd3 are important for the 
observed reprograming synergy with Nanog. It has been previously suggested that the N-
terminus of Mbd3 is required for protein-protein interaction (Aguilera et al., 2011). The Mbd3 
isoform used for the rescue and overexpression experiments was Mbd3b, the most abundant 
isoform by protein levels (Figure 3.2.1B). As shown in Figure 3.2.1F, due to alternative start 
sites, there are two more Mbd3 isoforms. To test if the N-terminus of Mbd3b is required for 
the synergy with Nanog, I tested whether overexpression of the Mbd3c isoform affected 
MEF-derived preiPSC reprogramming, since the Mbd3c isoform differs from Mbd3b in the 
first 60 N-terminal amino acids (Figure 5.2.9A). The same amount of Nanog-GFP
+
 colonies 
was scored after 12 days of 2i/LIF culture of both Nanog-EV and Nanog-Mbd3c transgenic 
lines (Figures 5.2.9B-C). Interestingly, Mta2 levels were not found to be elevated after the 
overexpression of Mbd3c (Figure 5.2.9D). As with the iPSCs generated from Nanog-Mbd3b 
preiPSCs, Nanog-Mbd3c iPSCs reactivated the core naïve pluripotency-associated 
transcriptional program (Figure 5.2.9E). 
In conclusion, the results presented in this chapter indicate that Mbd3 overexpression 
does not impair the induction of naïve pluripotency. Moreover, it specifically facilitates 
Nanog-mediated reprogramming. I also demonstrate that the N-terminal region of Mbd3b is 
required for Nanog-Mbd3 reprogramming synergy. 
 
 
(figure on next page) 
Figure 5.2.9 – The N-terminal sequence of Mbd3 is required for the synergistic effect with 
Nanog in reprogramming. 
(A) ClustalW2 sequence alignment between Mbd3b isoform (cDNA used in this study unless 
otherwise stated) and Mbd3c isoform (http://www.ebi.ac.uk/Tools/msa/clustalw2/). The isoforms 
differ in their N-terminus sequence, because of different translation start, Mbd3c being 8 amino acids 
shorter (dotted box). Sequence in red is hypothesized to be the domain responsible for Mbd3 protein-
protein interactions. (B) Phase and GFP images and AP staining of the iPSCs formed from preiPSCs 
overexpressing respective transgenes. (C) Quantification of Nanog-GFP+ colonies after 12 days of 
2i/LIF culture. Colony numbers are per 1.0 x 105 preiPSCs. (D) Western blot analysis of Nanog, 
Mbd3, Mta2 and -Tubulin (tub) protein expression in preiPSCs overexpressing Nanog or Nanog 
and Mbd3c. (E) qRT-PCR analysis of pluripotency-associated genes and Mbd3 in transgenic preiPSCs 
and corresponding derived iPSCs. qRT-PCR values are normalized to Gapdh value and shown as 
relative to the highest value. The error bars indicate STDEV. 
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5.2.3 – NuRD regulates gene expression in a context- and locus-dependent manner 
Nanog expression is known to be auto-regulated. Nanog, Oct4 and Sox2 are part of a 
regulatory circuitry consisting of auto-regulatory and feed-forward loops that control their 
expression (Boyer et al., 2005; Young, 2011). However, for these key pluripotency factors to 
be the expressed at normal levels and be responsive to stimuli, gene repression mechanisms 
have to be in place. The NuRD complex has been implicated in Nanog auto-repression in 
ESCs, and is recruited to the Nanog locus by the transcriptional repressor Zfp281, a Nanog 
protein-protein interactor (Fidalgo et al., 2012). Since Nanog and the NuRD complex seemed 
to be co-operatively acting as facilitators of primed gene expression during reprogramming, I 
decided to analyse the gene expression profiles of wild type, Mbd3
fl/-
 and Mbd3
-/-
 ESCs stably 
transfected with Nanog and/ or Mbd3 (Figure 5.2.10). Since it was recently observed that the 
NuRD complex promotes pluripotent gene expression heterogeneity in ESC cultured in 
S+LIF (Reynolds et al., 2012a), I performed my analysis in cells cultured in both 2i/LIF and 
S+LIF conditions. I did not observe any differences in Oct4 or Esrr expression between 
transgenic lines regardless of the medium the cells were grown in. Klf4 was found to be up-
regulated in Mbd3
-/-
 ESCs compared to Mbd3-expressing ESCs, both in 2i/LIF and S+LIF, a 
mis-expression previously described and hypothesized to contribute to the differentiation 
defects of Mbd3
-/-
 ESCs (Reynolds et al., 2012a). Nanog expression was found to be slightly 
elevated in Mbd3
-/-
 ESCs compared to wild type and Mbd3
fl/-
 ESCs cultured in 2i/LIF, which 
is in agreement with the existence of an auto-repressive Nanog mechanism involving NuRD 
activity (Fidalgo et al., 2012). Moreover, a lower total amount of Nanog was observed in cells 
transfected with Nanog and Mbd3 than that in Nanog-EV, indicating that higher levels of the 
NuRD complex in ESCs might somewhat repress endogenous Nanog expression. I have 
shown that although the forced expression of Nanog and Mbd3 in preiPSCs leads to primed 
expression of both Esrr and Oct4, no primed Nanog expression was detected (Figure 
5.2.6A). This indicates that even if the NuRD complex represses the endogenous expression 
of Nanog, if an external source of Nanog that is not target of the endogenous repression is 
provided, the combined action of the exogenous Nanog and NuRD can enhance the 
expression of other pluripotency genes, such as Esrr and Oct4, which, in a reprogramming 
setting, results in enhanced efficiency.  
Altogether, this data suggests that NuRD functions in a highly context- and gene-
dependent manner, acting both as an activator and as a repressor of gene expression. 
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Figure 5.2.10 – Gene expression of transgenic ESCs in 2i/LIF and S+LIF conditions. 
qRT-PCR analysis of pluripotency-associated genes in wild type, Mbd3fl/- and Mbd3-/- ESCs 
stably transfected with pPB-CAG-Nanog and pPB-CAG-Mbd3b or pPB-CAG-empty controls and 
plated in either 2i/LIF or S+LIF conditions for 12 days. qRT-PCR values are normalized to Gapdh 
value and shown as relative to the highest value. The error bars indicate STDEV.   
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5.3 – Discussion 
5.3.1 – Overexpression of Mbd3/NuRD can facilitate reprogramming 
I have demonstrated that Mbd3 overexpression, with resulting higher levels of the NuRD 
complex, can facilitate reprogramming in combination with Nanog expression (Figure 5.3.1). 
It has been previously shown by our laboratory that Nanog is able to overcome the 
reprogramming block of preiPSCs and is sufficient to reprogram EpiSCs to naïve 
pluripotency (Theunissen et al., 2011b). Is this chapter I demonstrate that this effect can be 
increased up to 30 fold by the forced expression of Mbd3 together with Nanog 
overexpression. Taking into account that Mbd3 alone failed to alleviate the reprogramming 
block of preiPSCs (Figures 5.2.4A-C), and that combined overexpression of Mbd3 with Klf4 
or Nr5a2 does not enhance reprogramming efficiency (Figures 5.2.8A-B), the observed 
synergistic effect is specific to Nanog.  
 
 
Figure 5.3.1 – Overexpression of Mbd3/NuRD facilitates Nanog-mediated reprogramming. 
Increased Mbd3/NuRD levels enhance reprogramming efficiency of preiPSCs and EpiSCs when 
co-expressed with the reprogramming factor Nanog. The synergy between Nanog and Mbd3 results in 
a 30 fold increase in reprogramming efficiency.  
 
An analogous synergy was recently reported in our laboratory, where the interaction 
between the transcription factor Nanog and the epigenetic regulators Tet1/2 facilitate 
reprogramming, in a Tet1/2 catalytic activity-dependent manner (Costa et al., 2013). In that 
study it was observed that Nanog recruits Tet1 to a subset of key pluripotency genes, such as 
Esrr and Oct4, which leads to increased hydroxymethylation of those genes, resulting in 
iPSCs
EpiSCs
preiPSCs
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primed expression before reprogramming to naïve pluripotency. This primed expression prior 
to the establishment of the pluripotency network is thought to be the reason behind the gain-
of-efficiency during preiPSC reprogramming, when Nanog-Tet1/2 are co-overexpressed 
compared to Nanog-alone (Costa et al., 2013). Interestingly, Nanog-Tet1 stably transfected 
MEF-derived preiPSCs reprogram 20-30 fold more efficiently than Nanog-EV ones, an effect 
in the same order of magnitude as that seen in Nanog-Mbd3 preiPSCs (30 fold). Since the 
synergies between Nanog-Tet1/2 and Nanog-Mbd3 during reprogramming are very similar, I 
looked at global hydroxymethylation levels in Nanog-Mbd3 preiPSCs lines. Surprisingly, 
higher levels of 5-hmC are observed in Nanog-Mbd3 preiPSCs compared to Nanog-EV or 
Mbd3-EV preiPCs. Moreover, as in the Nanog-Tet1 preiPSCs, primed Esrr and Oct4 
expression prior to the establishment of naïve pluripotency was also observed only in Nanog-
Mbd3 preiPSCs, indicating a direct relationship between these three major players Nanog, 
Tet1/2 and the Mbd3/ NuRD complex during reprogramming. In fact, a link between Mbd3/ 
NuRD and hydroxymethylation levels has been recently described in ESCs (Yildirim et al., 
2011). It was observed that Mbd3 controls 5-hmC levels in the chromatin and that Mbd3 
recruitment is dependent on 5-hmC (Yildirim et al., 2011). Since Mbd3 fails to bind 
methylated DNA (Hendrich and Bird, 1998; Zhang et al., 1999), how Mbd3 interacts with 
chromatin to regulate transcription is not known. The correlation between Mbd3 and 5-hmC 
levels led the authors to hypothesise that NuRD complex might bind chromatin through an 
interaction of the mbd of Mbd3 and 5-hmC. However, and as discussed in section 3.3.1, this 
does not seem to be the case since an Mbd3 isoform, Mbd3b, which lacks the domains 
believed to interact with 5-hmC, is able to rescue all the Mbd3
-/-
 phenotypes. From the above 
described data, and taking into account that NuRD complex subunits, like Mbd3, are high 
confidence protein interactors of Nanog (Costa et al., 2013; Ding et al., 2012; Gagliardi et al., 
2013; Liang et al., 2008), a more plausible model is where the Mbd3/ NuRD complex is 
recruited to its target genes by interactions with key transcription factors, such Nanog, where 
it executes its function. Since Tet1/2 are also high-confidence interactors of Nanog (Costa et 
al., 2013), it is possible that Nanog guides both NuRD and Tets to key pluripotency genes 
during reprogramming, enabling their activation and priming expression prior to the 2i/LIF 
medium switch (Figure 5.3.2). 
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Figure 5.3.2 – Working model for Nanog-Mbd3 synergy during reprogramming. 
I propose a model to explain the synergistic effect of combined forced expression of both Nanog 
and Mbd3 during reprogramming of preiPSCs. 1- In wild type preiPSCs, Esrr and Oct4 promoters 
are hypermethylated resulting in complete repression of their expression (Costa et al., 2013; 
Theunissen et al., 2011b). 2- Overexpression of Nanog and Mbd3, with resulting higher levels of the 
NuRD complex, results in primed expression of Esrr and Oct4 (5% and 3%, respectively, of the 
expression levels of WT ESCs in 2i/LIF), and also increased global levels of 5-hmC. Since Nanog 
interacts with both Mbd3 and Tet1 (Costa et al., 2013; Ding et al., 2012; Gagliardi et al., 2013; Liang 
et al., 2008), it is possible that Nanog recruits the NuRD complex to key pluripotency genes, and in a 
combined action with Tet1, alters their epigenetic status, resulting in higher hydroxymethylation and 
lower methylation, and primed gene expression. 3- This primed expression appears to facilitate 
reactivation of the core transcriptional program of naïve pluripotency after 2i/LIF culture, resulting in 
earlier up-regulation of gene expression of pluripotency genes, leading to increased reprograming 
efficiency. 
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Such a model assumes that if the hypothesized Nanog-Mbd3 interaction is abolished, then 
reprogramming synergy between these two factors would be lost. To test this assumption, I 
tested if reprogramming synergy during preiPSC reprogramming is maintained when an 
Mbd3 sequence that is thought to be responsible for protein-protein interactions is removed. It 
has been previously suggested that the N-terminus of Mbd3 is required for protein-protein 
interactions (Aguilera et al., 2011). It was observed that a 15-residue sequence 
(ARYLGGSMDLSTFDF – Figure 5.2.9) situated in the N-terminus of Mbd3 is necessary and 
sufficient for binding to c-Jun (Aguilera et al., 2011). I have also found that the N-teminus of 
Mbd3 is required for the observed synergistic effect with Nanog in reprogramming (Figure 
5.2.9), probably due to the abolishment of the Nanog-Mbd3 interaction. Moreover, Mta2 
levels were not found to be elevated after the overexpression of Mbd3c (Figure 5.2.9D), 
which leads to the assumption that the N-terminal sequence is required for the stabilization of 
the NuRD complex. Interestingly, the fact that protein-protein interactions with both Nanog or 
c-Jun (Aguilera et al., 2011) seem to be responsible for NuRD’s targeting to chromatin and 
might explain how this complex interacts with DNA and why a repressor complex might act 
as an activator in certain conditions. Lastly, since the methyl binding domain of Mbd3 does 
not bind methylated DNA but is required for protein-protein interactions, this indicates that 
this domain may have evolved from a methyl-CpG-binding domain into a protein–protein 
interaction module. Future work will aim to understand how Nanog and Mbd3 work together 
in driving cells blocked in reprogramming, such as preiPSCs, to pluripotency.  
 
5.3.2 – Conclusions 
In this chapter I demonstrated that the reprogramming efficiency of preiPScs and EpiSCs 
can be boosted by the combined overexression of Nanog and Mbd3. I observed that both the 
rate and extent of iPSC generation from preiPSC are increased after the forced expression of 
Nanog and Mbd3, which seems to be due to the primed expression of Esrr and Oct4, 
possibly due to increased hydroxymethylation, with respective reduced methylation, of their 
loci. 
  
 
 
 
 
 
 
 
 
 
CHAPTER 6 – General Discussion 
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6.1 – NuRD complex as a transcription modulator. 
Reprogramming of somatic cells to naïve pluripotency can be robustly driven by the 
combined action of transcription factors and culture cues. As described in section 1.3.5, 
among the reprogramming transcription factors, Oct4 and Nanog play a central role in the 
induction of pluripotent cells. The Oct4 and Nanog interactome studies in ESCs revealed 
members of the NuRD complex as its highest confidence interactors (Costa et al., 2013; Ding 
et al., 2012; Gagliardi et al., 2013; Pardo et al., 2010; van den Berg et al., 2010). NuRD is 
composed of six core subunits with at least two enzymatic activities involved in gene 
regulation: the histone deacetylase activity of HDAC1/2 subunits and the ATP-dependent 
chromatin remodelling activity of Mi-2a/ subunits (section 1.4.1). As described in section 
1.4.2, embryos lacking Mbd3, an essential scaffold protein in the NuRD complex, in the 
absence of which the complex is not assembled, die shortly after implantation (Hendrich et 
al., 2001; Kaji et al., 2007), and Mbd3-null ESCs are viable but exhibit limited differentiation 
capacity (Kaji et al., 2006; Reynolds et al., 2012a; Reynolds et al., 2012b). Taking into 
account that chromatin remodelling plays an important role in reprogramming to naïve 
pluripotency (section 1.3.4), and that the chromatin remodeller NuRD is a high confidence 
interactor of Oct4 and Nanog and a key regulator of developmental cell state transitions, I 
have investigated its involvement in the induction of pluripotency. 
To study the role of the NuRD complex during reprogramming, the levels of Mbd3 were 
manipulated in somatic cells which were induced to pluripotency using different systems. In 
the chapter 3, I demonstrated that Mbd3 facilitates the initiation of neural stem cell 
reprogramming, and that the amount of preiPSC colonies formed correlates with the amount 
of time cells express Mbd3 during this transition. In the chapter 4, using genetics or 
shRNA/siRNA to manipulate Mbd3 levels, I demonstrated that Mbd3/NuRD is also required 
for efficient iPSC generation from EpiSCs and preiPSCs. I also showed that Mbd3 deletion 
after OSKM induction does not impact MEF reprogramming. Finally, in the chapter 5, I 
present undisputable evidence that the overexpression of Mbd3/NuRD can boost Nanog-
mediated reprogramming (Figure 6.1.1). 
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Figure 6.1.1 – The requirement of Mbd3/NuRD in induced pluripotency. 
Schematic representation of the main findings of this thesis. By manipulation of the Mbd3 levels, 
I observed that Mbd3 depletion reduces efficiency of NSCs, EpiSCs and preiPSCs reprogramming to 
iPSCs. Mbd3 depletion does not seem to impact MEF reprogramming. However, it is important to 
notice that Mbd3 depletion in MEFs was only be carried out after induction of OSKM, not prior it, as 
in the other cells types. Combined forced expression of Nanog and Mbd3 enhance reprogramming 
efficiency of preiPSCs and EpiSCs. 
 
Due to its subunit composition, the NuRD complex has been regarded as a transcriptional 
repressor. However, the data presented in this thesis suggests that the NuRD complex might 
be facilitating gene activation under certain conditions. In agreement, recent literature has 
started to re-evaluate the role of the NuRD complex in gene regulation, providing clear proof 
that the NuRD complex regulates gene activation as well as gene repression. The first report 
involving the NuRD complex in gene activation came from the analysis of T cell development 
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(Williams et al., 2004). The authors reported that the NuRD component Mi-2 is required for 
T cell maturation by directly promoting CD4 expression. It was shown that Mi-2 binds to the 
CD4 enhancer and contributes to the recruitment of the transcriptional machinery for CD4 
transcription (Williams et al., 2004). Further studies by the same laboratory showed that the 
NuRD complex binds to many active genes involved in lymphoid maturation, and that its 
targeting is mediated by Ikaros, a key regulator of lymphocyte development (Georgopoulos, 
2002; Zhang et al., 2011). When Ikaros interaction with the NuRD complex is disrupted, 
NuRD is not targeted to lymphocyte development genes, but it is still bound to other genes, 
where it can act both as repressor and activator of expression (Zhang et al., 2011). In addition, 
it was also reported that the NuRD complex, dependent on cellular and genetic context, can 
mediate both the activating and the repressive transcriptional functions of FOG-1 and Gata-1 
during erythropoiesis (Miccio et al., 2010).  
Recent genome-wide studies revealed that Mbd3 is localized at both active and inactive 
promoters, marked by H3K4me3 and H3K37me3, respectively (Shimbo et al., 2013), and was 
found to be enriched at active demethylated promoters (Gunther et al., 2013). Mbd3 was also 
found to be enriched at active enhancers (Shimbo et al., 2013), just as Mi-2 (Whyte et al., 
2012), indicating that the NuRD complex is associated with active transcription. Surprisingly, 
Mbd3 was found to be enriched at super-enhancers in ESCs, which are enhancers associated 
with highly expressed genes (Hnisz et al., 2013). All these results suggest that the NuRD 
complex is not a classical “transcriptional repressor”. Rather than controlling “all-or-nothing” 
gene expression changes, the NuRD complex might function as a transcriptional modulator, 
fine tuning the expression of both active and repressed genes. In agreement with this notion, 
genome-wide expression analysis revealed that 61% of differentially expressed genes (839 
genes) are down-regulated upon Mbd3 deletion in ESCs (Reynolds et al., 2012b). Although a 
share of this decrease in transcription might be due to indirect effects, this reveals that the 
NuRD complex acts on enhancers and promoters as a mediator of transcription factor-induced 
gene activation.  
A model where NuRD acts to fine-tune expression levels is consistent with the results 
presented in this thesis. As described in section 1.3.4, the OSKM factors bind to chromatin to 
induce both the repression and the activation of gene expression. It is possible that the 
different outcomes of OSKM binding to the different genes might be controlled, at least in 
part, by the NuRD complex. The reprogramming factors, by interacting with the NuRD 
complex, might guide it to the key genes that need to be transcriptionally modulated in the 
original somatic cell. Lack of a functional complex is likely to result in a failure of the 
transcriptional modulation induced by OSKM, which impedes the switch between different 
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transcriptional programmes characteristic of different cell types. This means that, in a 
probabilistic manner, only rare NuRD-null somatic cells would engage in a fate switching and 
be reprogrammed. Such a view of the role of the NuRD complex in fate switch assumes that 
the rare cells that reprogram without NuRD exhibit delayed reprogramming kinetics, as active 
transcriptional modulation is not taking place. Indeed, the data presented in the chapter 3 
shows that Mbd3-null NSCs reprogram very inefficiently, and the ones which do reprogram 
take longer to do so. This role of the NuRD complex might also explain why no effect is 
observed if Mbd3 is depleted after OSKM induction during MEF reprogramming. Recent 
evidence implicates NuRD in the early stages of MEF reprogramming by transiently driving 
mTOR downregulation with subsequent activation of autophagy (Wang et al., 2013c). 
Moreover, the NuRD complex might also play a role in MET, a key event during early MEF 
reprogramming, which is thought to occur early during reprogramming. Thus, it is possible 
that Mbd3 deletion after this early stage of reprogramming has no effect on subsequent 
reprogramming stages because cells have already passed the critical stage where the NuRD 
complex might be particularly important. 
 The specific interactions established by individual NuRD subunits are thought to be the 
main mechanism of control of the different functions of the complex. In fact, NuRD’s 
interaction with the reprogramming factors is a possible mechanism to describe how OSKM 
drive the transcriptional changes required for induced pluripotency. It is then possible to infer 
that NuRD activity on a particular set of genes, such as pluripotent genes, might be enhanced 
if a hypothetical transcription factor that targets the complex to those genes is ectopically 
expressed. Indeed, experimental evidence presented in this thesis supports such statement. 
Forced Nanog expression in preiPSCs and EpiSCs, together with elevated levels of NuRD, 
increases the efficiency of the establishment of naïve pluripotency by enhancing the 
expression of the key pluripotency genes.  
In conclusion, the NuRD complex plays a key role during induced pluripotency, 
potentially by interacting with transcription factors to assist genome-wide reprogramming. 
Further insights into the function of the NuRD complex during different cell state transitions 
will help us understand the process of induced pluripotency as well as embryonic 
development. 
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6.2 – Future perspectives on the role of the NuRD complex in induced 
pluripotency. 
In this thesis I have shown that the NuRD complex facilitates induced pluripotency. In 
the future it will be important to understand how NuRD modulates this transition. To assess if 
NuRD’s function during OSKM-mediated reprogramming is dependent on its interaction with 
the reprogramming factors, it will be interesting to assess if members of the NuRD complex 
physically interact with any of the OSKM factors, which could be analysed by a pull-down 
assay after overexpression of these in somatic cells. Then, to further dissect how this 
hypothetical interaction might contribute to the transcriptional changes observed during 
induced pluripotency, high-throughput techniques such as RNA sequencing (RNA-seq) and 
chromatin immunoprecipitation followed by high-throughput DNA sequencing (ChIP-seq) 
can be employed. Mbd3 ChIP-seq together with RNA-seq prior to and after OSKM 
transduction, using wild type and Mbd3-null somatic cells, such as NSCs, will reveal if 
OSKM binding to genome or if OSKM-induced transcriptional changes are dependent on the 
NuRD function. These experiments will help us to understand if the reduced reprogramming 
efficiency of Mbd3
-/-
 NSCs is due to aberrant transcriptional silencing and/ or activation after 
OSKM induction. Moreover, by coupling ChIP-seq with RNA-seq it will be able possible to 
understand why NuRD acts as a facilitator during induced pluripotency, since the effect of 
NuRD binding to the genome can be correlated with gene expression profiles. Since in this 
thesis I showed that Mbd3 depletion after OSKM induction during MEF reprogramming does 
not affect reprogramming, it will be of interest to test the impact of Mbd3 depletion prior to 
the induction of expression of the reprogramming factors. Also, taking into account that MET 
is a key event during early MEF reprogramming, it will be important to test if the NuRD 
complex also plays a part in this transition, which would explain why its disruption a couple 
of days after induction does not impact induced pluripotency. 
ChIP-seq with RNA-seq approaches can also be used to dissect how Nanog and Mbd3 
work to induce the reprogramming of preiPSCs to naïve pluripotency. By comparing Mbd3 
and Nanog ChIP-seq tracks obtained from different preiPSC lines stably transfected with 
Nanog and/ or Mbd3 transgenes, NuRD changes in localization after the ectopic expression of 
Nanog can be assessed, and what genome-wide transcriptional alterations occur when Nanog 
and Mbd3 are overexpressed can be revealed. Since global 5-hmC levels are increased in 
Nanog-Mbd3 preiPSCs compared to Nanog-EV or Mbd3-EV preiPSCs, it will be interesting to 
understand how and why this occurs. It will be important to assess if Nanog, NuRD and 
Tet1/2 interact with each other, and whether the disruption of those interactions would affect 
Nanog-Mbd3 synergy during reprogramming. A comparison of Nanog, Mbd3 and Tet1/2 
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ChIP-seq tracks using Nanog-Mbd3 preiPSCs, together with 5-hmC mapping throughout the 
genome, will provide a compressive and integrative view of how transcription factors and 
epigenetic remodellers work together to modulate gene expression changes and induce fate 
switching. 
Such integrative approaches will help us to understand how reprogramming factors work, 
how the somatic epigenome is erased and how the naïve pluripotent one is established. Once 
the molecular mechanisms underlying induced pluripotency are understood, then the full 
potential of iPSCs for personalized medicine and disease modelling can be explored. This 
research will lead to the creation of better and safer iPSCs, bringing the applications in 
regenerative medicine a step closer. 
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The Nucleosome Remodeling and Deacetylase
(NuRD) complex is essential for embryonic develop-
ment and pluripotent stem cell differentiation. In this
study, we investigated whether NuRD is also
involved in the reverse biological process of induc-
tion of pluripotency in neural stem cells. By knocking
out MBD3, an essential scaffold subunit of the NuRD
complex, at different time points in reprogramming,
we found that efficient formation of reprogramming
intermediates and induced pluripotent stem cells
from neural stem cells requires NuRD activity. We
also show that reprogramming of epiblast-derived
stem cells to naive pluripotency requires NuRD com-
plex function and that increased MBD3/NuRD levels
can enhance reprogramming efficiency when coex-
pressed with the reprogramming factor NANOG.
Our results therefore show that the MBD3/NuRD
complex plays a key role in reprogramming in certain
contexts and that a chromatin complex required for
cell differentiation can also promote reversion back
to a naive pluripotent cell state.
INTRODUCTION
Reprogramming of somatic cells to naive pluripotency can be
robustly driven by the combined action of transcription factors
and culture cues. Among the reprogramming transcription fac-
tors, OCT4 plays a central role, as it is sufficient and essential
for the induction of pluripotent cells (Kim et al., 2009; Radzish-
euskaya et al., 2013; Radzisheuskaya and Silva, 2014). OCT4
interactome studies in embryonic stem cells (ESCs) revealed
members of the Nucleosome Remodeling and Deacetylase
(NuRD) complex as its highest confidence interactors (Ding
et al., 2012; Liang et al., 2008; Pardo et al., 2010; van den Berg
et al., 2010). NuRD is composed of six core subunits with at least102 Cell Stem Cell 15, 102–110, July 3, 2014 ª2014 The Authorstwo enzymatic activities involved in gene regulation: histone de-
acetylase activity of HDAC1/2 subunits and ATP-dependent
chromatin remodeling activity of Mi-2a/b subunits (Lai and
Wade, 2011; McDonel et al., 2009). Methyl-CpG binding domain
protein 3 (MBD3) is an essential scaffold protein of the NuRD
complex, in the absence of which the complex is not assembled
(Kaji et al., 2006; Zhang et al., 1999). Embryos lacking MBD3 die
shortly after implantation (Hendrich et al., 2001; Kaji et al., 2007)
and Mbd3-null ESCs are viable but show severely impaired
lineage commitment and exhibit limited differentiation capacity
(Kaji et al., 2006; Reynolds et al., 2012a, 2012b). Chromatin
remodeling plays an important role in reprogramming to naive
pluripotency (Apostolou and Hochedlinger, 2013; Papp and
Plath, 2013). Because the NuRD complex is a high confidence
interactor of Oct4 and a key regulator of developmental cell
state transitions, we have investigated its involvement in the
induction of pluripotency.RESULTS
MBD3 Facilitates the Initiation of Reprogramming from
Neural Stem Cells
To address the requirement of the NuRD complex in the reprog-
ramming process, we established an Mbd3/ clonal neural
stem cell (NSC) line fromMbd3fl/NSCs and anMbd3/ rescue
NSC line (Mbd3/:Mbd3) by stable transfection of an Mbd3
transgene (Figures S1A–S1C available online). These NSC lines
were transduced with retroviruses encoding cMyc, Klf4, and
Oct4 (rMKO) to initiate their reprogramming and were then
switched to serum plus LIF (S+LIF) conditions (Figure 1A), which
typically results in the formation of highly proliferative reprog-
ramming intermediates, or preiPSCs (Silva et al., 2008). When
we used retroviruses encoding GFP (rGFP), equal percentages
of GFP+ cells were observed 72 hr after transduction ofMbd3fl/
orMbd3/ NSCs, indicating thatMbd3 deletion does not affect
transduction efficiency (Figures S1D and S1E). Strikingly, the
kinetics of preiPSC emergence was markedly delayed in the
Mbd3/ cells. While Mbd3-expressing preiPSCs dominated
the culture by day 4 posttransduction (d.p.t.), Mbd3/
A B
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E
Figure 1. MBD3 Facilitates the Initiation of Reprogramming
(A) Experimental design used to address the kinetics and efficiency of initiation of reprogramming in NSCswith differentMbd3 genotypes. NSCswere transduced
with retroviruses encoding cMyc, Klf4, and Oct4 (rMKO), maintained in Egf+Fgf2 medium for 3 days, and then switched to S+LIF medium.
(B) Phase images of the reprogramming intermediates (preiPSCs) emerging from Mbd3fl/, Mbd3/, and Mbd3/:Mbd3 (rescue) NSCs at different days
posttransduction (d.p.t.).
(C) Efficiency of preiPSC colony formation per 2.5 3 105 NSCs as assessed by alkaline phosphatase (AP) staining at day 9 posttransduction.
(D) qRT-PCR analysis of retroviral transgenes (rOct4, rKlf4, and rMyc) and Mbd3 expression in the obtained preiPSCs maintained in S+LIF. Three independent
NSCs transductions were carried out and gene expression was assessed 12 days after transduction. Values are normalized to Gapdh value and shown as
relative to the highest value.
(E) Time course of MBD3 requirement during preiPSC formation. Mbd3fl/fl NSCs were stably transfected with pCAG-CreERt2 transgene, transduced with
retroviral transgenes, and treated with 4-OHT at indicated time points to induce Cre-mediated deletion of the floxed alleles during reprogramming. Ethanol (EtOH)
was used as a control. The encircled numbers correspond to different conditions. PreiPSC colony formation was assessed by AP staining at day 10 post-
transduction and is presented as the number of colonies per 7.5 3 104 NSCs. The error bars indicate STDEV.
Cell Stem Cell
MBD3/NuRD Facilitates ReprogrammingpreiPSCs emerged only by 7–8 d.p.t. (Figure 1B). In addition, the
number of emerging alkaline-phosphatase-positive (AP+)
Mbd3/ preiPSC colonies was significantly reduced compared
to parental and rescue cell lines (Figure 1C and Figure S1F).
Nevertheless, it was possible to establish and expand Mbd3/
preiPSCs, although less efficiently and with delayed kinetics.
Both Mbd3/ NSCs and Mbd3-null preiPSCs derived from
them exhibited slower proliferation, consistent with previous re-
ports ofMbd3/ ESCs (Kaji et al., 2006; Sims and Wade, 2011)
(Figures S1G and S1H). Mbd3/ preiPSCs expressed slightly
higher levels of retroviral transgenes compared to control cells
(Figure 1D), suggesting that dosage of reprogramming factors
is not the reason for the reduced efficiency of reprogramming
initiation that we observed.
To further dissect the requirement for MBD3 in the initiation of
reprogramming, we analyzed the effect of Mbd3 deletion at
different experimental time points. For this experiment, we stably
transfected Mbd3fl/fl NSCs with Cre-ERt2, which enabled Cre-
mediated excision of the floxed Mbd3 alleles upon addition of
4-hydroxytamoxifen (4-OHT) (Figures S1I–S1L). We found thatearlier removal ofMbd3 reduced the number of preiPSC colonies
formed (Figure 1E). We also obtained similar results after condi-
tional deletion of Mbd3 exon 1 (ex1fl) which removes all but a
small amount of a truncated MBD3 protein isoform (MBD3C)
(Aguilera et al., 2011; Kaji et al., 2006) (Figures S1M and S1N).
Taken together, these results demonstrate that lack of a
functional NuRD complex strongly impairs the initiation of
reprogramming from NSCs.
MBD3 Is Required for Efficient iPSC Generation
from NSCs, preiPSCs, and EpiSCs
We then evaluated the role ofMBD3 in later stages of reprogram-
ming. To induce completion of the reprogramming process,
Mbd3fl/, Mbd3/, and rescued Mbd3/:Mbd3 preiPSCs
were switched to serum-free medium containing LIF and
inhibitors of both mitogen-activated protein kinase and glyco-
gen synthase kinase-3 signaling (2i/LIF) (Silva et al., 2008),
and the resulting iPSC colonies were scored 12 days later.
We observed that the efficiency of conversion to naive pluripo-
tency of Mbd3/ preiPSCs is strongly reduced compared toCell Stem Cell 15, 102–110, July 3, 2014 ª2014 The Authors 103
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MBD3/NuRD Facilitates ReprogrammingMbd3fl/ andMbd3/:Mbd3 preiPSCs (Figure 2A). TheMbd3fl/,
Mbd3/, and Mbd3/:Mbd3 iPSCs that were obtained could
be expanded clonally in 2i/LIF, and they exhibited reactivation of
the pluripotency transcriptional program and silencing of the
retroviral reprogramming transgenes as expected (Figure 2B).
The Mbd3/ iPSCs were phenotypically similar to previously
reported Mbd3-null ESCs (Kaji et al., 2006), exhibiting impaired
embryoid body differentiation and slower proliferation (Figures
S2A and S2B). We also observed thatMbd3 deletion in an estab-
lished preiPSC line before the 2i/LIF medium switch impaired
reprogramming to naive pluripotency (Figures S2C and S2D).
Next we performed a time course experiment to define the
time frame during reprogramming for which MBD3 is required.
For this analysis, we transduced Mbd3fl/fl:Cre-ERt2 NSCs with
rMKO and rGFP and treated them with 4-OHT at different
experimental time points (Figure 2C). The growth medium was
changed to S+LIF 4 days after transduction and subsequently,
4 days later, to 2i/LIF. The number of iPSC colonies exhibiting
silencing of retroviral GFP expression was assessed 12 days
after 2i/LIF medium switch (Figure 2C and Figure S2E). We
observed that the number of iPSC colonies formed was propor-
tional to the amount of time cells expressed MBD3 during the
initiation phase of reprogramming (prior to 2i/LIF culture). We
observed neither a reduction nor a gain of reprogramming effi-
ciency when Mbd3 was deleted at the 2i/LIF stage. Regardless
of the stage of Mbd3 deletion, the resulting iPSCs displayed a
pluripotency-associated transcriptional signature (Figure S2F).
Thus, our data suggest that MBD3 is specifically required for
the initiation and intermediate stage of NSC reprogramming
rather than establishment of pluripotency.
Epiblast stem cells (EpiSCs) can be reprogrammed to naive
pluripotency by a combination of overexpression of at least
one transcription factor, such as KLF4, KLF2, or NANOG, and
the use of serum-free 2i/LIF medium, which not only promotes
reprogramming of EpiSCs but also blocks their self-renewal
(Guo et al., 2009; Silva et al., 2009). To examine the role of
MBD3 in reprogramming in this context, we stably transfected
wild-type EpiSCs carrying an Oct4-GFP reporter with piggyBac
(PB) vectors constitutively expressing Klf2 and Nanog (K2N) or
Klf4, and we then transfected these with either small interfering
RNA (siRNA) against Mbd3 or control siRNA (Figure 3A).
Strikingly, Mbd3 knockdown led to a complete impairment of
KLF4-mediated reprogramming and to a 6-fold reduction in
the reprogramming ability of K2N (Figure 3B and Figures S3A
and S3B). Similar results were obtained when EpiSCs with
Mbd3 genetic knockout were used (Figure 3C and Figures
S3C and S3D).
All the results described above indicate that MBD3 is critical
for efficient reprogramming in the contexts that we examined,Figure 2. MBD3 Is Required for Efficient iPSC Generation
(A) Quantification of iPSC colonies generated fromMbd3fl/,Mbd3/, andMbd3
per 1.0 3 105 preiPSCs.
(B) qRT-PCR analysis of retroviral transgenes,Mbd3, and pluripotency-associate
normalized to Gapdh value and shown as relative to the highest value.
(C) Mbd3fl/fl:Cre-ERt2 NSCs were transduced with rMKO and rGFP, maintained
preiPSC emergence, and then switched to 2i/LIF conditions to induce iPSC fo
emergence) to induceMbd3-floxed alleles excision. The encircled numbers corre
were counted and subsequently stained for AP. The number of colonies is presecontrasting with previous reports (Luo et al., 2013; Rais et al.,
2013). To examine whether this difference is a reflection of the
specific reprogramming systems that we used, we performed
PB-mediated reprogramming of mouse embryonic fibroblasts
(MEFs) combined with Mbd3 depletion using two different ap-
proaches (Figure 3D). First, we used an Mbd3 knockdown sys-
tem in which Nanog-GFP MEFs were treated with doxycycline
(DOX) for the induction of the MKOS or STEMCCA reprogram-
ming cassettes (Kaji et al., 2009; Sommer et al., 2009) and
cultured in S+LIF medium supplemented with vitamin C and
Alki (Tgfb signaling inhibitor). Twenty-four hours after induction
they were transduced with lentiviruses expressing shRNA
against Mbd3 (Figure 3E and Figures S3E–S3G). Second, we
depleted Mbd3 by treating Cre-ERt2-transduced Mbd3ex1fl/ex1fl
MEFs with 4-OHT at 0 hr or 48 hrs after induction of reprogram-
ming factor expression (Figure 3F and Figures S3H and S3I).
While both systems demonstrated about 80% downregulation
of MBD3 protein, neither impacted on the efficiency of MEF
reprogramming. However, depletion of MBD3 protein would
take a few days from the time of 4-OHT administration, so it is
possible that in this system cells go through the most critical
stage of reprogramming with MBD3 protein still present at a
sufficient level.
From our experiments we therefore found that, depending on
the reprogramming context, MBD3/NuRD depletion can either
have no apparent effect on reprogramming or significantly impair
the transition to naive pluripotency.
Overexpression of MBD3/NuRD Can Facilitate
Reprogramming
Because the complete removal of Mbd3 or a decrease in its
expression can significantly impair the generation of both pre-
iPSCs and iPSCs from NSCs, and iPSCs from preiPSCs and
EpiSCs, we tested whether MBD3 levels are limiting for reprog-
ramming. For that, Oct4-GFP reporter NSCs and Nanog-GFP
MEF-derived preiPSCs were stably transfected with Mbd3
(Figures 4A and 4E). MBD3 overexpression had neither a positive
nor detrimental effect on the efficiency of iPSC formation in both
systems (Figures 4B, 4C, 4F and 4G). However, combined over-
expression of MBD3 and NANOG in MEF-derived preiPSCs led
to accelerated reprogramming kinetics and an up to 30-fold in-
crease in reprogramming efficiency compared to Nanog-Empty
vector (EV) control (Figures 4F and 4G and Figures S4A and
S4B). This synergistic effect correlated with the upregulation of
both Esrrb and endogenous Oct4 expression, to 5% and 3%
of the expression levels of wild-type ESCs, respectively, prior
to induction of pluripotency by 2i/LIF medium switch (Figure 4I).
Interestingly, MBD3 overexpression in these cell lines caused an
increase in protein levels of MTA2, a core subunit of the NuRD/:Mbd3 (rescue) preiPSCs after 2i/LIF culture for 12 days. Colony number is
d factors in preiPSCs and corresponding derived iPSCs. qRT-PCR values are
in Egf+Fgf2 medium for 3 days, switched to S+LIF for 4 more days to allow
rmation. 4-OHT was added at different time points (before or after preiPSC
spond to different conditions. At day 20 after transfection, GFP iPSC colonies
nted per 7.5 3 104 NSCs. The error bars indicate STDEV.
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Figure 3. Requirement of MBD3 in Other Reprogramming Systems
(A) Experimental designs used to analyze the effect ofMbd3 KD and KO on EpiSC reprogramming efficiency. For the KD experiments, wild-type EpiSCs (carrying
an Oct4-GFP cassette), stably transfected with pPB-CAG-Klf2.2A.Nanog (K2N) or pPB-CAG-Klf4, were transfected with either siMbd3 or siControl (siCtrl) and,
after 24 hr, were plated in 2i/LIF for 12 days. For the KO experiments,Mbd3/ orMbd3fl EpiSCs carrying an Oct4-GFP reporter (EOS-GiP), stably transfected
with K2N (or empty vector control, EV), were plated in 2i/LIF for 12 days.
(B and C) The efficiency of EpiSC reprogramming afterMbd3 removal, either by KD (B) or KO (C), was assessed by countingOct4-GFP+ colonies. Representative
AP stained plates are also indicated. 1.0 3 104 EpiSCs were plated in (B). 1.5 3 104 EpiSCs were plated in (C).
(D) Experimental designs used to analyze the effect ofMbd3 KD andMbd3 exon 1 KO. For the KD experiments, Nanog-GFP MEFs transfected with doxycycline-
inducible MKOS piggyBac transposon (iMKOS) were cultured in S+LIF + DOX + vitamin C (vitC) + Alki 24 hr before lentiviral infections of shMbd3 or shControls.
For the KO experiments,Mbd3ex1fl/ex1flMEFs transfectedwith iMKOSwere infectedwith pMX-Cre-ERt2. Reprogrammingwas carried out in S+LIF +DOX + vitC +
Alki, and 4-OHT was added either at the time of DOX administration (0h) or 48 hr later (48h).
(E) Number of Nanog-GFP+ iPSC colonies at day 13 of reprogramming upon infection of indicated shRNAs.
(F) Number of Nanog+ colony numbers determined by immunofluorescence after 13 days of reprogramming of Mbd3ex1fl/ex1fl:Cre-ERt2 MEFs. The error bars
indicate STDEV. Typical iMKOS positive cell number at day 2 of reprogramming is 1.0–3.0 3 104 cells per well, providing 1%–2% reprogramming efficiency.
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(Kaji et al., 2006). This suggests that the effects of MBD3 overex-
pression are potentially attributable to the total amount, and sub-
sequently total activity, of the NuRD complex.We also found that
EpiSCs overexpressing both Nanog and MBD3 showed a
30-fold increase in the ability to generate iPSCs relative to a
Nanog only control (Figures 4K–4N). Importantly, all iPSCs
generated by the overexpression of NANOG and MBD3 ex-
hibited the molecular properties expected for naive pluripotent
cells (Figures S4C–S4F) as well as chimera and germline compe-
tence after the excision of reprogramming transgenes (Figures
4J and 4O). We did not see reprogramming synergy with the
NuRD complex for two other known reprogramming factors,
KLF4 and NR5A2 (Figure 4P and Figure S4G).
The MBD3 isoform that we used for the rescue and overex-
pression experiments was MBD3B, the most abundant isoform106 Cell Stem Cell 15, 102–110, July 3, 2014 ª2014 The Authorsby protein levels in ESCs (Figure S4K). In contrast to MBD3B,
we found that MBD3C did not synergize with NANOG (Figure 4Q
and Figures S4H–S4J). The two isoforms differ in only the first
60 N-terminal amino acids (Figure S4H), indicating that this re-
gion is of importance for NANOG-dependent MBD3 ability to
facilitate reprogramming.
These results demonstrate that MBD3 overexpression does
not impair induction of naive pluripotency and that it can in fact
facilitate reprogramming in conjunction with enhanced NANOG
expression.
DISCUSSION
In this study we have identified a positive facilitator role for
MBD3/NuRD in transcription-factor-mediated reprogramming
of NSCs and EpiSCs. In our analyses, we found that genetic
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MBD3/NuRD Facilitates Reprogrammingor siRNA-mediated depletion of Mbd3 led to a reduction in
the efficiency of reprogramming in these contexts, but not in re-
programming of MEFs. More specifically, we found through time
course experiments that MBD3/NuRD function is particularly
important during the initiation phase of reprogramming of
NSCs and is more dispensable in the later stages when the
pluripotency network is becoming more stably established.
We also found that MBD3 overexpression, with resulting
higher levels of the NuRD complex, facilitates reprogramming
of MEF-derived preiPSCs and EpiSCs when combined with
expression of NANOG, but not with other tested reprogramming
factors, which is consistent with previous observations that
NuRD complex subunits are high confidence protein interactors
of both OCT4 and NANOG (Costa et al., 2013; Ding et al., 2012;
Gagliardi et al., 2013; Liang et al., 2008; Pardo et al., 2010; van
den Berg et al., 2010). In our experiments the N teminus of the
MBD3B isoform, which has previously been suggested to be
required for protein-protein interactions (Aguilera et al., 2011),
appeared to be required for the observed synergistic effect
with NANOG in reprogramming (Figure 4Q). In the future we
will aim to understand how NANOG and MBD3 work together
to drive cells (preiPSCs) that are arrested in the reprogramming
process toward pluripotency.
Our data suggest that the NuRD complex might be facilitating
gene activation during reprogramming. Interestingly, MBD3 was
recently shown to localize to the regulatory sequences of active
genes (Gu¨nther et al., 2013; Reynolds et al., 2013; Shimbo et al.,
2013), including ESC super-enhancers (Hnisz et al., 2013). More-
over, genome-wide expression analysis revealed that 61% of
differentially expressed genes are downregulated after Mbd3
deletion in ESCs (Reynolds et al., 2012b). Although some of
this decrease in transcription might be due to indirect effects,
it seems likely that the NuRD complex acts at enhancers as a
mediator of transcription-factor-induced gene activation and
thus could also interact with pluripotency factors such as
NANOG to support genome-wide reprogramming. In addition,
NuRD has been proposed to mediate transient mTOR downre-
gulation and subsequent activation of autophagy, a key step dur-
ing early stages of reprogramming (Wang et al., 2013).
Our results are in apparent disagreement with two recent
reports that suggested an inhibitory role for MBD3 in reprogram-
ming (Luo et al., 2013; Rais et al., 2013), including one (Rais et al.,
2013) that argued that reduction or deletion of Mbd3 leads to
rapid deterministic reprogramming with 100% efficiency. There
are a number of differences between our study and these two
previous reports, including the choice of reprogramming cas-
settes and the reprogramming culture conditions. In contrast
to our study, Rais et al. (2013) used a secondary system for
somatic cell reprogramming and lentiviral cassette delivery,
and it has been reported that both of these factors influence
iPSC generation efficiency (Stadtfeld and Hochedlinger, 2010).
Moreover, distinct reprogramming factor stoichiometry can pro-
vide varying intracellular environments, which may show
different dependencies on MBD3 activity for reprogramming. In
addition, in our hands heterozygous Mbd3fl/ ESCs express
MBD3 at nearly wild-type levels (Figures S4K–S4M; Reynolds
et al., 2012b), but Rais et al. (2013) reported that their Mbd3fl/
ESCs expressed MBD3 at 20% of wild-type levels. Further
examination of these and other practical and procedural differ-ences between our study and the previous work should help
clarify the basis of the apparent differences seen.
Overall, taking into account the results that we report here and
previous studies, our conclusion is that at least in some contexts
MBD3/NuRD plays a positive role in reprogramming, and that
loss of MBD3 expression leads to a reduction in the efficiency
of the reprogramming process.
NuRD plays well-documented roles in controlling gene
expression and developmental transitions in a wide variety of
different metazoan systems (Ahringer, 2000; McDonel et al.,
2009; Reynolds et al., 2013). MBD3 is known to be required
for embryonic development and pluripotent cell differentiation
(Kaji et al., 2006, 2007), and the composition of the complex or
specific interactions of its individual subunits may regulate
different aspects of its function (Allen et al., 2013; Reynolds
et al., 2013). Further insights into the function of the NuRD com-
plex during different cell state transitions will help us understand
the process of induced pluripotency as well as embryonic
development.EXPERIMENTAL PROCEDURES
Cell Culture
Platinum-E, preiPSCs, and MEFs were cultured in GMEM (Sigma-Aldrich)
supplemented with 10% FCS, 13 NEAA, 13 Pen/Strep, 1 mM sodium pyru-
vate, 0.1 mM 2-mercaptoethanol, 2 mM L-glutamine, and 20 ng/ml of LIF
(homemade), indicated as S+LIF medium throughout. ESCs and iPSCs were
maintained in N2B27-based medium (DMEM/F12 and Neurobasal [both Life
Technologies] in 1:1 ratio, 13 Pen/Strep, 0.1 mM 2-mercaptoethanol, 2 mM
L-glutamine, 1:200 N2 [PAA], and 1:100 B27 [Life Technologies]) supple-
mented 20 ng/ml of LIF and 2i inhibitors: CHIR99021 (3 mM) and PD0325901
(1 mM), indicated as 2i/LIF throughout (Ying et al., 2008). NSCs were cultured
in DMEM/F12 (GIBCO) supplemented with 13 NEAA, 0.1 mM 2-mercaptoe-
thanol, 13 Pen/Strep, 1:100 B27, 1:200 N2 supplement, 4.5 mM HEPES,
0.03 M glucose, 120 mg/ml BSA, 10 ng/ml of Egf (Peprotech), and 20 ng/ml
of Fgf2 (homemade), indicated as Egf+Fgf2 medium throughout. EpiSCs
were maintained in N2B27-based medium containing 12 ng/ml of Fgf2 and
20 ng/ml of Activin A (homemade), indicated as Fgf2/Act.A medium
throughout. EpiSCs and NSCswere cultured on plastic coated with fibronectin
(10 mg/ml, Millipore) or laminin (10 mg/ml, Sigma-Aldrich), respectively. All
other cell types were grown on gelatine. All cell types were maintained at
7% CO2. For Cre-mediated transgene excision, cells were treated with
500 nM of 4-OHT.Derivation of Cell Lines
NSCs
Brains fromMbd3fl/fl andMbd3ex1fl/ex1fl E13.5 embryos were dissected, disso-
ciated in Egf+Fgf2 medium, and plated onto the laminin-coated cell culture
flasks. Mbd3fl/ NSCs were derived from ESCs as described (Pollard et al.,
2006). Briefly, ESCs were seeded on gelatinized 10 cm dishes in N2B27
medium for 7 days. After this period, cells were trypsinized and plated on
nongelatinized dishes for 3 days in Egf+Fgf2 medium. The emergent
neurospheres were then seeded on gelatinized plates and maintained in
monolayer in Egf+Fgf2 medium. For Cre-excision of the Mbd3 floxed allele,
Mbd3fl/ NSCs were nucleofected with a pCAG-Cre-ires-Puro plasmid and
clonal lines of Mbd3/ NSCs were expanded.
MEFs
Organ-deprived carcasses from E12.5 or E13.5 embryos were dissociated into
small pieces, trypsinized, and plated in S+LIF medium.
EpiSCs
Mbd3fl/ and Mbd3/ EpiSCs were derived from ESCs as previously
described (Guo et al., 2009). Briefly, ESCs transfected with pPB-EOS-GFP-
ires-Puro (EOS-GiP; GFPiresPuro under the control of early transposon
promoter and Oct4 and Sox2 enhancers) were cultured in Fgf2/Act.A mediumCell Stem Cell 15, 102–110, July 3, 2014 ª2014 The Authors 107
Figure 4. Overexpression of MBD3/NuRD Facilitates NANOG-Mediated Reprogramming
(A) Experimental design used to address the effect of MBD3 overexpression on NSC reprogramming. NSCs carrying an Oct4-GFP cassette were stably
transfectedwith pPB-CAG-Nanog and pPB-CAG-Mbd3b or pPB-CAG-empty controls, transducedwith rOKM, cultured in Egf+Fgf2medium for 3 days, switched
to S+LIF medium for 6 days, and then switched to 2i/LIF conditions.
(B) Quantification of Oct4-GFP+ colonies after 12 days in 2i/LIF conditions. Colony number is per 1.0 3 105 NSCs.
(C) Phase and GFP images and AP staining of the iPSCs obtained from NSCs overexpressing respective transgenes.
(legend continued on next page)
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Cell Stem Cell
MBD3/NuRD Facilitates Reprogrammingfor at least 10 passages before analysis. To obtain a pure EpiSC culture, GFP+
cells were removed by FACS.
SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes four figures and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.stem.2014.04.019.
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ART I C L E S
A defined Oct4 level governs cell state transitions of
pluripotency entry and differentiation into all
embryonic lineages
Aliaksandra Radzisheuskaya1, Gloryn Le Bin Chia2, Rodrigo L. dos Santos1,3, Thorold W. Theunissen1,5,
L. Filipe C. Castro4, Jennifer Nichols2 and José C. R. Silva1,6
Oct4 is considered a master transcription factor for pluripotent cell self-renewal, but its biology remains poorly understood. Here,
we investigated the role of Oct4 using the process of induced pluripotency. We found that a defined embryonic stem cell (ESC)
level of Oct4 is required for pluripotency entry. However, once pluripotency is established, the Oct4 level can be decreased up to
sevenfold without loss of self-renewal. Unexpectedly, cells constitutively expressing Oct4 at an ESC level robustly differentiated
into all embryonic lineages and germline. In contrast, cells with low Oct4 levels were deficient in differentiation, exhibiting
expression of naive pluripotency genes in the absence of pluripotency culture requisites. The restoration of Oct4 expression to an
ESC level rescued the ability of these to restrict naive pluripotent gene expression and to differentiate. In conclusion, a defined
Oct4 level controls the establishment of naive pluripotency as well as commitment to all embryonic lineages.
Naive pluripotency characterizes the cells that can give rise to all cell
types of an organism except extraembryonic tissues. In mouse embryos
these cells arise during pre-implantation development in the naive
epiblast. This transient cell population can be captured in vitro as ESCs.
In addition to its developmental potential, the naive pluripotent state
is characterized by a unique set of properties, including the lack of
an inactive X chromosome in female cells, self-renewing response to
Mek/Erk signalling inhibition, and simultaneous expression of Esrrb,
Nanog, Rex1, Klf2 and Klf4 (ref. 1).
Oct4 plays a fundamental role in mammalian development as
a master transcriptional regulator of naive pluripotency mainte-
nance. It belongs to the POU family of transcription factors and
possesses the POUDNA-binding domain characteristic of this family2–4.
Oct4 is expressed in oocytes, blastomeres, inner cell mass (ICM),
naive and post-implantation epiblast, germ cells, and in pluripotent
cells in vitro2,3,5. Its knockout causes pre-implantation lethality of
mouse embryos due to failure to form a pluripotent ICM (ref. 6).
Moreover, both cessation and overexpression of Oct4 cause exit
from ESC self-renewal7,8. Oct4 is also sufficient to trigger repro-
gramming of mouse and human somatic cells in the absence of
1Wellcome Trust—Medical Research Council Cambridge Stem Cell Institute and Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge
CB2 1QR, UK. 2Wellcome Trust—Medical Research Council Cambridge Stem Cell Institute and Department of Physiology, Development and Neuroscience, University
of Cambridge, Tennis Court Road, Cambridge CB2 1QR, UK. 3Doctoral Programme in Experimental Biology and Biomedicine, Centre for Neuroscience and Cell Biology,
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other reprogramming transgenes, albeit with decreased efficiency and
delayed kinetics9–12.
Here, we established a system usingOct4−/− somatic cells and 2i/LIF
culture medium, containing LIF and inhibitors of mitogen-activated
protein kinase signalling and glycogen synthase kinase-3β. Using this,
we uncovered the existence of biological roles of Oct4 that have a critical
impact on pluripotency acquisition, self-renewal and on in vitro and in
vivo cell differentiation.
RESULTS
An ESC level of Oct4 marks acquisition of naive pluripotency
To investigate Oct4 function during induced pluripotency we
generatedOct4−/− neural stem cells (NSCs; Supplementary Fig. S1a–e).
Oct4−/− and control Oct4+/− NSCs were transduced with retroviruses
expressing c-Myc and Klf4 (rMK) and transfected with a piggyBac
(PB) vector containing a ubiquitous promoter (CAG) driving Oct4
expression (PB-Oct4; Fig. 1a). The CAG promoter, unlike the
retroviral promoter, does not undergo silencing during reprogramming.
This strategy produced reprogramming intermediates in serum/LIF
conditions that, on medium switch to 2i/LIF, formed induced
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Figure 1 An ESC level of Oct4 marks pluripotency acquisition.
(a) Generation of rMK+PB-Oct4 iPSCs−/−. Reprogramming intermediates
are represented in orange, and iPSCs in yellow. (b) Phase images
and alkaline phosphatase (AP) staining of rMK+PB-Oct4 iPSCs+/− and
iPSCs−/−. (c–e) Quantitative PCR with reverse transcription (qRT-PCR)
analysis of retroviral transgenes (c), pluripotency markers (d) and total
Oct4 (e) expression in rMK+PB-Oct4 cells before and after 2i/LIF
induction. Serum/LIF indicates reprogramming intermediates; 2i/LIF
indicates iPSCs. ESCs were grown in 2i/LIF. Data shown are the
mean of 3 replicates and are from 1 of 3 representative experiments.
(f) Oct4 locus genotyping for rMK+PB-Oct4 iPSCs+/− and iPSCs−/− and
control Oct4−/− NSCs (NSCs−/−), Oct4flox/− (ESCsF/−) and Oct4flox/+
(ESCsF/+) ESCs. (g) qRT–PCR analysis of Oct4 3′UTR expression
in rMK+PB-Oct4 iPSCs+/− and iPSCs−/−. Data shown are the mean
of 3 replicates and are from 1 of 2 representative experiments.
(h) me3H3K27 immunostaining of NSCs−/− and rMK+PB-Oct4 iPSCs−/−.
White arrowheads indicate representative inactive X chromosomes.
(i) Phase and Cherry images of rMK+PB-Oct4.2A.Cherry reprogramming
intermediates, the rMK+PB-Oct4.2A.Cherry iPSC−/− colony with
surrounding Cherry-high reprogramming intermediates (white arrowheads)
in 2i/LIF and of the established rMK+PB-Oct4.2A.Cherry iPSC−/−
line. (j,k) Cherry flow cytometry analysis of rMK+PB-Oct4.2A.Cherry
Oct4−/− cells before and after 2i/LIF induction (j) and of two
independently derived pools of rMK+PB-Oct4.2A.Cherry iPSCs−/− (k).
Serum/LIF indicates reprogramming intermediates; 2i/LIF indicates
iPSCs. (l) Scatter plot comparing global gene expression profiles of
ESCs and rMK+PB-Oct4.2A.Cherry iPSCs−/−. (m) Alkaline phosphatase
staining demonstrating the comparable ability of Cherry-high and
-low reprogramming intermediates to acquire pluripotency. (n) Cherry
flow cytometry analysis of rMK+PB-Oct4.2A.Cherry iPSCs−/− derived
from Cherry-high and -low reprogramming intermediates. (o) qRT–PCR
analysis of piggyBac and total Oct4 expression in rMK+PB-Oct4 Oct4−/−
cells before and after 2i/LIF induction. Serum/LIF (S/L) indicates
reprogramming intermediates; 2i/LIF (2i/L) indicates iPSCs. PB-Oct4
1 and 2 indicate biological replicates. ESCs were grown in 2i/LIF. Data
shown are the mean of 3 replicates and are from 1 of 2 representative
experiments. (p) Oct4 protein quantification in rMK+PB-Oct4 cells before
and after 2i/LIF induction. Data shown are the mean of 3 independent
experiments; error bars represent± s.d. See Supplementary Fig. S9 for
uncropped data.
580 NATURE CELL BIOLOGY VOLUME 15 | NUMBER 6 | JUNE 2013
© 2013 Macmillan Publishers Limited.  All rights reserved. 
 
ART I C L E S
pluripotent stem cell (iPSC) colonies (Fig. 1b). PB-Oct4 iPSCs−/−
exhibited silencing of retroviral transgenes and upregulation of naive
pluripotency markers (Fig. 1c,d). Strikingly, the total Oct4 level
was similar between iPSCs+/−, iPSCs−/− and ESCs (Fig. 1e). The
absence of endogenous Oct4 expression in iPSCs−/− was confirmed
by genotyping (Fig. 1f) and undetected expression of the Oct4 3′UTR,
which is absent in the knockout loci and PB-Oct4 transgene (Fig. 1g).
Acquisition of a naive pluripotent cell state was further confirmed
by the loss of the trimethyl(me3)H3K27 nuclear focus indicative
of X chromosome reactivation (Fig. 1h). Thus, we generated and
maintained iPSCs−/−dependent exclusively on constitutively expressed
PB-Oct4 transgene. We also observed that, independently of the source
of Oct4 expression, iPSCs exhibit an ESC level of Oct4 transcript on
pluripotency establishment.
To monitor PB transgene expression at the single-cell level during
reprogramming, we used a PB-Oct4.2A.Cherry construct. Consistent
with gene expression data (Fig. 1e), reprogramming intermediates
showed a strong Cherry signal, whereas iPSCs−/− obtained after
2i/LIF induction demonstrated a lower Cherry expression level
(Fig. 1i,j and Supplementary Fig. S1f). Notably, in each experiment
PB-Oct4.2A.Cherry iPSCs−/− represented a pool of hundreds of
colonies formed as a result of multiple independent reprogramming
events. Importantly, the pools of iPSCs−/− obtained in independent
experiments demonstrated a similar small range of Cherry and,
thereby, Oct4 expression (Fig. 1k). This indicates selection and/or
modulation of Oct4 transgene expression during reprogramming. The
PB-Oct4.2A.Cherry iPSCs−/− had a global gene expression profile
similar to ESCs, with only 17 genes differentially expressed bymore than
twofold (Fig. 1l). To assess whether a particular level of Oct4 transgene
expression facilitates reprogramming intermediates to transit into naive
pluripotency, we sorted the highest and lowest Cherry-expressing cells
and plated these in 2i/LIF. We did not observe any difference in the
ability of Oct4 high- and low-expressing cell fractions to undergo
reprogramming (Fig. 1m). Importantly, obtained iPSCs−/− exhibited
similar Cherry expression profiles (Fig. 1n). Combined gene expression
and western blot analysis of independently derived iPSC−/− lines
further confirmed that these exhibit an ESC level of Oct4 on entry
into the pluripotent cell state (Fig. 1o,p and Supplementary Fig. S1g).
We also generated Oct4−/− iPSCs from an independent somatic cell
type, mouse embryonic fibroblasts, and, consistently, these exhibited
an ESC level of Oct4 expression (Supplementary Fig. S1h). This shows
that pluripotent cell state acquisition and/or maintenance requires
modulation of Oct4 transgene expression to an ESC level.
Low Oct4 expression sustains self-renewal
It is established that abolishment of Oct4 expression in ESCs in
serum/LIF leads to differentiation towards trophectoderm7. As theOct4
transgene in the PB vector is flanked by loxP sites and our iPSCs−/−
express 4-hydroxytamoxifen (4OHT)-inducible Cre recombinase, we
tested these for the capacity to undergo trophectoderm differentiation
on Oct4 deletion. Consistent with previous reports, 4OHT treatment in
serum/LIF resulted in some trophectoderm differentiation judging by
morphology and expression of trophectoderm marker Pl-1 (Fig. 2a,b).
However, Oct4 expression was not completely abolished (Fig. 2c). As
cells probably containmultiple PB transgene integrations, this indicates
that not all of the inserts were excised. Surprisingly, an average 12-fold
reduction in Oct4 expression level did not affect the average expression
of naive pluripotency markers Nanog and Rex1 (Fig. 2c). When the
same cells were treated with 4OHT in 2i/LIF conditions (Fig. 2d),
we observed a sevenfold reduction in the Oct4 level (Fig. 2e). Again,
both Rex1 and Nanog expression remained unchanged, indicating
that these cells maintain a naive pluripotent cell state (Fig. 2e). Oct4
and Nanog immunocytochemistry revealed a wide range of Oct4
expression in 4OHT-treated cells, with some of the Oct4-low cells
showing strong Nanog signal, above that of control cells (Fig. 2f and
Supplementary Fig. S2a).
We picked a colony of 4OHT-treated iPSCs−/− and established a
cell line with reduced Oct4 transcript and protein levels (Fig. 2h,i).
It retained ESC morphology (Fig. 2g), Nanog expression (Fig. 2h)
and could be serially passaged without any signs of differentiation.
To validate this, we 4OHT-treated an independent cell line, PB-
Oct4.2A.Cherry iPSCs−/−, and subsequently single-cell sorted them
for low Cherry-expressing cells. This allowed establishment of
several Oct4-low iPSC−/− lines (Fig. 2j). These clones exhibited a
similar decrease in Oct4 transcript and protein levels (Fig. 2k,l)
and retained expression of naive pluripotency genes at levels
comparable to ESCs (Fig. 2m). To further demonstrate that, despite
reduced Oct4 expression, Oct4-low iPSCs−/− match the molecular
criteria of the naive pluripotent state, we performed global gene
expression analysis of these in 2i/LIF. This revealed a very similar
profile to parental iPSCs−/− with an ESC Oct4 level (Oct4-WT
iPSCs−/−; Fig. 2n), and to ESCs (data not shown). We also confirmed
that Oct4-low cells do not express epiblast stem cell markers
(Supplementary Fig. S2b). Moreover, Oct4-low iPSCs−/− contained
unmethylated Nanog and Oct4 regulatory regions (Supplementary
Fig. S2c), and exhibited absence of the H3K27me3 nuclear focus
(Supplementary Fig. S2d).
To determine the highest Oct4 expression level permissive of
pluripotent cell self-renewal, we transfected wild-type ESCs with
PB-Oct4.2A.Cherry construct. Consistent with previous findings7,
we observed that the cells expressing the highest level of Cherry
had differentiated morphology and were lost on passaging (Sup-
plementary Fig. S2e). Self-renewing cells exhibited lower Cherry
levels than cells transfected with PB-Cherry alone, further indicating
that high Oct4 expression is detrimental for the pluripotent state
(Supplementary Fig. S2f). We picked and expanded the highest
Cherry-expressing ESC-like clones. All demonstrated similar total
Oct4 levels but lower endogenous Oct4 when compared with parental
ESCs (Supplementary Fig. S2g). They also had lower Cherry ex-
pression levels than PB-Oct4.2A.Cherry iPSCs−/− (Supplementary
Fig. S2h). This indicates that Oct4 transgene expression is com-
patible with self-renewal only if ESCs+/+ compensate by equally
downregulating endogenous Oct4 expression. We also overexpressed
Oct4 episomally13 in ESCs to determine which differentiation genes
become upregulated. An average 11-fold Oct4 overexpression led
to significant upregulation of differentiation markers representing
all three embryonic lineages: Gata4; Zeb2 and Snai2; and Sox1
(Supplementary Fig. S2i).
In conclusion, expression of up to fivefold lower levels of Oct4
sustains naive pluripotent cell self-renewal. This signifies that an
ESC level of Oct4 expression is a requirement for pluripotency entry
but not self-renewal.
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Figure 2 Low levels of Oct4 expression sustain self-renewal. (a) Phase
images of ESCs and rMK+PB-Oct4 iPSCs−/− treated and untreated with
4OHT in serum/LIF culture conditions. (b,c) qRT–PCR analysis of Pl-1
(b) and pluripotency markers (c) expression in ESCs and rMK+PB-Oct4
iPSCs−/− treated and untreated with 4OHT in serum/LIF culture conditions.
Data shown are the mean of 3 replicates and are from 1 of 2 representative
experiments. (d) Phase images of rMK+PB-Oct4 iPSCs−/− treated and
untreated with 4OHT in 2i/LIF culture conditions. (e) qRT–PCR analysis of
total Oct4, Nanog and Rex1 expression in rMK+PB-Oct4 iPSCs−/− treated
and untreated with 4OHT in 2i/LIF culture conditions. Data shown are
the mean of 3 replicates and are from 1 of 2 representative experiments.
(f) Nanog and Oct4 immunocytochemistry in rMK+PB-Oct4 iPSCs−/− treated
and untreated with 4OHT in 2i/LIF culture conditions. (g) Phase image of
rMK+PB-Oct4 (low) iPSCs−/− in 2i/LIF conditions. (h) qRT–PCR analysis of
total Oct4 and Nanog expression in PB-Oct4, PB-Oct4 (low) iPSCs−/− and
ESCs in 2i/LIF culture conditions. Data shown are the mean of 3 replicates
and are from 1 of 2 representative experiments. (i) Western blot analysis
of Oct4 protein levels in PB-Oct4 and PB-Oct4 (low) iPSCs−/− in 2i/LIF
culture conditions. See Supplementary Fig. S9 for uncropped data. (j) Flow
cytometry analysis of PB-Oct4.2A.Cherry (low) iPSC−/− clones obtained as
a result of 4OHT treatment of PB-Oct4.2A.Cherry iPSCs−/− and subsequent
single-cell sorting. PB-Oct4.2A.Cherry is indicated as O2C. Clones for
which the median is indicated in red were chosen for subsequent analysis.
(k) qRT–PCR analysis of total Oct4 expression in PB-Oct4.2A.Cherry (low)
iPSC−/− clones 1, 5 and 12. Data shown are the mean of 3 replicates
and are from 1 of 2 representative experiments. (l) Oct4 protein levels in
PB-Oct4.2A.Cherry (low) iPSC−/− clones 1, 5 and 12. (m) qRT–PCR analysis
of pluripotency gene expression in PB-Oct4.2A.Cherry (low) iPSC−/− clones
1, 5 and 12. Data shown are the mean of 3 replicates and are from 1
of 3 representative experiments. (n) Scatter plot comparing global gene
expression profiles of PB-Oct4.2A.Cherry iPSCs−/− and PB-Oct4.2A.Cherry
(low) iPSC−/− clone 5.
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Figure 3 Oct4 expression at an ESC level is required for in vitro differen-
tiation. (a) qRT–PCR analysis of pluripotency (total Oct4, Nanog, Rex1),
endoderm (FoxA1, Gata4), ectoderm (Fgf5 ) and mesoderm (T-Brachyury,
Zeb2, Snai2, Nkx2.5, N-cadherin) markers and E-cadherin expression
during embryoid body differentiation of ESCs+/+ and rMK+PB-Oct4
iPSCs−/−. D0–D7 indicate the number of days of differentiation. Data
shown are the mean of 3 replicates and are from 1 of 4 representative
experiments. (b) qRT–PCR analysis of pluripotency (total Oct4, Nanog,
Rex1, Esrrb), endoderm (FoxA1, Gata4), ectoderm (Fgf5 ), mesoderm
(T-Brachyury, Zeb2, Snai2, Nkx2.5, N-cadherin) and trophectoderm (Pl-1)
markers and E-cadherin expression during embryoid body differentiation
of PB-Oct4.2A.Cherry iPSCs−/−, PB-Oct4.2A.Cherry (low) iPSC−/− clone
1, 5 and 12 iPS−/− and PB-Oct4.2A.Cherry (low) clone 1 + CAG-Oct4
(rescue line). Data shown are the mean of 3 replicates and are from
1 of 3 representative experiments. (c) qRT–PCR analysis of Sox1, total
Oct4, Rex1 and Nanog expression during neural induction by monolayer
culture of control ESCs+/+, PB-Oct4 iPSCs−/− and PB-Oct4 (low) iPSCs−/−.
D0–D5 indicate the number of days of differentiation. Data shown are
the mean of 3 replicates and are from 1 of 2 representative experiments.
(d) Immunocytochemistry detection of βIII-tubulin and Nanog expression
after 7 days of neural induction by monolayer culture of control ESCs+/+,
PB-Oct4 iPSCs−/− and PB-Oct4 (low) iPSCs−/−.
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In vitro differentiation requires an ESC level of Oct4
To further define the properties of Oct4-low and Oct4-WT iPSCs−/−
we analysed their ability to differentiate in vitro. Despite constitutive
expression of the Oct4 transgene, Oct4-WT iPSCs−/− underwent
efficient embryoid body differentiation into all three germ layers, as
judged by the upregulation of mesoderm, endoderm and ectoderm
markers (Fig. 3a). Efficient E-cadherin downregulation demonstrated
successful epithelial-to-mesenchymal transition (Fig. 3a). These
also efficiently formed beating heart cells on embryoid body
outgrowth (Supplementary Video S1). Strikingly, Oct4-low iPSCs−/−
differentiated poorly in embryoid body assays, exhibiting failure
to downregulate pluripotent gene expression and to upregulate
differentiation markers (Fig. 3b and Supplementary Fig. S3a). They
also showed trophectoderm marker upregulation (Fig. 3b and
Supplementary Fig. S3a) and did not form beating heart cells.
Importantly, restoration of Oct4 expression to an ESC level in Oct4-low
iPSCs−/− by the introduction of a CAG-Oct4 transgene rescued
their differentiation defect (Fig. 3b). In addition, whereas Oct4-WT
iPSCs−/− differentiated into the neural lineage in the monolayer
protocol14, judging by Sox1 upregulation and the formation of β-III
tubulin-positive neurons, Oct4-low iPSCs−/− failed to downregulate
Nanog and Rex1 and to upregulate neural lineage markers (Fig. 3c,d
and Supplementary Fig. S3b,c). Importantly, restoration of Oct4
expression to an ESC level in Oct4-low cells reinstated their ability to
form neural lineage (Supplementary Fig. S3b,c).
These data show that Oct4 expression at an ESC level is required for
efficient in vitro differentiation.
In vivo differentiation requires an ESC level of Oct4
To address the ability of PB-Oct4.2A.Cherry and PB-Oct4.2A.Cherry
(low) iPSCs−/− to contribute to mouse development we performed
morula aggregations. Consistent with their naive pluripotent state,
by the blastocyst stage both iPSC−/− lines efficiently incorporated
into the pre-implantation epiblast (Fig. 4a). Despite constitutive
Oct4 expression, embryonic day (E)6.5 PB-Oct4.2A.Cherry chimaeric
embryos appeared normal with the whole epiblast consisting of Cherry-
positive cells (Fig. 4b). Strikingly, despite efficiently incorporating into
the naive epiblast, PB-Oct4.2A.Cherry (low) iPSCs−/− failed to proceed
in development. Only 4/30 E6.5 embryos showed some contribution
to the post-implantation epiblast (Fig. 4b and Supplementary Fig. S4a).
The remaining embryos were either Cherry-negative or contained
Cherry-positive cells between the epiblast and trophectoderm (Fig. 4b,c
and Supplementary Fig. S4a,b). These remaining embryos were lost on
in vitro culture of the embryos (Supplementary Fig. S4c), potentially
reflecting cell exclusion fromdevelopment due to failure to differentiate.
This is supported by the fact that when compared with the blastocyst
stage, few E6.5 embryos show the presence of Cherry-positive cells. To
validate this, we dissociated PB-Oct4.2A.Cherry (low) E6.5 chimaeric
embryos into single-cell suspension and plated them in 2i/LIF, which
would select for cells remaining in a naive pluripotent state. As a result,
we observed the emergence of numerous Cherry-positive colonies
(Supplementary Fig. S4d), which retained Nanog, Klf4 and Rex1
expression (Supplementary Fig. S4e). This indicates that most, if not
all, of the PB-Oct4.2A.Cherry (low) cells retained a naive pluripotent
state. Together, these results highlight a requirement for an ESC level
of Oct4 expression for post-implantation development. In agreement
with this, restoration of Oct4 expression to an ESC level rescued the
ability of PB-Oct4.2A.Cherry (low) iPSCs−/− to efficiently incorporate
into the post-implantation embryo (Fig. 4d).
Subsequently, we analysed PB-Oct4.2A.Cherry iPSC−/− E7.5
chimaeric embryos. Strikingly, constitutive Oct4 expression at an
ESC level was compatible with contribution to all embryonic lineages
(Fig. 4e,f and Supplementary Fig. S4f), specifically, early mesoderm
marked by T-Brachyury15 and presumptive neuroectoderm marked
by Sox2 (ref. 16; Fig. 4f). Foxa2, marking early progenitors of all germ
layers at the anterior primitive streak17, was largely co-expressed with
Cherry in the chimaeric embryos (Fig. 4f). Moreover, Cherry was
co-expressed with Sox17 exclusively in the inner layer of Sox17-positive
cells, representing nascent definitive endoderm18 (Fig. 4f).
At E8.5, PB-Oct4.2A.Cherry embryos appeared morphologically
normal and, judging by Cherry and Oct4 protein expression, virtually
all embryonic tissues were of iPSC−/− origin (Fig. 4g,h). However,
chimaeric embryos inefficiently proceeded in development after this
stage (Supplementary Fig. S4g). This is also a developmental stage when
Oct4 expression becomes restricted to the germ lineage5,19. As obtained
embryos demonstrated high if not 100% chimaerism, we performed
blastocyst injections with 1–5 cells to determine whether chimaeric
embryos can develop further in the presence of host embryo cells.
Widespread iPSC−/− contribution was observed in E12.5 chimaeric
embryos, which was the latest time point analysed (Supplementary Fig.
S4h). Analysis of genital ridges at E12.5 demonstrated contribution
of PB-Oct4.2A.Cherry iPSCs−/− to the germline (Fig. 4i). We also
observed that PB-Oct4.2A.Cherry iPSCs−/− are more efficient at
entering embryonic development than control ESCs (Fig. 4j,k). This
suggests that premature loss of Oct4 expression in ESCs on embryo
injection leads to decreased chimaerism and further shows that Oct4
facilitates cell state transitions during pluripotent state exit. We also
performed teratoma assays for Oct4-WT and Oct4-low iPSCs−/−.
Whereas teratomas derived from Oct4-WT and rescue iPSCs−/−
contained various tissues representing all three embryonic lineages,
teratomas derived from the two Oct4-low iPSC−/− lines had only
discernible areas of trophectoderm-like and undifferentiated cells
(Supplementary Fig. S5).
In summary, Oct4 expression at an ESC level is required for efficient
in vivo differentiation into all three germ layers.
Oct4 genomic binding is converse to Nanog and is linked to
downregulation of naive pluripotency genes
Pluripotent cell cultures in 2i/LIF are homogeneous and do not contain
differentiated cells or cells primed for differentiation.However, pluripo-
tent cultures in serum/LIF have subpopulations of cells with variable lev-
els of naive pluripotency marker expression20–24. We analysed these in
Oct4-WT and Oct4-low iPSCs−/− in 2i/LIF compared with serum/LIF
in the presence of selection for Oct4 promoter activity to eliminate
differentiated cells (Supplementary Fig. S1b). There were no major dif-
ferences in pluripotency marker expression, at both transcript and pro-
tein levels, between analysed cell lines in 2i/LIF (Fig. 5a,c). However, in
serum/LIF, we observed higher expression levels of naive pluripotency
markers in all of the Oct4-low iPSC−/− lines, at both transcript and pro-
tein levels, when compared with parental iPS−/− and rescued Oct4-low
iPSCs−/− (Fig. 5b,d). The observed expression differences could not be
attributed to differentiation (Supplementary Fig. S6a,b). To gain insight
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Figure 4 Oct4 expression at an ESC level is required for in vivo differentiation.
(a) Phase and Cherry images of embryos obtained 48h after morula
aggregations of PB-Oct4.2A.Cherry or PB-Oct4.2A.Cherry (low) clone
1 iPSCs−/−. Representative contribution to naive epiblast is indicated
with white arrowheads. (b) Phase and Cherry images of E6.5 embryos
obtained as a result of PB-Oct4.2A.Cherry or PB-Oct4.2A.Cherry (low)
clone 1 iPSC−/− morula aggregations. (c) High-magnification images of
E6.5 PB-Oct4.2A.Cherry (low) clone 1 chimaeric embryos. (d) Phase and
Cherry images of E7.5 embryos obtained after rescuing PB-Oct4.2A.Cherry
(low) clone 1 iPSCs−/− with CAG-Oct4. (e) Phase and Cherry images of
E7.5 PB-Oct4.2A.Cherry chimaeric embryos. (f) E7.5 PB-Oct4.2A.Cherry
chimaeric embryos immunostained for Sox17, FoxA2, Sox2 and T-Brachyury.
(g,h) E8.5 PB-Oct4.2A.Cherry chimaeric embryos. Phase and Cherry images
(g) and immunostaining for Oct4 (h). (i) Confocal images of the genital ridges
from E12.5 PB-Oct4.2A.Cherry chimaeric embryos immunostained for Mvh.
(j) Flow cytometry analysis of PB-Oct4.2A.Cherry iPSCs−/− and ESCs+/+ with
CAG-Cherry reporter. (k) Representative Phase and Cherry images of litters
of PB-Oct4.2A.Cherry iPSC−/− and CAG-Cherry ESC+/+ chimaeric embryos.
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Figure 5 Oct4 binding is converse to Nanog and is linked to downregulation
of naive pluripotency genes. (a,b) qRT–PCR analysis of total Oct4, Klf4,
Nanog, Tbx3, Esrrb and Rex1 expression in PB-Oct4 (Oct4-WT and -low),
PB-Oct4.2A.Cherry (Oct4-WT and -low) iPSCs−/− and PB-Oct4.2A.Cherry
(low) + CAG-Oct4 iPSC−/− rescue clones in 2i/LIF (a) and serum/LIF with
selection for geneticin (G418) resistance driven by the Oct4 promoter
(Supplementary Fig. S1b; b). Oct4-low lines are indicated with red
rectangles. Data shown are the mean of 3 replicates and are from 1
of 2 representative experiments. (c,d) Western blot analysis of Oct4,
Nanog, Esrrb and Klf4 protein expression in PB-Oct4 (Oct4-WT and -low),
PB-Oct4.2A.Cherry (Oct4-WT and -low) iPSCs−/− and PB-Oct4.2A.Cherry
(low) + CAG-Oct4 iPSC−/− rescue clones in 2i/LIF (c) and serum/LIF with
selection for geneticin (G418) resistance driven by Oct4 promoter (d).
Oct4-low lines are indicated with red rectangles. See Supplementary Fig.
S9 for uncropped data. (e,f) ChIP analysis of Oct4 (e) and Nanog (f) binding
at the regulatory regions of pluripotency genes in PB-Oct4.2A.Cherry and
PB-Oct4.2A.Cherry (low) iPSCs−/−. Data shown are the mean of 3 replicates
and are from 1 of 2 representative experiments.
into why Oct4-low cells fail to downregulate naive pluripotency gene
expression, we performed chromatin immunoprecipitation (ChIP)
for Oct4, Nanog and Esrrb in serum/LIF conditions in Oct4-low and
Oct4-WT cells at regulatory sequences of key naive pluripotency genes.
Strikingly, Oct4 genomic occupancy was markedly reduced and Nanog
and Esrrb significantly increased at these targets in Oct4-low cells
(Fig. 5e,f and Supplementary Fig. S6c). This suggests that in suboptimal
self-renewing culture conditions and on induction of cell differentiation
Oct4 can act as a repressor of key naive pluripotency genes and that a re-
duction in theOct4 level leads to an incapacity to downregulate these.
To assess whether the phenotype ofOct4-low cells could be attributed
to the high levels of Nanog, we performed Nanog knockdown in
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Figure 6 Oct4-low iPSCs self-renew in the absence of pluripotent culture
requisites. (a) Phase images of PB-Oct4 iPSCs−/− treated or untreated with
4OHT for 24h and subsequently cultured in N2B27 conditions with selection
for geneticin (G418) resistance driven by Oct4 promoter (Supplementary
Fig. S1b). Untreated cells differentiated and died after the first passage,
whereas treated cells self-renewed indefinitely. (b) qRT–PCR analysis of total
Oct4, Socs3, Nanog, Rex1, Klf2 and Klf4 expression in PB-Oct4 iPSCs−/−
cultured in 2i/LIF and 4OHT-treated iPSCs−/− cultured for 15 passages in
N2B27 conditions. Data shown are the mean of 3 replicates and are from
1 of 2 representative experiments. (c) Alkaline phosphatase (AP) staining
of 4OHT-treated PB-Oct4 iPSCs−/− (passage 15 in N2B27) plated at clonal
density. Two thousand cells were plated per well and cultured for 8 days
in N2B27. (d) Immunocytochemistry detection of Nanog in 4OHT-treated
PB-Oct4 iPSCs−/− cultured in N2B27 conditions. (e) Phase image of the
previously established (Fig. 2j–l) PB-Oct4.2A.Cherry (low) clone 1 iPSCs−/−
cultured in N2B27 conditions. (f) qRT–PCR detection of Socs3, Nanog,
Rex1, Esrrb, Klf2 and Klf4 in PB-Oct4.2A.Cherry (low) clone 1 iPSCs−/−
cultured in 2i/LIF and N2B27 conditions. Data shown are the mean of 3
replicates and are from 1 of 3 representative experiments. (g) ChIP analysis
of Nanog binding at main target genes in PB-Oct4.2A.Cherry (low) clone 1
iPSCs−/− cultured in N2B27 conditions for 15 passages. Data shown are
the mean of 3 replicates and are from 1 of 2 representative experiments.
Oct4-low cells and subjected these to either a self-renewal assay at
clonal density in serum minus LIF or to embryoid body differentiation.
We confirmed Nanog knockdown and observed decreased expression
of Klf4 and Esrrb, known Nanog targets25. However, the expression
of these and other naive pluripotency genes remained higher than
in self-renewing Oct4-WT cells (Supplementary Fig. S6d). Oct4-low
cells with Nanog knockdown did not differentiate (Supplementary
Fig. S6e,f), suggesting that ongoing high-level expression of other
naive pluripotency genes such as Klf2 and Tbx3, which can confer
LIF-independent self-renewal26,27, prevents differentiation. Together,
these data further confirm that Oct4-low cells are robustly locked
in a self-renewing state.
Low Oct4 is sufficient to sustain self-renewal in the absence of
pluripotent culture requisites
Failure to differentiate together with robust expression of naive
pluripotency genes led us to investigate whether Oct4-low iPSCs−/−
can self-renew after removal of 2i and LIF from the serum-free
medium (N2B27). Under these conditions, pluripotent cells undergo
differentiation14,28. Oct4-WT iPSCs−/− were treated with 4OHT
for 24 h, which induced partial Oct4 transgene loss (Fig. 2e), and
then switched to N2B27 with selection for Oct4 promoter activity
to eliminate differentiated cells. In contrast to untreated cells,
which differentiated and died after the first passage, we were able
to maintain 4OHT-treated cells indefinitely (Fig. 6a). These cells
expressed naive pluripotencymarkers but lost Socs3 and downregulated
Klf4 expression, indicating an absence of LIF/STAT3 signalling
(Fig. 6b and Supplementary Fig. S7a). Oct4 transgene expression
was decreased by at least 2.5-fold (Fig. 6b and Supplementary
Fig. S7a,b). These cells self-renewed at clonal density (Fig. 6c and
Supplementary Fig. S7c) and expressed Nanog protein (Fig. 6d and
Supplementary Fig. S7d). We were also able to maintain previously
established (Fig. 2j–l) Oct4-low iPSC−/− clones indefinitely in N2B27
(Fig. 6e,f). Nanog binding at key genomic targets in these cells was
also maintained (Fig. 6g).
To confirm our observations in an independent system we
established ESCs with low Oct4 expression levels. To derive these,
we co-transfected Oct4flox/− ESCs with CAG-Oct4 and CAG-CreERT2
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Figure 7 A defined Oct4 level is also required for downregulation of key naive
pluripotency genes in ESCs. (a) Experimental design used to obtain Oct4-low
ESCs. ESCsflox/− were stably transfected with CAG-Oct4 and CAG-CreERT2
transgenes and subsequently treated with 4OHT to induce Cre-mediated
excision of the floxed Oct4 allele but not the CAG-Oct4 transgene, which
is not flanked by loxP sites. (b) 4OHT-treated and untreated CAG-Oct4
ESCsflox/− after the first passage in N2B27 culture conditions with selection
(G418) for Oct4 promoter activity. (c) qRT–PCR detection of total Oct4,
Socs3, Nanog, Rex1, Esrrb, Klf2 and Klf4 in Oct4-low ESCs (CAG-Oct4
ESCs−/−) cultured in N2B27 conditions for 15 passages in comparison
with 4OHT-untreated cells and wild-type ESCs cultured in 2i/LIF conditions.
Data shown are the mean of 3 replicates and are from 1 of 2 representative
experiments. (d) qRT–PCR detection of total Oct4, Klf4, Nanog, Tbx3,
Esrrb and Rex1 in CAG-Oct4 ESCsflox/− and ESCs−/− cultured in serum/LIF
conditions. Data shown are the mean of 3 replicates and are from 1 of 2
representative experiments. (e) qRT–PCR detection of Gata4, T-Brachyury
(T) and Fgf5 in CAG-Oct4 ESCsflox/− and ESCs−/− cultured in serum/LIF
conditions. Data shown are the mean of 3 replicates and are from 1 of
2 representative experiments. EB, embryoid body. (f) qRT–PCR detection
of Oct4, Nanog, Rex1, Gata4, FoxA1, T-Brachyury, Snai2, Zeb2, Nkx2.5,
Pl-1, E-cadherin, N-cadherin and Fgf5 expression during embryoid body
differentiation of CAG-Oct4 ESCsflox/− and ESCs−/− clone 2. Data shown are
the mean of 3 replicates and are from 1 of 3 representative experiments.
(g) qRT–PCR analysis of Sox1, total Oct4, Rex1 and Nanog expression during
5 days of neural induction in monolayer culture of CAG-Oct4 ESCsflox/− and
ESCs−/− clone 2. D0–D5 indicate the number of days of differentiation.
Data shown are the mean of 3 replicates and are from 1 of 2 representative
experiments. (h) Immunocytochemistry detection of βIII-tubulin and Nanog
expression after 7 days of neural induction in monolayer culture of CAG-Oct4
ESCsflox/− and ESCs−/−.
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Figure 8 A defined Oct4 level controls cell state transitions around
pluripotency. The combined transduction and transfection of reprogramming
transgenes into Oct4−/− somatic cells results in the generation of highly
proliferative reprogramming intermediates. On exposure to 2i/LIF culture
conditions some of these undergo conversion to a pluripotent cell state.
Remarkably, independently of the Oct4 expression level in reprogramming
intermediates, generated iPSCs−/− always show an invariable ESC level
of Oct4 expression. Once cells have entered a pluripotent state they can
be maintained within a range of Oct4 expression from an ESC level to
up to sevenfold less without loss of self-renewing capacity. This indicates
a specific requirement for a defined Oct4 level for the acquisition rather
than maintenance of the naive pluripotent state. As shown before for
ESCs, complete abolishment of Oct4 expression in iPSCs−/− leads to
differentiation towards the trophectoderm lineage. Surprisingly, pluripotent
cells with a constitutive ESC level of Oct4 can efficiently differentiate into
the three germ layers and germline on the provision of appropriate signalling
cues. At the same time ESCs/iPSCs with low Oct4 levels demonstrate
enhanced self-renewing capabilities independently of culture conditions and
fail to exit the pluripotent state on the induction of differentiation. Overall
these data demonstrate that Oct4 actively controls cell state transitions
taking place during the entry into and exit from the naive pluripotent cell
state.
transgenes. Similarly to the above results (Supplementary Fig. S2g),
the obtained self-renewing cells exhibited an ESC level of Oct4
(Fig. 7c). Subsequently, we treated these with 4OHT to induce
Cre-mediated excision of the floxed Oct4 allele but not the CAG-Oct4
transgene, as the latter was not loxP-flanked (Fig. 7a). The cells
were then switched to N2B27 with selection to eliminate non-self-
renewing cells. Untreated cells differentiated and died after the first
passage. Consistent with iPSCs−/−, 4OHT-treated ESCs (CAG-Oct4
ESCs−/−) exhibited 5–7-fold lower than ESC Oct4 levels and could
be maintained in N2B27 indefinitely (Fig. 7b,c). Moreover, when
placed in serum/LIF, they exhibited higher expression levels of naive
pluripotency markers than parental cells (Fig. 7d,e). Furthermore,
CAG-Oct4 ESCs−/− failed to undergo embryoid body and neural
differentiation, instead remaining locked in a naive pluripotent state
(Fig. 7f–h and Supplementary Fig. S7e).
Next we investigated whether the DNA-binding capacity of Oct4
is important for its function in cell differentiation. We used the
Oct4-267VP mutant, which cannot bind DNA or sustain ESC self-
renewal in doxycycline-repressible ZHBTc4.1 cells29,30 (Supplementary
Fig. S7f). We transfected Oct4-low ESCs−/− with the PB-Oct4-267VP
transgene and established lines with an ESC level of total Oct4
(Supplementary Fig. S7g). Importantly, mutant Oct4 could not
rescue the differentiation defect of Oct4-low ESCs−/− (Supplementary
Fig. S7g), demonstrating that the capacity of Oct4 to bind DNA is
required for differentiation.
In summary, the naive pluripotent state can be maintained
in the absence of pluripotency medium requisites, if the Oct4
expression level is decreased.
DISCUSSION
In this study, using optimized culture conditions for the induction and
maintenance of pluripotent cells31,32 and Oct4−/− somatic cells as a
starting point to provide a stringent functional assay, we demonstrated
that a defined Oct4 level is critical for naive pluripotency acquisition.
Once pluripotency is established, Oct4 levels can be decreased without
loss of self-renewal. However, an ESC level of Oct4 is then required for
the efficient downregulation of the naive pluripotent program during
cell differentiation (Fig. 8).
It has previously been proposed that more than 50% Oct4 downreg-
ulation would lead to trophectoderm differentiation in doxycycline-
repressible ZHBTc4.1 ESCs (ref. 7). This apparently differs from our
observations. However, we found that by titrating the doxycycline con-
centration self-renewing Oct4-low ZHBTc4.1 ESCs with around 30%
of the startingOct4 level could be established (Supplementary Fig. S8).
Several studies reported the involvement of Oct4 in ESC differen-
tiation in vitro. Ref. 33 claimed that Oct4 suppresses neuroectoderm
differentiation and promotes mesendoderm differentiation of mouse
ESCs in vitro. Ref. 34 claimed that Oct4 suppresses human ESC differ-
entiation into definitive endoderm. Both studies, however, are based on
Oct4 overexpression and knockdown experiments in ESCs. In contrast,
our system allowed investigation of the effect of biological Oct4 levels
on pluripotent cell differentiation. Thus, and in apparent disagreement
with what was expected from the published literature, constitutive
Oct4 expression at an ESC level led to a robust contribution to nascent
ectoderm, mesoderm, endoderm and germline in the embryo. This
result is however consistent with the observed Oct4 expression in the
progeny of all germ layers until the late somite stage5,19.
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It was reported that episomal overexpression of an Oct4 DNA-
binding mutant (Oct4-267VP; ref. 30) causes spontaneous ESC
differentiation29. In our system, this did not rescue differentiation
defects of Oct4-low cells. As the transactivation activity of Oct4-267VP
depends on the recruitment by a functional POU factor30, we believe
that Oct4-267VP induces differentiation only on strong overexpression
and in the presence of an ESC level of wild-type Oct4.
In conclusion, this study redefines our previous understanding of
the biological roles of Oct4 from a factor known to be important for
reprogramming and self-renewal6,7 to one also actively controlling cell
state transitions during entry into and exit from the naive pluripotent
state. The future challenge will be to define the molecular mechanisms
underlying this dual function of Oct4. 
METHODS
Methods and any associated references are available in the online
version of the paper.
Note: Supplementary Information is available in the online version of the paper
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